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SCREENING FOR LOW BONE MINERAL DENSITY IN PATIENTS
WITH RESPIRAT ORY DISEASE
Abstract
patients with respiratory disease have decreased mean bone mineral density (BMD)
and thereby increased risk of fractures compared to people without respiratory
disease. We developed a clinical screening tool to identify patients unlikely to have
low BMD who do nof require bone densitometry, and estimated number needed to
screen (NNS) and number needed to treat (NNT) to prevent one hip fracture in this
patient grouP.
Methods: A cross-sectional convenience sample (N=239) of patients from public
hospitals and general practice with respiratory disease had their BMD assessed
using dual-energy X-ray absorptiometry (DXA). Risk factors for low BMD (Z-score 
<-
1.5 at lumbar spine, neck of femur or total femur) were analysed using multiple
stepwise logistic regression. NNS to prevent one hip fracture using daily alendronate
(1gmg) at 1 and 10 years were developed using equations in Kanis, 2OOO,1 and by
extending the results to ten years using a Markov simulation.
Results: Participants with respiratory disease and ALL of: BMI >20; smoked 
<80 pack
years; not currently using warfarin; FEVr >60% predicted were NOT recommended
for DXA, thereby eliminating 35% of participants. At selected sensitivity of 86%, this
tool has specificity of 41o/o, positive predictive value 27o/o and negative predictive
value of 920/o., area under the Roc curve was 0.7. Number needed to screen for 65
year old women with respiratory disease and low BMD (2.-1.5) is -1800 for treating
with alendronate for 1 year and 165 for 10 years of treatment. Using the screening
tool to reduce the number of patients screened by eliminating the 35% not requiring
densitometry may reduce NNS for 'l year of treatment by 35% to -1,4OO for 65 year
old women with copD and BMD of Z<-1.5, and NNT to -440 to prevent one hip
fracture.
conclusions: our pre-screening tool has high negative predictive value, and
therefore may assist clinicians to identify those who would benefit most from
densitometry. NNS estimates for 65 year old women are reasonable. Using this
screening tool together with NNS may enable the development of a cost-effective
screening program for low BMD in respiratory patients'
Page 1 1
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Chapter 1
Chapter 1 - lntroduction
1.1 What ls osfeoporosis?
Osteoporosis is a "progressive, chronic disease which is characterised by low bone
mass and a microarchitectural deterioration of bone tissue, leading to enhanced bone
fragility and a consequent increase in fracture risk".2 Osteoporosis constitutes a
major public health problem through its association with fractures, costing Australian
taxpayers $7.4 billion per annum, and over 25,000 healthy lives lost in the financial
year 2000-01.3
People with chronic lung diseases such as chronic obstructive pulmonary disease
(COPD) and asthma are at high risk of osteoporosis, with on average 10o/o lower
bone mineral density (BMD) than controlsa with the largest deficits seen in patients
with most severe disease. The rates of actual bone fracture in people with COPD are
also high, with estimates of 11-56% in oral corticosteroid-dependent asthmatics,
compared with 0-8% in people taking intermittent oral corticosteroids or inhaled
corticosteroids only.5'6
High quality tests.are available to determine bone mineral density and hence
diagnose low BMD. Effective treatments exist, although the efficacy and cost-
effectiveness of full screening and treatment programs are yet to be evaluated in
people with respiratory disease.
1.2 Key questions for this fhesrb
ln order to decide whether screening and treatment of low bone density in people
with airways disease is likely to be efficacious and cost effective, the following
questions must be considered.T'8
. Does low bone density cause sufficient mortality and morbidity to warrant routine
screening?
The magnitude of the problem of low bone density in the general population and in
people with COPD or airuvays disease need to be considered, as does why patients
with COPD or ainrvays disease are at high risk of having or developing low bone
density than the general population.
Is early treatment for low bone density during the asymptomatic (pre-fracture)





. ls the screening test reasonably inexpensive, safe and acceptable to patients?
. Does the screening test have adequate predictive value?
lf screening and treatment appear efficacious, then how can combinations of clinical
risk factors be used to identify the patients at highest risk of developing low bone
mineral density?
1.3 Project aims and hypofheses
Based on the above considerations, this thesis will investigate the following aims by
original research:
1 .3.1 Aim 1 : To identifv risk factors for low bone densitv
"To investigate whether suggested risk factors predict low bone density in people
with asthma/ainvays disease by studying a large cohort of "at risk" subjects."
r needed to needed to treat
estimates in the oeneral population and subqroups with COPD
To determine the number needed to screen in the general population and a subgroup
of the general population who have COPD by screening with DXA, to identify a high-
risk population - and in that population, the number needed to treat for treatment with
daily alendronate for one and ten years to prevent one hip fracture.
These lead to hypotheses 1 and 2:
1.4 Hypothesis 1
That patients with "lov/' (Z<-1.5) or "not lot¡/' (Zr-1.5) BMD (matched for age and
gender) at either total femur or neck of femur or lumbar spine differ significantly for
one or more risk factors for low BMD usin g an X2 test for categorical variables, or
logistic regression for continuous variables.
1.5 Hypothesis 2
That the number needed to treat and number needed to screen will be able to be
estimated for treating patients in the general population and the COPD population




Chapter 2- Literature review: ls screening for and treating low bone
density effective in people with airways disease?
2.1 Does low bone density cause sufficient mortality and morbidity to
w a rra nt ro uti n e'sc reen i n g?
2 1 1 Maonitude of the oroblem in the oeneral population
Osteoporosis presents clinically as bone fractures. Traditionally osteoporosis is linked to the proximal
femur (hip), vertebrae (spine), and distalforearm (wrist), although because bone is lost throughout the
skeleton, fractures can occur at other sites, such as the ribs.s
Following a peak in early adulthood, bone density in absolute units (g/cm2) declines with advancing
age. Men have a higher peak bone mass than women, and thus have higher bone density than
women in middle and old age.to't'
The most widely used definition of low bone density is the (Wor1d Health Organisation (WHO)
definition.l2 Medicare uses additional defìnitions for determining rebates after bone densitometry
using dual emission X-ray absorptiometry (DXA) (See Table 1).13
Table I - Definitions of "osteoporosis" currently in use in Australia based on
low BMD
As above As above T<-2.5






"low BMD" based on
actual BMD13
Mean BMD of young







definition of low BM.D12
Reference Matched for CutoffName
Medicare rebates can also be obtained for densitometry (using DXA) if patients have
one or more fractures occurring after "minimal trauma" (males or females), where
DXA will be confiiming a presumptive diagnosis of low BMD, or for the diagnosis or
monitoring of prolonged glucocorticoid therapy, conditions associated with excess
glucocorticoid secretion, male hypogonadism, or female hypogonadism lasting >6
months after age 45.13 These conditions essentially constitute clinical definitions for
low BMD. However, low BMD as measured by densitometry will be the focus of this
thesis because it is more objective.
The WHO definition of low BMD identifies age-related bone loss relative to the young
adult mean (aged 20-29 years) in standard deviation units, and these measurements
are referred to as l-scores. Consequently, the prevalence of men and women with
low bone density according to the World Health Organisation (WHO) increases with
advancing age. An estimated 2-17o/o of women and2-7o/o of men in European/US
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Chapter 2
reference populations aged 50-79 have low bone density at the total femur using this
definition (See Table 2).'o











As indicated in Table 1, there are two definitions of low BMD (based on actual BMD)
for Medicare rebate purposes. One is equivalent to the WHO definition of low BMD
(T<-2.5). The other is unique to Medicare, and this definition of low BMD identifies
causes of reduced bone density beyond age, such as that related to medication or
illnesses. The proportion of a population with low BMD at any particular site
according to this definition (2.-1.5) is always the same for each gender regardless of
age because Z-scores are standardised for age and gender (6.68%).
between BMD and
BMD is a good predictor of fracture risk,la with each standard deviation decrease in
hip BMD conferring a2.6xincrease in age-adjusted hip fracture risk,15 and a two
standard deviation reduction in vertebral BMD conferring a 4-6-fold increase in
vertebral fracture risk.
There are other predictors of fracture risk that are independent of BMD. These
include age (as a surrogate for bone quality, medical illness, and propensity to fall)16
17 pre-existing fractures,ls corticosteroid use,1e hip geometry eg hip axis length,20 and
bone turnover.2l ln addition, quantitative ultrasound (QUS), which is often used as a
radiation-free, more accessible alternative to BMD assessment is also a strong
predictor of fractures,22 despite being only modestly correlated with BMD (r=0.4 -
0.7), raising suggestions that QUS may measure other aspects of fracture risk that
BMD is unable to,assess, such as bone quality. Therefore, despite the evidence that
BMD as assessed by D)(A is not the only predictor of fracture risk, and the fact that
other risk factors can add extra information to fracture prediction, BMD is still a good
measure of fracture - similar to or better than serum cholesterol concentrations for
cardio-vascular disease,lT or of blood pressure to predict stroke.23
Cross-sectional studies show linear changes in BMD,2a33 whereas longitudinal
studies indicate that the rate of bone loss is not strictly linear, but increases with
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advancing age,"'?n" with rates of change of 0.51-0.96% per year at the neck of
femur in women34,35,37 and 0.4-0.82o/o per year in men.to'tt Similar patterns were also
reported at the calcaenus,tu but not the spine,37 probably due to coexistent spinal
degenerative disease.
possible reasons explaining the apparent difference between findings in cross-
sectional and longitudinal studies include limitations in sample size,38 cohort effects
such as increase in heights in younger generations compared to older people, which
would overestimate rates of bone loss with aging in cross sectional studies,3s and low
BMD is associated with increased mortality rates in older women, with sicker women
under-represented in cross-sectional studies.æ The DXA machine used in the
research described in this thesis uses reference populations from Europe and the UK
from cross-sectional dala.3a'3a'41-45 The use of cross-sectional data may slightly over-
estimate age-adjusted mean BMD in the oldest age groups (>70 years)'
2.1.3 closer look at fractures
Hip fractures cause the most morbidity and mortality, with hip fracture patients 30%
more likely to be institutionalised and 18% more likely to have died one year post-
fracture compared to community based controls.a6 Hip fractures also result in loss of
independence, with 31% o'f previously ambulatory patients unable to walk one year
after the hip fracture.ao Older patients were more likely to have a poorer outcome eg
non-ambulation or death.aT Some morbidity was associated with fractures of the
spine or distal forearm eg higher rates of depression and poorer quality of life,€ but
patients who sustained these fractures were no more likely to have died than patients
without fractures.Æ
Most fractures (70-80%) occur in women,on due to lower peak bone mass and longer
lifespan in women compared to men.so The numbers of actual fractures and fracture
risk in men and women in the general population and in the COPD population will be
discussed in order to decide whether fractures are of public health significance'
2.1.4 Australian estimates of fracture incidençe
Community fracture incidence has been estimated in three large Australian
studies.sl,u',tt As.fracture rates increase with advancing age,10'11 and the Australian
population ages (median age 34 in 1996 compare with 32 years in 1991t0¡ the
incidence of many (if not all) fractures are likely to increase as there are more people
than ever before in the older age groups most susceptible to hip fractures.
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Estimates from the Geelong Osteoporosis Study group suggest that over the period
1996 - 2006, total number of fractures may increase by 25%. Hip fractures may
increase by 36% over 1996-2006, and may double by 2O26-s5
Assuming these projections are correct, by 2006 31,000 Australians aged over 45
may experience ä fracture per annum. lf these figures are extrapolated to the entire
Australian population,to then by 2006, the number of hip fractures may have risen so
greatly that over 14,000 people aged over 45 will experience a hip fracture per
annum, and by 2051 this may increase to over 42,OO0 Australians per annum. With
a corresponding yearly post-fracture mortality rate of 27o/o,47 by 2026 an estimated
11,4OO Australians over 45 may die each year after sustaining a hip fracture.
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2.1 e ofl tn le PD
ainvavs disease
chronic lung disease is common in Australia, with the prevalence of moderate to
severe chronic lung disease in South Australia estimated to be 5% in people aged
45-54,6% in people aged 55-64, and 1 1o/o inpeople aged 65 and over.uu
A number of small studies of patients with coPD have found high numbers of bone
fractures in addition to low BMD. The prevalence of rib or vertebral fractures in
patients with asthma or COPD taking daily oral corticosteroids is 42% - 507o,5'6 and
the prevalence of vertebral fractures alone is estimate d al34o/o,6 compared to none
(0%) in patients with asthma or COPD patients taking intermittent oral
corticosteroids,s although people taking inhaled corticosteroids may have been X-
rayed less frequently than those taking OCS as they would have had less severe
respiratory disease. Despite the small numbers of patients included (and likely
selection bias), the large number of fractures observed highlights a clinically
important problem, particularly in subjects with advanced disease'
A review article which summarised bone density reduction in nine cross-sectional
studies in patients with asthma or airways disease.a The review concluded that
patients with asthma or coPD afe a group at high risk of developing low bone
density. An averag e 1Oo/o BMD reduction compared to controls was found, with
greatest deficits in patients with more severe disease, although all the trials were in
small numbers of Patients.a
A i}o/o average decrease in BMD for patients with airways disease suggested by
Smith et al.a equates to approximately one standard deviation, with an associated 2'6
times increase in hip fracture risk.s7
Estimates for fracture burden in the Australian COPD population can be made by
using the fracture rate for the general population, multiplying this by the prevalence of
coPD in each age group, multiplying by 2.6 (increase in fracture risk due to coPD
status,a) then mulliplying by literature estimates of future fracture burden-s5
Assuming these estimates are accurale, T .5o/o of the Australian population with
COpD may contribute around 7,900 fractures per annum in 1996-2006, including
around 3,600 hip fractures. By 2026 this may increase to 4,300 hip fractures and
11,500 per annum for the Australian COPD population by 2051. Mortality rates at
one year after the hip fracture are 18% higher than expected (in non-COPD
subjects),a7 therefore approximate numbers of deaths in the COPD population
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attributable to the hip fracture in the year following the fracture are 650 per annum
1996-2006 ,775 per annum by 2026,2050 per annum by 2051.a7
2.1.6 Conclusion - Does the tion cause cient mo litv and morbiditv in
pe with ain¡vavs disease to warrant utine screeninq?
Large numbers of Australians sustain fractures (particularly hip fractures) and the
associated poor outcomes have significant public health implications. This
magnitude of the problem will increase dramatically over time as Australia's
population ages, and there are more people in the age groups with high fracture
incidence. People with chronic ainvays limitations such as asthma, emphysema and
COpD have high levels of actual bone fracture, low BMD, and associated high risk of
developing osteoporotic fractures. Consequently, the morbidity and mortality
associated with oSteoporotic fractures for this group is particularly large. The
projected number of fractures in the next 30-50 years is sufficiently large to consider
a case for screening for low BMD in patients with moderate to severe ainruays




Dor d¡ at ed
developino low bone densitv
The use of clinical risk factors has been suggested to aid in identifying people who
have low BMD or are at high risk of developing low BMD. Risk factors are indicators
of an individual's likelihood of developing low BMD, and can therefore be used as
part of a screening strategy - provided they predict low BMD with sufficient precision
to enable bone mass measurements to be avoided.ss
Risk factors that may predispose an individual to develop low BMD or be associated
with low BMD will be discussed in women and men in the general population or with
respiratory disease.
Articles describing research on the effect of lifestyle or anthropomorphic factors on
bone density in women and men in the general population or in people with
respiratory disease were sought from the literature using the following keywords.
("risk-factors" AND "bone-density''AND "questiOnnaire*") or ("risk-factors" AND
"questionnaire*" AND "explode "Osteoporosis"/ all subheadings"). Hand searching of
the reference lists of identified studies was also conducted to yield additional relevant
articles not identified using the above method.
The search found studies that tested whether an individual risk factor was associated
with low bone density (univariate analysis), and also studies that tested whether a
number of risk factors considered together were associated with low bone density
(multivariate analysis). These analyses have different purposes - univariate
analyses show that the individual risk factor is or is not associated with low BMD.
Multivariate analyses show the contribution of each risk factor to predicting low BMD,
enabling us to see which risk factors best predict low BMD when a number of risk
factors are considered at once. Multivariate analyses are preferable to univariate
analyses because they simulate reality more effectively as risk factors do not operate
in isolation.
A summary of the studies referred to in this section is tabulated on Table 74,Table
75, and Table 76 (Appendix 1, pages 192 - 194), including numbers of patients and
sampling frame. Risk factors applicable to the general population and those
applicable specifically to patients with asthma or COPD will be discussed Both




2.1.7.1 R isk factors aoolicable to the oeneral oooulation
The following risk factors will be discussed in this section: age, body size (body mass
index (BMl), weight, and height), previous fractures, low levels of physical activity or
immobilisation, cigarette smoking, family history of osteoporosis, and calcium intake.
2.1.7.1.1 Aoe
Data from cross-sectional surveys of reference populations show that bone density
(as measured in gtcm2) declines with advancing age. 10 " The bone density of
women peaks in early adulthood, declining slightly until menopause, then declining
faster after menopause, with the rate of loss increasing into old age. The bone
density of men peaks in early adulthood then decreases in a similar manner to
women, except without any change in the rate of bone loss around middle age.
Advancing age is also associated with low bone density in most sub-groups in
manyse-ou but not al167'64'66 cross-sectional studies tabulated in Table 3. No
association was found between age and BMD in the study by Reid & Heap, 199067
who used Z-scores to measure BMD, (which are standardised for age, gender, and
weight), and therefore no relationship between age and BMD in this study would be
expected. Whilst age is independently related to low BMD,16'17'1n it may also be a
surrogate marker for other age-related factors including decreased physical activity,
and increasing severity of respiratory disease, which may also affect BMD.
Advancing age may also accelerate differences in BMD between smokers and non-
smokers.6s
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Ward's trianglelp, 1994b3 <0.03
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Chapter 2
Table3-Associationof and bone densi
LS = lumbar spine, NOF = neck of femur, n.s. = not statistically significant
Conclusion
Advancing age is associated with decreasing bone density in many but not all cross-
sectional studies listed in Table 3, and the association appears strong.
2.1.7.1.2 Bodv size
Small body size is associated with low BMD, as higher weight for a given height
increases the skeletal loading on the body, encouraging the body to make bones
thicker and stronger to support extra weight, and also affects the rate of change of
BMD.37 lnvestigations of factors relating to body size (BMt, height, and weight) in
cross-sectional studies are investigated in Table 4, Table 5 and Table 6. The studies
described in Table 4 were mostly asthmatics,63'64'65'6e'70 with one study including
patients with COPD71 Thompson et a\.70 included only a minority of patients with
respiratory disease (See TableTl for more detailed information on the sampling
frame of these studies). lf body size parameters demonstrate significant
associations with low BMD, this is advantageous because weight and height are
routinely collected at many hospital outpatient clinics and general practices.
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2.1.7.1.2.1 Body /nass index (BMI)
Table 4 - Association of bo mass index BMI and bone den
LS = lumbar spine, NOF = neck of femur
* Only 12% of lhe patients in the study by Thompson, 199770 had respiratory disease
(asthma). The remaining patients were postmenopausal women who required daily oral
corticosteroids for non-respi ratory medica I cond itions.
BMI was significantly associated with low BMD in these patients (see Table 4),
although only one of these six studies used BMI in a multivariate model (Thompson
et at.7o)
BMI was significantly associated with low BMD in these respiratory patients (see
Table 4), although only one of these six studies used BMI in a multivariate model
(Thompson et al.7o).
Some studies separated weight and height instead of combining them in BMl. These
are presented in Table 5 and Table 6. Where both weight and BMI are included in a
multivariate model, BMI is preferred,6s as it gives additional information regarding
build and body size.6a
Conclusion
High body mass index is associated with high bone density at the lumbar spine, and
femur (neck of femur, proximal femur and trochanter) in men and women with
respiratory disease, and the associat¡on appears strong. Therefore, as BMI











































Table 5 - Association of weight and bone density in men and women 
in the





LS = lumbar spine,
Only Laatikainen, 1
include particiPants
NOF = neck of femur
9996a and Wong, 200065 include subjects with respiratory disease, others
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Higher body weight is associated with higher bone density in men and women with
and without respiratory disease, at the lumbar spine, neck of femur and radius, and
the association aþpears strong. Therefore, as body weight decreases, so does BMD
Studies utilising BMI in multivariate models were mostly in patients with respiratory
disease, whereas studies utilising weight in multivariate models were mostly in the
general population. Therefore, it is difficult to decide whether weight or BMI is a
better predictor of low BMD from these studies as they both appear equally good'
However, BMI theoretically provides more information on body build and therefore




Table 6 - Association between height and bone density in men and women





LS = lumbar spine, NOF = neck of femur
Only Wong, 200065 included patients with respiratory disease
ln multiple regression models which predict whether individuals will have low BMD,
height and weight both make statistically significant contributions to the bone density
prediction algorithms in pre-menopausal66'72 and post-menopausal women,sn 
ut but
not in men.60'74 Mixed results were found in studies that included participants with a
wide range of ages.uo A possible explanation for this may be that the relationship

































































































together a wide range of ages the effect may be diluted and is therefore no longer
statistically significant. In univariate regression models, weight is statistically
significant but not height65'73'62 with the exception of the pre-menopausal group in
Stevenson et a\.62 No studies included height alone. This mixed picture is consistent
with studies investigating risk factors for hip fractures, with most finding that height
does not predict risk of hip fractures in the larger studies,Ts-77 although increased
height does predict hip fracture in some studies.Ts'7s Possible explanations for these
discrepancies are that increased risk of hip fractures could be mediated through hip
axis length, which is an independent predictor of hip fracture risk,2o and is positively
correlated with height. Another explanation is that people with the lowest BMD and
highest fracture risk may be losing height as they age due to vertebral deformities, as
one study found that height at age 25 was associated with hip fracture risk, but not
heightT6 - thereby diluting the association.
Conclusion
ln the studies presented here, height does not appear to independently add extra
information to enable bone density to be predicted over that contributed by weight
when weight and height are entered into regression models separately.
2.1.7 .1. Previous fractures
Fracture risk increases as BMD decreases, with every one SD decrease in age-
standardised hip BMD conferring a 2.6-fold increase in risk for hip fractures,sT and
decreases of 2 standard deviations in spine BMD are associated with 4-6 fold
increase in vertebral fracture risk.8o Therefore, reduction in BMD increased the risk
of sustaining a fracture. Patients with existing fractures should, therefore, have lower
BMD than patients without existing farctures, and should also be at high risk of
sustaining future fractures.
Luengo et al.6 and Toogood ef a/.81 investigated differences in BMD among
asthmatics with and without vertebralfractures. Luengo et al.6 also included a group
of non-asthmatics with fractures (See Table 7). According to Luengo et al'6
asthmatics with fractures have lower BMD than those without fractures.o This can be
attributed to advancing age, because the effect disappears when standardised for
age by the use of Z-scores,8l although the standard deviation is large, making a

























No asthma.No fractures, Fractures. asthma
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Table 7 - Lumbar BMD and fractures in asthmatics and non-asthmatics
"t "no fractures, asthma" group is younger than "no asthma,
fractures" group
The data from Luengo ef a/.6 has also been used to support a hypothesis that
asthmatics fracture at a higher BMD than non-asthmatics, and that this phenomenon
is corticosteroid-induced. This was also investigated by another research group, who
found no evidence of such an effect.82
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" denotes result significantly different from
reference group (patients with clinical CT
examination unrelated to skeletal disease)
Authors did not cite p-values
These results show that people who have fractures at a particular site also have
lower BMD at that site,6'83'8a although the findings for the lumbar spine are mixed,6'81
possibly due to small sample sizes. Patients in these studies with one fracture
sometimes had low BMD at anatomical sites other than the sites of the fracture. Of
most note, men and women with spine fractures also had low BMD at the hip, but
men and women with hip fractures did not have significantly lower age and gender-
matched sp¡ne BMD than the reference group.sa Results in the Ooms et al.B3 study
are more difficult to analyse than that of Kroger et al.8a because the bone density
measurements were not standardised for age.
"Previous fractures" has been used as a r¡sk factor for predicting low BMD by the use
of multivariate risk factor models. Goemaere et a|.85 found that having a fracture




Table 9 - Association between presence of wrist fractures after age 50 and
BMD in women in the eneral lation
LS = lumbar spine, NOF = neck of femur, TF = totalfemur
Regression coefficients were not specified by the author
While BMD has been shown to be lower in people who have sustained a fracture,
there is no one BMD cutoff that separated fracture and non-fracture cases.uu
Conclusion
people who have already sustained a fracture are more likely to have low BMD than
people who have not sustained a fracture - both in respiratory patients and patients in
the general population. Low BMD at one site is also associated with low BMD at
some other skeletal sites. The studies investigating associations between previous
fractures and low BMD are all quite different, but the association between the two
appears moderate. Therefore, utilising pre-existing fractures as a risk factor adds
information to multivariate risk factor models for predicting low BMD.
2.1.7.1.4 Low levels of physical activity or periods of immobilisation
patients who have asthma or COPD have low levels of exercise compared to normal
subjects.Tt The lowest levels of daily exercise are found in the patients with the most
serious respiratory disease (in this case, patients taking intermittent OCS), who also
have the poorest lung function and the highest cumulative steroid dose (See Table
10). These are also known risk factors for low BMD, and will be discussed later' No
studies include all three factors in a multivariate model - therefore the independent
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Table 10 - Daily exerc¡se, lung function and cumu¡at¡ve steroid dose in men
with COPD and normal control su b ects 1 gggTral
{p<0.05 vs control subjects
fp<0.05 vs COPD, no CS
While the COPD subjects as a whole had lower exercise levels than the control
group, the authors did not offer any explanat¡ons for the variation in exercise levels
between the three groups of patients with COPD'
ln addition to low levels of exercise, people with asthma or COPD have frequent
periods of immobilisation due to bed-rest during infective exacerbations of their
respiratory disease. lmmobilisation entails considerable loss of trabecular bone in
normal subjectssT.(-1% per week), and a sedentary lifestyle reduces skeletal loading
on the bones, which may reduce bone mass over t¡me'
Table 11 - Results from risk factor studies utilising multivariate analyses to
investi ate reduced ical as a risk factor for low BMD
Epidemiological studies listed in Table 1'1 found associations between low levels of
physical activity and low BMD in most60'72'ss but not all65 studies investigating
physical activity and BMD by various definitions, some of which used units not readily
applicable or relevant to clinical practice.sn Only one study specifically investigated






































activity during work time,6s finding no association between occupational activity and
low BMD.
The effect of immobilisation on BMD (using risk factor models) has been less well
studied than physical activity in general. ln the one study found on the topic,
immobilisation for >2 months was not significantly associated with low BMD.61
However, this patient group had few people that had been immobilised continuously
for this length of time (6%), which is not unexpected for a patient group drawn from
the general population.
Conclusion
Physical activity of various types appears to be associate with higher BMD, and
conversely inactivity appears to be associated with low BMD. These results are
consistent in men and women, and at most sites investigated, and the association
appears moderate. There is insufficient data to decide what type of activity, if any,
would be the best to include in a risk factor model to predict low BMD eg
occupational or lifetime activity levels.
There are insufficient studies on periods of immobilisation to conclude if including
immobilisation in a risk factor model for predicting low BMD would add any
information not conferred by other factors.
2.1 .7.1 .5 Ciqarette Smokinq
Many patients with respiratory disease are current or former smokers.
There were no significant differences between the BMD of pre-menopausal smokers
and non-smokers (O.1o/o, not statistically significant)
A meta-analysis of cross-sectional and cohort studies found that post-menopausal
women who smoked had lower BMD than non-smokers of the same age (0.14 SD or
2o/o, p<0.001). There were no significant differences between the BMD of pre-
menopausal smokers and non-smokers (0.1o/o, t1ot statistically significant).uu Results
in men were not significant, but fewer studies have been undertaken and therefore
there may be insúfficient sample size to show an effect should it exist. The few
studies that have been undertaken in men show a similar proportionate effect to that
found in women. The difference between smokers and non-smokers increased
linearly with age, with 2% difference between female smokers and non-smokers at
menopause, which increased threefold to 6% by age 80 (p=g gg1¡ Estimates were
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consistent for the radius, NOF, and calcaneus. The effect of smoking on spine BMD
was not investigated.
Studies that investigated associations between BMD and smoking in multivariate
models are tabulated in Table 12.
Table 12 - Multivariate associations of BMD and smokin
* authors did not specify p-value
The meta-analysis by Law et a\.68 concluded that smoking reduces BMD at the NOF,
radius, and calcaneus in post-menopausalwomen, but not pre-menopausal
women.68 Since this meta-analysis was published, two large studies have showed a
large effect of smoking in pre-menopausal women in Australia,se and Denmark,e0 with
lower BMD at the NOF, LS but not at the radius. Both studies found interactions
between measures of fatness (fat mass and BMI) and BMD, with lower BMD in
groups with lowest BMD or fatness, consistent with earlier research.et Other effect
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Outside the meta-analysis by Law et a\.,68 evidence for low BMD in men is scarce,
with conflicting results in the other two studies outside the meta-analysis at both the
neck of femur and lumbar spine.60'74
Smoking is particularly important to consider in a population of people with ainruays
disease, as the prevalence of ever smoking is high.
Conclusion
These findings show small but significant differences between the BMD of ever- and
past- or never-sm.okers in pre-menopausal Women,sn'no lexcept at the spine).
lf any conclusions can be drawn in men, it may be that smoking reduces BMD in
older men rather than younger. Nguyen et al.7a found significant associations
between smoking and low BMD in their older cohort but not in the study population
with a wider range of ages in Elliot et al.60
As the absolute difference between the smokers and non-smokers is small, studies
with large numbers of participants, or meta-analyses required to achieve statistically
significant results. However, a small effect multiplied over many smokers in both the
normal population and patients with COPD or asthma means that the negative effect




The genetic contribution to bone mass is high, and varies by site.s8 Therefore,
investigating family history of osteoporosis as a risk factor for low BMD has face
validity.
Table 13 - Association of fami h¡ of osteo rosis and BMD
x #= fracture
FH= family history
Of all the sites investigated, the neck of femur has the strongest association with low
BMD, compared to the lumbar spine and radius, although results are mixed. The
"component" of family history of osteoporosis most closely associated with low BMD
are fractures sustained by the mother, either all fractures, or low trauma fractures.se's2
However, family history of osteoporosis is poorly associated with BMD overall. One
explanation may be that "family history of osteoporosis" is a notoriously difficult risk
factor to record accurately, with one research group claiming lhal24% of their cohort
could not remember if their mother had a fracture or not.se Study participants may
have differences in recall as to whether or not family members had fractures or not,

























































# at any age, Sister
Grainge, 199 Univariate
# at any age, Mother
Low trauma fractures
aged >50, Mother or
Sister
# at any age, other
female relative
# at any age,
Mother or Sister
# at any age, any
female relative
Ballard 1 998 FH osteo LS & NOF nla 0.06 Univariate
1 FH osteo LS nla Multi-variaten.s.
Wong, 200 FH osteoporosis LS 076 O.25 Univariate
Maternal #- >50 yrs
Paternal # >50 yrs

























"osteoarthritis"). This may result in misclassification bias, and thereby dilute the true
effect of the factor towards zero so the risk factor is no longer statistically significant.
An alternative explanation is that a family history of osteoporosis may not explain any
extra variation in multivariate models not accounted for by other model items.
Conclusion
Of all the sites investigated, the neck of femur is most strongly associated with family
history of osteoporosis or fractures (followed closely by the radius), and the best
"component" to include in a risk factor model appears to be fractures sustained by
the mother (allfractures, or solely low trauma fractures). There would only be
benefits of including family history of osteoporosis or fractures in relatives in a risk
factor model for identifying patients with low BMD if the participants' recall of their
family's history of'osteoporosis is reasonably accurate.
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21 7 1.7 Calcium intake
Dietary intake of calcium is reduced in patients with respiratory disease,6a associated
with the health belief that "milk makes mucous".e3
Table 14 - Risk factor studies investigating associations between calcium
intake and bone de
Calcium intake appears to be positively correlated with BMD. However, the effect is
probably small (changing BMD by O.1-O7% in Bauer et al.5s). Patients with asthma
or COPD may require more dietary calcium than normal individuals due to inhibition
of intestinal calcium absorption by glucocorticoids, which has been investigated in
people taking oral corticosteroids.ss
Conclusion
Calcium intake is associated with BMD, but the effect is small and would be detected
only in large studies (such as Bauer et al.ss¡. Of the sources of calcium, whose
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Multivariate linear regression (univa
level)
Calcium from O.7O% <0.05
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Current calcium levels or intake




relationship with BMD has been investigated, the best factor may be calcium sources
from current food intake (from Bauer ef a/.ss¡. No skeletal sites seem to be more
strongly associated with BMD than others. Therefore, including calcium intake in 
a
risk factor study to predict low BMD adds less information than other factors 
with
stronger associations with low BMD.
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2.1.7.2 sk factors relevant oarticularlv to oati nts with resoiratorv disease
These include the use of corticosteroids and poor lung function
2.1 .7 .2.1 Corticosteroids
Corticosteroids are commonly used as therapy for patients with COPD and asthma,
ingested either orally as tablets (prednisolone) or inhaled into the lungs using
inhalers which deliver a measured dose of beclomethasone, budesonide, or
fluticasone. High corticosteroid intake has been associated with low BMD- Smith ef
a/.a summarised BMD reductions in cross-sectional and cohort studies of asthma or
COPD patients taking corticosteroids in a literature review (see Table 15).
Table 15 - BMD reduction in patients with asthma and ai rsease
stratified for corticosteroid intake - data from Smith ef
"Hip" is listed where no particular anatom icalsegment of the femur was stated in
original paper
Therefore, from the data in Table 15, there are insufficient studies to decide if BMD
reduction is different between anatomical sites, although BMD reduction appears to
be greatest in patients taking the highest amounts of corticosteroids, and least in
patients taking the lowest amounts. Dose response and BMD or fracture risk has
been studied by two separate research groups - with one investigating this dose-
response effect on BMD, estimating that doubling cumulative dose of ICS decreased
BMD by 0.'13 - 0.18 SD at the lumbar spine and the femur in young asthmatics,
concluding that the higher the amount of inhaled corticosteroids asthmatics
consumed, the lower their BMD was at the lumbar spine and neck of femur.6s Van
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Site specifìc lncluding all sites
Corticosteroid
intake
Site % reduction comPared to controls
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Staae6 studied fracture risk (rather than BMD) and oral corticosteroid use. Relative
rates of non-vertebral, hip and vertebral fractures all increased from the lowest to
highest categories of daily dose of OCS, compared to age-, sex- and medical-
practice matched controls, with relative risks for hip fractures 0.99, 1 .77 and 2-27 for
2.Smg,2.S-7.Smg and >7.Smg groups, and vertebral fractures having relative risks of
1 .55, 2.5g and 5.18 for the same dosage groups. ln addition, fracture risks declined
towards baseline rapidly following cessation of OCS treatment, suggesting that
increased fracture risk conferred by daily OCS use may be reversible to some extent.
Corticosteroid intake has been used as a risk factor in risk factor models for
predicting low BMD (See Table 16), of which only one uses the risk factors in a
multivariate analysis (Thompson et a/o¡. More information on sampling frames of
these studies are found in Table 75 in Appendix 1 on page 195'
Table 16 - Risk factor studies investigating association between corticosteroid
intake and bone densi
n.s. = not statistically significant
Only two factors were studied by more than one research group - years on oral
corticosteroids, (significant addition to model in all three studies), and daily dose of
ICS (significant addition to model using Z-scores,81 but not using BMD
unstandardised for age and gender.70¡ However, the association of high cumulative
dose of ICS with high bone density found by Toogoo d et a1.81 is unexpected, and the
LS Years on OCS BMI n.s
p<0.01NOF Years on OGS BMl, years on OCS
NOF & Years on OCS
LS



























































c e in lumbar spine
Study name Site Risk factor p-value
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authors suggest that the high past and current usage of oestrogen by the women in
their study (41 of 43 women) might account for this finding, as oestrogen use
correlated positively with higher spine Z-scores (p=0.049).
While observing that BMD decreased with increasing steroid intake, Smith et al.a
(Table 15) also noted that subjects who had never had any ICS or OCS still had up to
a60/o reduction in BMD, suggesting that corticosteroid use appears to contribute
significantly to BMD reduction, but is not the only factor contributing to such an effect.
Clarifying a causal link between corticosteroid intake and low BMD has been difficult
due to a number of confounding variables, including the patient's underlying disease,
and co-existent disease-related factors, which include differences in physical activity
levels or disease severity.sT Some of the effect of corticosteroids on fracture risk is
independent of BMD,1e probably mediated through osteocyte apoptosis,ss thereby
reducing the numbers of bone cells.
Conclusion
BMD decreases with increasing corticosteroid intake. Using measures of
corticosteroid intake is useful for predicting low BMD, and the best risk factors to use
in risk factor modelling appear to be daily dose of lCS, years on OCS, and duration of
ICS treatment (years). Corticosteroids are not the only factor contributing to BMD
reduction in respiratory patients, and confounders include the patient's underlying




patients with respiratory disease have reduced lung function (as measured by forced
expiratory volume in one second, or FEVr), with the lowest BMD found in patients
with the poorest lung function.se'100 Worsening osteoporosis, demonstrated by
thoracic wedge fractures, have been shown to further impede respiratory function in
patients known to have low BMD but without respiratory disease.101
packe et al.se and praet et al.loo investigated FEVr and BMD in respiratory patients
stratified by corticosteroid usage. When FEVr was standardised to percent
predicted, the two groups of patients were shown to be functionally equivalent for
their age,100 although the patients taking maintenance OCS had more severe disease
because they required more medications to treat their respiratory symptoms.
Table 17 -FÊYt and bone densi tn rato atients
Conclusion
Low FEVr is associated with low BMD, and the association is moderate, although it
has been investigated by few studies and is confounded by corticosteroid intake,
age, and non-respiratory co-morbidities. FEVr is able to be easily, objectively and
reliably reported in patients with respiratory disease, and despite the confounders, it
may add information to a multivariate model.
21731 eoendence of risk factors
ln addition to the confounders between low BMD and corticosteroids, the same
phenomena observed in Guyatt's revieweT can be seen in the evidence considered
earlier in this thesis. BMD decreases with advancing age (Table 3), but fracture risk
increases with advancing age independent of BMD.l6 
tt Advancing age also widens
the BMD gap between smokers and non-smokers, and may be a marker for other
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lung function also have higher current dose of corticosteroids and poor general
health (Table 17), which are also related to low levels of physical activity and high
cumulative corticosteroid dosage (
Table 10)
2.1 .8 Strenqth of evidence of risk factors
The strength of evidence of risk factors discussed in this review is rated as
. "Strong" (statistically significant relationship with BMD in most studies)
. "lntermediate" (Statistically significant relationship with BMD in some studies)
. "Weak" (Statistically significant relationship with BMD in few studies)
Table 18 - Stren of evidence of risk factors for low BMD
2.1 .9 Conclusion
Risk factors for low BMD in patients with asthma or COPD include both risk factors
applicable to the wider community (such as activity, corticosteroid intake, advancing
age, low body weight) and also risk factors specific to respiratory disease (such as
poor lung function). Both general population and disease-specific risk factors ought to
be considered when designing a screening strategy to identify patients at higher risk
of developing low BMD.
ln people with more severe disease, the negative effect of taking corticosteroids, high
alcohol and cigarette consumption may overshadow small effects of other factors eg
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2.2 ls early treatment for low BMD during the pre-fracture phase effective in
preventing or reducing morbidity and mortality?
What avat n or low B
The use of numerous agents as treatments or prophylaxis for low bone density in
patients with respiratory disease has been studied in three systematic reviews of
trials undertaken solely in post-menopausal women,n and in patients taking daily oral
corticosteroids. 1 o2-l 04
The studies conducted in post-menopausal women will not be discussed here,
because women with secondary causes of low BMD, such as corticosteroid usage,
are routinely excluded from population studies of treatments for low BMD and
therefore these trials exclude the patients of greatest relevance to this thesis.
There are similar reviews of clinical trials for treatments for low BMD in patients
taking daily oral corticostero¡ds102'10s'106 for conditions such as rheumatoid arthritis
and Crohn's disease, as well as patients with respiratory disease.los The effect of
treatments for low BMD on bone density and fractures of the hip and spine in patients
taking daily oral corticosteroids is summarised in Table 19 and Table 20.
A number of studies have investigated the effect of some of these treatments on
patients taking daily oral corticosteroids where none of the trial participants had
respiratory disease. The results from these studies can probably be extrapolated to
patients with respiratory disease. However, studies not including at least a minority
of patients with respiratory disease will not be considered here in favour of studies
that do. There were no studies found which investigated treatments for low BMD in
patients with resp.iratory disease not taking daily oral corticosteroids. The
pharmaceutical preparations currently available in Australia for treating low BMD are
listed in Table 21.
atments rou
The trials discussed in this section can be found in Table 19 and Table 20 on pages
52-53.
Calcium supplementation
There have been no trials comparing calcium with placebo in corticosteroid treated
patients or people with respiratory disease. Calcium supplementation decreases
bone resorption, although it does not completely prevent bone loss.107'10u
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Participants who receive calcium supplements alone usually lose bone, eg Sambrook
et aljol and Saag et al.1oe who found that patients receiving calcium plus placebo lost
1-4% of their bone density over one year at the spine and hip. Of the trials in Table
19 and Table 20 only four did not include calcium supplementation.ll0-113 Therefore,
it is good clinical practice to provide calcium supplementation to patients with
respiratory disease, and patients receiving oral corticosteroid therapy, although it will
not completely prevent bone loss, and there is no evidence that it prevents fractures.
tamin entati
Adachi et al1la investigated vitamin D supplementation, although two studies included
vitamin D supplementation in addition to calcium.t'u Adachi et al.11a did not
demonstrate increase in BMD or reduction in fracture rates, and some subjects
developed hypercalciuria. Vitamin D supplementation in addition to calcium has
been suggested by some authors,116 based on limited evidence. ln summary, there
is litile evidence that it is beneficial to give patients vitamin D supplementation in
addition to calcium.
Bisohosphonates
All bisphosphonate trials listed in Table 19 and Table 20 demonstrated increases in
spine BMD, and all except oral pamidronate demonstrated reduction in spine
fractures,1l7 although the two bisphosphonate trials listed in Table 20 were not
properly controlled trials,1l2'113 and therefore their findings are less robust.118 Of all
the bisphosphonates in Table 19 and Table 20, only risedronate significantly
increased hip BMD, and none demonstrated reduction in hip fractures. The most
common side effects were upper Gl symptoms and nausea. Etidronate can only be
given cyclically as continuous usage impairs bone mineralisation.lls There have
been some safety concerns about the upper-Gl side eflects of bisphophonates,
which is discussed further in due course. ln summary, bisphosphonates (especially
alendronate and risedronate) increase BMD of the spine and/or the hip, and prevent
spine fractures in'this patient group.
Fluoride
Fluoride (with or without phosphate or cyclical etidronate) has been studied in 5 trials
in this patientgroup.110,120-123 All studies showed significant increases in spine but
not hip BMD, and no reductions in fractures at either the hip or spine. Side effects




Calcitonin significantly increased spine BMD in all four trials, but not hip BMD, and
did not prevent fractures of the spine or hip.108'111"t24'125 Side effects included nasal
symptoms, and the nasal preparation had lower bioavailability compared to the
subcutaneous route. ln summary, calcitonin increased spine BMD but does not
reduce fractures of the hip or spine.
Calcitriol
Calcitriol (with or without nasal calcitonin) increased spinal BMD but not hip BMD,
and did not prevent fractures of the hip or spine.108 The major side effect is
hypercalcaemia, which must be monitored on calcitriol-treated patients. Therefore,
calcitriol increases BMD of the spine but not hip, and does not prevent fractures at
either spine or hiP.
Hormonal preparations
Three different types of hormonal treatments have been studied in this population (all
three in OCS-dependent respiratory patients,126-128 see Table 20). All increased
spine but not hip BMD, and none prevented fractures of hip or spine. All had small
sample sizes and unusual or poor study designs. Therefore, more evidence is
required before the efficacy of these treatments in this patient group is clear.
Raloxifene
The selective estrogen receptor modulator raloxifene has not been trialed in this
patient group yet, but has recently shown encouraging results in postmenopausal
women, increasing spine and hip BMD and reducing spine fractures.l2e
Co on safetv co s of bisoho ates from collected in the qeneral
population
Bisphosphonates are associated with some reports of severe oesophagitis, as post-
marketing surveillance of alendronate in the United States of America revealed cases
of chemical oesophagitis in some patients.130 However, at least 60% of the patients
on whom the relevant information was available had not followed the dosing
instructions correctly, and at leasl 14% had relative contra-indications to alendronate
treatement,l30 and clinical reports of bisphosphonate-related oesophagitis appear to
have declined in frequency once the importance of proper administration was
explained to physicians.ltl There were no differences in the incidence of upper Gl
tract adverse events between the control and intervention groups in the large trials of
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bisphosphonates in post-menopausal women.1t2-137 p"trlts from endoscopy trials
that evaluated gastro-oesophageal lesions before, after and during alendronate and
risedronate treatment showed that none detected any increase in incidence of
oesophageal lesions.l3r lnformation about gastric side-effects of bisphosphonates
has been conficting,l3l with the one double-blind placebo controlled endoscopy study
of alendronate, risedronate and placebo over 28 days showing similar potential for
gastro-duodenal irritation at the dosage levels approved for Paget's disese.138
However, two 2-week non-placebo controlled endoscopy studies showed that
risedronate is associated with significantly lower incidence of gastric ulcers and lower
gastric endoscopy scores than alendronate, showing better condition of the
oesophagus.l3e'140 However, asymptomatic endoscopic lesions, like mild upper Gl
symptoms, are relatively common and generally fail to predict ulcer-related events.lal
14" Upper Gl tract adverse events reported during therapy may reflect a high
background incidence of upper gastro-intestinal tract complaints, and an increased
sensitivity to detection rather than a causal relationship to therapy,la3 and
rechallenge studies have shown that most patients who previously reported
intolerance to open-label bisphosphonates were subsequently able to continue
treatment, and the tolerability profile was similar to placeb o.143'144 Therefore,
bisphophonates are well-tolerated overall, but both doctors and their patients need to
remain vigilant to make sure patients are taking their bisphosphonates.
Conclusion
All treatments listed in Table 19 significantly increased spinal BMD, although only
three (intermittent cyclical etidronate, alendronate, and risedronate) demonstrated a
statistically significant decrease in fracture rates at the spine. Most drug trials other
than studies trialing bisphosphonates had small number of participants, thereby
reducing the likelihood that the trialwould demonstrate reduction BMD increases or
reduction in fracture rates at non-spine anatomical sites. Risedronate is the only
treatment in Table 19 to increase BMD of the hip, although this did not translate to a
decrease in hip fractures. The bisphosphonates are welltolerated, but have been
associated with some upper Gl side effects. Therefore, of the treatments reviewed in
Table 19 and Table 20, the bisphosphonates appear to have the greatest effect in
preventing bone loss and reducing fractures. However, alendronate has been
associated with erosive contact oesophagitis, and therefore caution should be
exercised in prescribing alendronate to patients with existing Gl symptoms or people
prescribed medication for Gl symptoms, or with more severe underlying disease or
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several co-morbidities other than their respiratory illness. These severe side effects
of alendronate (gastritis and oesophagitis) are rare in post-menopausal women in the
large randomised trials eg Liberm an et a/.1Æ but more troublesome in patients seen
in regular clinical practice,l6 possibly due to differences between ordinary patients
and patients selected for clinical trials,laT such as number and severity of co-
morbidities, or the patients' commitment to the study. Of all the bisphosphonates,
risedronate has both good results in increasing BMD of the hip and spine, and the











































































































































































































































Table 20 - Su of treatments for low BMD in res irato ents taki dai oral cort¡costeroids*
f compared to baseline











Even groups known to be at high-risk of developing low BMD (such as people taking
oral corticosteroids regularly, or people with asthma or airways disease) have
difficulty accessing treatments for low BMD. Of the treatments currently available in
Australia (See Table 21), all treatments except for testosterone and calcium require a
prior fracture (defined as loss of vertebral height of >2Oo/o on X-ray) before the patient
can obtain the authority script required to buy the medications at PBS prices. lf no
fracture is demonstrated on X-rays (as yet), and the patient wants to take the
medication, they must pay $227-747 per annum to obtain the treatments. This is out
of the financial reach of a large section of the community who would benefit from
treatments as they have a very high probability of sustaining a fracture. Published
cost-effectiveness analyses show that treating women over 65 years of age with low
BMD and at least one vertebral fracture for 1O years is cost-effective,ls3 and reduced
the proportion of patients utilising health care resources.rs4 ln corticosteroid-treated
women with rheumatoid arthritis, treating women with l-scores <-1 was found to be
cost-effective compared to "watchful waiting",155 as were treating various other
groups of corticosteroid-treated people with low BMD but no fractures.ls6 Therefore,
these analyses show that alendronate treatment is most cost-effective in groups at
high risk of developing fractures, not necessarily just people with existing fractures.
Therefore, broadening the range of patients who can access bisphosphonates such
as alendronate through the PBS may also be cost-effective.
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Table 21 - Drugs available in Australia under the Pharmaceutical Benefits
Scheme for treatin low BMD Jul 157
*= Authority not required for prescription
Conclusion
There are a number of treatments available for preventing osteoporotic fractures that
have been trialed in patients with respiratory disease, and people requiring daily oral
corticosteroids. The most effective treatments are bisphosphonates (especially
risedronate and alendronate). Most of the treatments studied in people taking daily
oral corticosteroids (including people with respiratory disease) are available in
Australia, but most treatments available are very expensive for the majority of
patients who are not able to meet the PBS authority indications to receive the
treatment at a subsidised price.
Selective estroqen receptor modifiers
Raloxifene 60 mg 28
(Evista)

























































































2.2.3 Utilisation of available treatments for low BMD in people with respiratorv
disease
Rates of prophylaxis for low BMD and bone density testing have been investigated in
patients taking maintenance doses of oral corticosteroids. Patients identified through
tertiary hospitals in the United States of America, the United Kingdom, and Australia
had prophylaxis rates of 6-58%,1s8-162 while patients surveyed through general
practice in the United States of America, and the United Kingdom had prophylaxis
rates of 1 4-55%.163-'16s
An estimaled 27-31% of patients identified through hospital outpatient clinicslse 
l6s'r66
and 1 6o/o of patients identified through general practice had undergone bone density
testing.l6a ln another study, 23o/o of respiratory patients taking continuous oral
corticosteroids received any drug therapy for low BMD, 35% had bone density testing
and 55% had "any intervention" (this was a group which pooled interventions,
including drug therapy, and recommendations for weight-bearing exercise);16s other
estimates show that low BMD was considered in 48o/o of respiratory patients taking
continuous oral corticosteroids.l66 No estimates are available for patients with
respiratory disease not taking continuous oral corticosteroids.
A cross-sectional study of patients presenting to orthopaedic clinics for low trauma
wrist fracture estimated that 29% of patients received "any osteoporosis
management" prior to the fracture. This included physician discussion regarding low
bone density, or referral for BMD testing. Post fracture, 38%o were taking hormone
replacement therapy (HRT) or bisphosphonates, and 62o/o were taking calcium or
vitamin D. These rates of prophylaxis were similar to that prior to fracture, indlcating
that the presence. of a fracture does not influence the prescribing of interventions for
preventing or treating low BMD. Half the patients (50%) received osteoporosis
follow-up, which included discussion with a physician regarding low bone density.167
2 2 4 Utilisation of screeni no technoloov for identifvino low BMD in people with
respiratorv disease
Offering bone density screening by D)(A has been investigated in one RCT only.
Torgerson et a\.168 randomised 1,600 peri-menopausal women to either screening or
no screening, and subsequently recommended that women with bone density in the
lowest quartile of the screened group commence taking HRT. Screening increased
HRT use by around 7% (p=9.92), but no reduction in fracture rates was seen,
although this would have been unlikely to be achieved, given the low fracture rate
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(participants aged 45-54), small sample size (799 women randomised to screening)
and short period of follow up (2 years).
Jones et al.8s also screened pre-menopausal women for low BMD, although as part
of a cohort study, and without a placebo group for comparison. They provided
feedback on BMD results, notifying women with ß-1.0 that they had low BMD.
Compared to women with "normal" BMD (Tr-1.0), those with "Low" BMD (ß-1.0)
were more likely to increase calcium intake, usage of calcium supplements, and
physical activity, and there was no impact on smoking cessation.
Despite forecasts of large lifetime fracture risk and sizeable fracture burden in people
with respiratory disease, rates of treatment for low bone density in ainvays disease
are minimal, whether that treatment is taken as prevention, or if low bone density has
already been identified. Most patients (40-94o/ofsatø2, were not offered prophylactic
treatment, and in half the patients (52%) a diagnosis of low BMD was not even
considered.166 However, evidence from the screening trial of Torgerson et a|.168 and
bone density feedback studyse are encouraging, suggesting that if patients receive
bone densitometry and are found to have low BMD, they are more likely to make
lifestyle changes to reduce some risk factors, or to take treatment for low BMD. lf
this were applied to other patient groups such as patients with respiratory disease,
the increase in participation in bone densitometry and subsequent reduction in risk
factors and increase in treatment for low BMD may result in a reduction in the rate of
clinically important fractures in patients with respiratory disease.
2.2.5 Conclusion
. There are numerous anti-osteoporotic treatments available in Australia for
increasing BMD and preventing fractures. Of those investigated in people taking
oral corticosteroids (especially with respiratory disease), the bisphosphonates
appear most effective
. Effective pharmacological treatments available today in Australia are expensive
for all except the patients at extremely high risk of future fractures
. Rates of prophylaxis for low BMD are currently low. However, screening has
been shown to change health related behaviours, and increase the uptake of
treatments for low BMD
. Therefore, treatment to increase BMD before fractures occur is likely to prevent
morbidity and possible mortality from low BMD in people with respiratory disease
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2.3. ls a screening test availabte that is reasonably inexpensive, safe and
acceptable to patients?
Many tests are available for determining BMD, such as single photon absorptiometry
(SPA), single X-ray absorptiometry (S)(A) dual X-ray absorptiometry (DXA), dual-
photon absorptiometry (DPA), quantitative computed tomography (QCT), and
radiographic absorptiometry (RA) (See Table 22). DXA has the advantage of being
able to measure BMD at the hip and spine as well as peripheral sites (such as the
radius). This is advantageous because BMD measurements at a given site (such as
the hip), are the best predictor of fracture risk at that site, although the BMD at one
site are highly correlated with BMD at other sites - for example, the correlation
between the spine and neck of femur is r=0.76.1un DXA is now the most widely used
technique for measuring bone density in clinical trials and epidemiological studies
due to low radiation dose per test, wide availability, and ease of use,170 and good
precision and accuracy, increasing the likelihood that changes detected in BMD over
time are meaningful. DXA is currently the "gold standard" technique in use in
Australia for measuring BMD.171
Table 22 - Comparison of bone density measurement techniques (Adapted
from Edd 1998s.
SA$1= US$o.5
The measurement of bone density using DXA is precise, but extremely high precision
is required if DXA is to identify very small changes in bone density, which would
occur if sequential scans take place over a short period of time (such as 6 months),
or if the rate of change of bone density is low. ln sequential monìtoring, the largest






















































software),173 although interaction between subjects and operators (such as
positioning errors) also contributed significantly to variation in bone density
Table 23 - Costs of selected radi ical testsl3
f All costs are in Australian dollars
DXA tests are inexpensive, however, the costs of the individual tests must not be
viewed in isolation as they are more important when considered as component c,csts
of a screening program, for which estimates such as life years gained (LYG) and
quality adjusted life years gained (QALY's) are obtained.
Bod WE ht and s odol
There has been increasing interest in recent years in the link between BMD
measurement by DXA (the current "gold standard" technique for measuring bone
densitylTl) correlations between body mass parameters, such as body mass index.
Weight and BMI are certainly positively correlated with BMD,71'6s'64 and low BMI has
been associated with increased risk of fractures of the hip,"''n wrist and ankle,17a
with every increase of l Okg/m2 conferring a decrease in hip fracture risk of 40%
(RR=O.58 (Cl 0.36-0 .sz).'n
However, the biological plausibility of the association has been questioned because
no mechanism sufficient to explain the association has been proposed. Associations
between low BMl, low bone mass, and an increased rate of bone loss were
independent of age or years since menopause.
It has been postulated that there are inaccuracies inherent lo in vivo BMD, and that
the source of these inaccuracies is derived from the "two-component DXA limitation",
in which DXA is unable to distinguish more than two absorptiometrically dissimilar
mediums in the region of interest.175-177 All bone sites are comprised of more than
two different types of tissue eg bone mineral, lean muscle tissue, fat mass, as well as
red and yellow bone marrow. Therefore, in vivo, DXA cannot completely satisfy the
"two component" methodological limitation, and therefore must be inaccurate in
measuring "true" bone density to a greater or lesser degree, and the key to DXA
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tissue areal density ratio.178 Simulation studies undertaken in vivo at the lumbar
spine and femur showed that patient-specific in vivo inaccuracies exceed +20%o, and
that these inaccuracies are likely to be largest in postmenopausal, osteopenic,
osteoporotic and elderly individuals't7s-181 - exactly the groups in which accurate
estimates of BMD are the most important. These claims may seem simply incredible,
as they are at odds with the general understanding of the extent of inaccuracies in
DXA measurement of BMD (See Table 22). However, the body of research into
inaccuracies inherent in the measurement of BMD is sound and careful research that
is not easily dismissed.
The implications for a screening study are.
1. whether or not the measurement of BMD by D)(A is undermined and if so, is it
important
2. what potential alterations should be made as to what risk factors are included in
screening models.
Therefore, there appear to be systematic errors in the measurement of bone density
using DXA. However, the accuracy of bone density measurements are difficult to
achieve as the experimental design does not lend itself to continuous evaluation of
results available in standard laboratory practices for measuring chemicals, and no
universal calibration standards are currently available. DXA is still the most
dependable current technique for measuring bone density, and is still a useful
surrogate marker for fracture risk, because it is a stronger long-term predictor of
fractures per standard deviation change (relative risk 1 .5-2.O) than markers used for
other common diseases, such as cholesterol measurements for cardiovascular
events (relative risk 1.3).tt'
Given the findings listed above, weight and BMI may be more accurately described
as confounders rather than risk factors for low BMD. Therefore, in a screening study,
weight or BMI should be measured - either as a risk factors or potential confounders,
until such time as a better measure of true BMD other than DXA is found.
Conclusion




2.4 Does the screening test have adequate predictive value?
2 41 How do we decide which oatients are at the hiohest risk. and what is the best
wav to identifv them?
Treating a patient with low BMD to prevent a fracture is clearly the last stage in a
series of steps or decision pathways, which begin with the decision by the clinician to
refer the patient for bone densitometry (See Figure 1).
Figure 1 - Nomogram for flow of steps in diagnosing and treating low bone
density
Some guidelines would not recommend densitometry unless the results could
influence a treatment decision,e'183 on the premise that the inconvenience, risks and
costs of testing would outweigh the benefit of improved health outcomese. ln these
cases, the decision to treat would be based on non-BMD risk factors, and on the
benefits, risks and costs of the treatment. However, assuming that the patient would
benefit from treatment, asking the patient to attend densitometry would enable
monitoring of the effects of any treatment, or assess the rate of decline in BMD in
these patients, even if the densitometry result would not have altered the treatment
the patient received.
Examples of recommendations forwhich patients in the general population,ls4-186 
"n¿
patients with medical conditions requiring regular corticosteroidslsT-18s should be sent













2.4.2 Current recommendations for identifvinq patients to refer for bone
densitometrv
Table 24 - Summary of guidelines for identifying patients to refer for bone
densitomet
The recommendations of the evidence-based guidelines listed above can be
summarised as recommending that patients should undergo screening DXA if they
have "risk factors" for low bone density, or receive daily oral corticosteroids.
However, there is no consensus as to what constitutes a "risk factor" for low bone
density, and the NIH guidelinesls6 are very vague about their recommendations
about what constitutes a "high risk' condition for low BMD. Also, the evidence basis
of many of the guidelines is informal, with some not using in-text citations to
reference articles, instead listing references atthe end in a bibliography,tuu'tuo leaving
the reader unsure of the origin of the supporting evidence for their recommendations.
The action(s) recommended by the guidelines in Table 24 (lhal people at increased





Consider DXA - asthmatics taking >800 mg/day
beclomethasone dipropionate (or equivalent)
Recommend DXA - daily OCS for 4 weeks or
more OR 4 week-lonq courses of OCS in '1 Vear
Panel of
a llerqists/imm u nolooists
(literäture review¡ 18r
taking >7.5m9/day OCS for > 6 monthsPatients taking
corticosteroids







Rheumatology Task Force on
Osteoporosis GuidelineslsT
Patients with non-traumatic fractures, or
commencing long term corticosteroid therapy
Recommend individualised approach with
current evidence.
Consider D)(A in patients:
taking corticosteroids for >2 months, or who
have other conditions "high risk"









Population screening is inappropriate.
Bone densitometry only recommended for
people who would consider therapy if
appropriate. Recommend DXA as part of
patient care rather than screening.
Recommend DXA for high risk groups who can
obtain Medicare rebate'", or low body weight,
low calcium intake, minimal physical activity,
family history of osteoporosis, falls
Australian Fracture Prevention
Summitl83
Women over 65; minimal trauma fracture >40
years; family history of fracture; current cigarette
smoking; weight <57.6 kg; used HRT for
prolonged periods
Bone densitometry only recommended for








should receive treatment to increase their BMD) are in sharp contrast to what is
occurring in clinical practice. BMD tests had taken place in an estimated 16-31% of
patients receiving daily oral corticosteroids,l66'1se'164'16s and up lo 27% in patients with
minimal trauma wrist fracturesl6T whereas the guidelines would have recommended
that all patients taking OCS for 1-6 months should have a DXA.r86'188'18e A time lag
between the publication of research findings and the implementation of the research
into clinical practice is unlikely to account for the discrepancy, given the recent nature
of these studies. 1s8-1 67
Conclusion
The guidelines listed in Table 24 correctly identify patients at high risk of osteoporotic
fractures and low BMD. However, the actions they recommend are inconsistent. ln
addition, the approach of "case finding" by individual physicians implicit in these




243 Svstematicanoroaches to icJentifvino oatients at hioh risk of low BMD
A more systematic approach using pre-screening techniques to separate those at
high and low risk of having low BMD has been suggested. This would complement
existing "case-finding" strategies by physicians by identifying higher-risk populations
to whom screening could be targeted.
Pre-screening questionnaires such as the Simple Calculated Osteoporosis Risk
Estimation (SCORE)1eo in Table 25 combine a short-list of known risk factors for low
bone density into.a questionnaire that can be easily and quickly completed by either
patient or clinician from readily available information. lf the patient has a score above
a pre-determined threshold (the authors recommend >6), then the patient is
recommended to have bone densitometry. The SCORE questionnaire has been well
validated with sensitivity of 88-99% and specificity of 12-519/01s0-1ss (See Table 27).
Table 25 - Scori for SGORE
t Women with SCORE>6 would be selected for densitometry
See examples
The Osteoporosis Risk Assessment lnstrument (ORAI)1e6 ¡s a similar type of pre-
screening questionnaire to SCORE, but without the risk factors race, rheumatoid
arthritis, or fracture history (See Table 26).
Table 26 - Scori s for the ORAI
Current estrogen use
f Women with a ORAI> 9 would be selected for bone densitometry
See examples
s For example, a 70kg (=1541b), 70 year old white woman without rheumatoid arthritis, who had not
had a fracture after age 45, and was taking oestrogen, would be recommended for densitometry as














For EACH type of fracture (wrist, rib, hip) of non-
traumatic fracture after age 45 (Maximum score=12)
Times first digit of age in years
lf NEVER received estrogen therapy


























ORAI has not been as well validated as SCORE, and has lower reported levels of
sensitivity (S0-89%) but similar ranges of specificily (32-48%¡re6'1s5 (See Table 27).
Cadarette et al.1e5 assessed the diagnostic properties of 4 decision rules -
SCOREIso, ORAI'nu, ABONEle7, and body weight <70kg,1e8 plus the WHO definitions
of osteoporosis and osteopenia.l2 They found that the area under the receiver
operating characteristic (ROC) curve was greatest using SCORE and ORAI, and at
90% sensitivity, SCORE had slightly better specificity than ORAI for this population
(SCORE specificity -5O%; ORAI specificity -35o/o), and therefore of the tests
developed so far, SCORE is the best at discriminating patients with and without low
BMD.
Sensitivity and specificity of the published studies that have used SCORE are
tabulated inTable 27.
s The woman described on the previous page who would be selected for densitometry using SCORE
would also be selected fordensitometry using ORAI (70 years of age, currently using oestrogen,
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lf studies with sensitivity >90% are considered, the corresponding specificity of
SCORE is 13-51%, with 2O-55o/o of patients able to be excluded from densitometry.
Many non-SCORE questionnaires did not reach the target 90% sensitivity usually
aimed for in screening toolsre0 which minimises the number of people whose low
BMD was not identified by the test. The non-SCORE questionnaires that did have
sensitivity over 90% had corresponding specificity of 30-45%, with 1O-33o/o of
patients being able to be excluded from densitometry (Table 24). Therefore, at high
sensitivity, specificity of these pre-screening questionnaires is poor, with many
participants with normal BMD recommended for screening DXA. Receiving a
recommendation for densitometry may result in significant societal burden. This
includes increased anxiety in women recommended for DXA, as they consider the
possibility of an abnormal result; and also for the funding body who finances the
DXA's, as many tests will be performed on women who do not benefit from the
intervention.
However, even though these screening tools only reduce the number of women
referred for densitometry by 10-33%, these screening tools may prove to be a cost-
effective addition to bone densitometry. Using SCORE as a pre-screening tool prior
to DXA in one study reduced the number of patients who required densitometry by
21%. They did this by eliminating those with SCORE<6 and giving densitometry only
to those with SCORE>6. This reduced the cost per patient by US$38 (or 19%), while
trading off only 2o/o in sensitivity (84% sensitivity) to give DXA (of the radius as well
as hip and spine) to all patients, and 82%o sensitivity to give hip and spine DXA to
those with SCOREt6).
Few risk factors relevant to COPD-specific factors were explored in the studies
summarised in Table 27 and Table 28. One explanation may be that many of the
screening tools used l-scores (standardised to the young adult mean), making the
inclusion of age-related risk factors over disease-specific factors more likely. Also,
the populations in which the tools were developed were otherwise healthy
postmenopausal women, with very low or zero prevalence of asthma or COPD
However, prevalence of rheumatoid arthritis was high (5-24%) in the cohorts of the
initial SCORE study,ls0 as one of the source groups of the study was rheumatology
outpatients, and this may have contributed to the presence of rheumatoid arthritis
being selected as one of the components of SCORE. Presence of "rheumatoid
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arthritis" is confounded by many variables, such as cortícosteroid intake, or reduced
mobility levels. The inclusion of this factor is relevant for future risk factor studies in
respiratory patients because of many similarities in these confounders between
respiratory and rheumatology patients.
Conclusion
Evidence-based systemic approaches to identifying high-risk subgroups for low BMD
prior to densitomêtry have been investigated. Most non-SCORE questionnaires did
not reach the target of 90% sensitivity, but SCORE validations did in most
populations studied. These screening tools may prove to be a cost-effective addition





. Low bone density causes sufficient mortality and morbidity because of its'
association with fractures to warrant routine screening since the magnitude of the
problem is large, both in the general population and also in people with asthma
and ainvays disease.
. Early treatment for low bone density during the pre-fracture phase of the condition
is effective in preventing or reducing morbidity and mortality, which have been
studied in and are available to patients with asthma or airways disease.
. Screening DXA's are widely available, reasonably inexpensive, safe and
acceptable to patients for diagnosing low bone density
. Evidence based, systemic approaches to identifying high-risk subgroups for low
bone density prior to densitometry have been investigated, and these screening
tools may prove to be cost-effective additions to densitometry.
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Chapter 3 Methodotogy of the development of a risk factor
analysis to develop a screening tool to identify patients with
respiratory disease who are at increased risk of low bone density
3.1 Recruiting
We collected data from patients according to the flow chart in Figure 2. Patients
were recruited from metropolitan hospitals (outpatients and inpatients), and from
general practices and the community in general. People who met the criteria of the
pre-screening questionnaire (see also Table 32 and Appendix 2) were contacted, and
if they were willing to participate in the study and did not meet any of the exclusion
criteria, they were booked for densitometry. At the time of their densitometry, some
patients were asked questions about their health (Screening questionnaire - See
Table 33 for study factors, and Appendix 3 for the original questionnaire). The data
from this questionnaire have been analysed in a multivariate logistic regression to
determine risk factors for predicting which people have low age- and gender-matched
BMD (Z<-1.5). People who had low BMD (either low age- and gender-matched BMD
(2.-1.5) or low BMD compared to young adults (T<-2.5)), were eligible to participate
in a randomised controlled trial of daily alendronate (10m9) versus placebo, with
calcium supplements for one year. The randomised controlled trial will not be
discussed as part of this thesis.
The data collected using the screening questionnaire was used to test hypothesis 1:
Hvpothesis 1:
Patients with "low" (2.-1.5) or "not low" (Zr-1.5) BMD (matched for age and gender)
at either total femur or neck of femur or lumbar spine differ significantly for one or
more risk factors ior low bone density using an X2 test for categorical variables, or
logistic regression for continuous variables
This hypothesis investigates Aim 1, which is:
"To investigate whether suggested risk factors predict low bone density in people
with asthmaiairways disease by studying a large cohort of "at risk" subjects
(See also Chapter 1.3 Project aims and hypotheses).
All patients completed the pre-screening questionnaire. The screening questionnaire
was a composite of the baseline RCT questionnaire and the pre-screening
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questionnaire, designed to gain maximum information in a limited period of time
(whilst the patíent was in the waiting room for densítometry). There was some








Figure 2 - Flow chart of recruiting steps in the "Osteoporosis fracture
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BELOW
. Women aged over 50 (2)
. Respiratory admission in last 5
years (2)
. Bone fracture after age 40 (21
. Light for height (BMl <18) (1)
. FEVr <75o/o predicted (1)
. FEVr <50% predicted (2)
. Exercise tolerance < 300m (1)
. Exercise tolerance < 100m (2)
¡ >3 courses oral prednisolone in last
2 years (21
. High dose inhaled steroids (1500¡rg
becloforte) for >2 years (1)




The following recruiting pools were utilised (See Figure 3):
. Respiratory outpatients (public and private) at
ÞThe Queen Elizabeth Hospital
ÞLyell McEwin Health Service
ÞRoyal Adelaide Hospital
. Patients presenting for pulmonary function tests at the Lyell McEwin Health
Service
. Inpatients discharged from the above hospitals (identified retrospectively)
. lnpatients interred in the Lyell McEwin Health Service or The Queen Elizabeth
Hospital with asthma, emphysema, chronic bronchitis or COPD
. Patients participating in the Western Respiratory Health Plus Coordinated Care
Trial
. Adelaide Western Division of General Practice
. Media (Messenger Press 1999; "The Pulse" 1999, 2000; Radio SDN and sAN)
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Figure 3 - Summary of patient recruiting sources
Recruiting through these sources took two general paths
3.2.1 Outpatients
Over 1999-2000 potential participants' hospital case notes read to ascertain study
el i gi bility, completed pre-screening questionnai re if patient considered el ig ibl e
Clinicians discussed study with patients at outpatient consultation, and indicated patient
willingness to participate to study researchers. Patients who were still eligible and
willing were phoned regarding study, then booked for densitometry.
3.2.2 lnpatients.
3.2.2.1 Retrospective inpatients (lT run)
lnformation obtained from central hospital databases regarding patients discharged over
1997-2OO1 with nominated ICD-9 and ICD-10 codes for chronic bronchitis, emphysema,
chronic airway obstruction, respiratory failure, and asthma.
ICD-9 codes
491.1 Mucopurual chronic bronchitis



































Chronic airway obstruction, not elsewhere classified
Bronchitis, not specified as acute or chronic
Respiratory failure
Extrinsic asthma without status asthmaticus
Extrinsic asthma with status asthmaticus
lntrinsic asthma without status asthmaticus
lntrinsic asthma with status asthmaticus
COAD/asthma without status asthmaticus
COAD/asthma with status asthmaticus
Standard asthma without status asthmaticus




J4O Bronchitis, not specified as acute or chronic
J41.0 Simple chronic bronchitis
J41.1 Mucopurulent chronic bronchitis
J42 Unspecified chronic bronchitis
J43.8 Other emphysema
J43.9 Emphysema, unspecified
J44.O COPD with acute lower respiratory infection
J44.1 COPD with acute exacerbation, unspecified
J44.8 Other specified COPD
J44.9 Chronic ainarays obstruction, not elsewhere classified
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J451 lntrinsic asthma without status asthmaticus
J45.9 Standard asthma without status asthmaticus
J46 Status asthmaticus
J69.9 Respiratory failure unspecified.
J96.0 Acute resPiratory failure
J96.1 Chronic respiratory failure
J96.9 Respiratory failure, unspecified
Details of potentially suitable patients obtained from information technology lists of
patients who discharged from each hospital over a given time frame (ranging from
1997 to present) with any of the above ICD codes as the primary diagnosis. Hospital
case notes were read to ascertain study eligibility, and a pre-screening questionnaire
was completed if the patient was considered suitable for the study. Potential
participants' were sent a letter signed by the admitting consultant inviting them to
have a BMD test.
Letters were sent in accordance with the approach listed in Phase 1 or Phase 2 (see
below). Recruiting was altered from Phase 1 style to Phase 2 style to allow more
streamlined recruiting based on the patient response achieved.
Phase 1: One letter was sent, and if no response was received, potential recruits
received a follow up phone call from the doctor's staff inviting them to have a BMD
test.
Phase 2'. One letter was sent, and if no response was received, a photocopy of the
original letter was sent. lf no response was received, no further action was taken.
Patients responded by returning consent slips sent with the original letters or
contacted us by telephone indicating whether they were willing to participate.
Patients were booked for BMD tests if this was appropriate.
Patients presenting for pulmonary function fesfs had notes read as for outpatients,
and then had letters as for inpatients.
Recruiting began at each hospital at different times (first at The Queen Elizabeth
Hospital, then the Lyell McEwin Health Service, and finally the Royal Adelaide
Hospital). More patients were in the earlier stages of recruiting at the Royal Adelaide
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Hospital than at the other two hospitals. The numbers in the flow charts reflect this,
with fewer people having undergone densitometry responses received from fewer
people at the Royal Adelaide Hospital compared to the other two hospitals. A large
proportion of patients from all three hospitals was not interested in the study (15-
2BYo).
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Notes were read on site at wards at The Queen Elizabeth Hospital and the Lyell
McEwin Health Service and then had letters sent to them as for retrospective
inpatients.
Participants in the Western Respiratory Health Plus Coordinated Care Trialwere
recruited in 1999 in a similar manner lo retrospective inpatients except that only one
letter was sent out and patients who did not respond were not followed up due to
ethics restrictions.
Patients recruited through the l4lesfern Division of General Practice were recruited
through computerised lists generated by eleven General Practitioners in the Adelaide
Western Division of General Practice in 2000. Patients who indicated interest in the
study were then contacted in a similar manner lo retrospective inpatients with letters
signed by individual GP's. No follow-up calls were made if patients did not respond
to letters.
Patients recruited through media were volunteers who contacted us following media
coverage of the study. lf they were suitable we booked them in for a BMD test.
3.2.3 Generalisabilitv of results
Comparisons between the patients whose screening questionnaires are presented as
part of this thesis, and non-responders are presented below. This is equivalent to the
"not interested" and "no response" arms of Figure 4 to Figure 6 on pages 79-8'1, and
excludes those who we had not yet contacted about the study, and those who had
missing data for age or gender.
Table 29 - Age and gender of participants completing screening questionnaire
co d to "non ders"
P=0.36Binary test of propofiíons
p=0.44p=0.0725One sample t-test
64+1 068+8"Non-responders" 202 (55%)161 (44o/o)






Table 30 - Recruitin source of nts and "non-responders"
Table 31 - Reasons for non artici ation ass lied "non-responders"
From the above data, it appears that study participants and "non-responders" are not
significantly different in ages or in proportions of men to women (Table 30). Of those
not participating, more were inpatients, and fewer were from general practice (Table
30) Most of the people citing a reason for non-participation said they were not
interested or too sick to participate, although nearly a third of non-responders either
did not cite a reason or did not reply to our letters (Table 31). Therefore, people who
completed the study questionnaire were representative of the overall population in
terms of age and gender, but were potentially less sick and therefore lower risk than
the group we targeted overall.
3.3 lnclusion criteria for screening DXA
Men and women with asthma, emphysema, COPD or chronic bronchitis were eligible
to participate. Different types of ainruays obstruction were not separated, due to well-
documented difficulties in distinguishing between different types of breathing deficits
in epidemiological studies.lss FEVr was used in preference to any attempt to
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more objective and provides more relevant information on lung function in any given
subject.2oo
The age range of study participants was limited to 45-80 to enable future cost-
effectiveness studies on this study population. Patients aged under the lower age
limit (45 years) were considered to be a low risk population for low bone density,
based on literature evidence suggesting that treatment needs to be targeted to higher
risk populations to maximise cost-effectiveness.20l Patients over the upper limit (80
years) were excluded as a high mortality rate was expected in this group, related
both to advancing age and presence of respiratory disease.2o2
Patients needed to score 5 or more on our "pre-screening questionnaire" (See Table
32 and Figure 2) of risk factors for low BMD to be eligible for our study. This enabled
us to select a sample of people who had a medium to high risk of having low bone
density compared to the general population. Heterogeneity exists within the sample,
and this is vital to allow us to find factors that effectively differentiate between
patients at high and low risk of having low bone density.
Risk factors and associated weights were chosen from the literature.a'71'65'88'ee'70'200
Chosen risk factors are listed below and also on the flow chart listed in Figure 2. The
questionnaire layout used in the study is in Appendix 2 - Pre-screening
questionnaire.
Table 32 - Pre-screeni estionnaire
. Women aged over 50
. Respiratory admission in last 5 years
. Bone fracture after age 40
. Light for height (BMl <18)
. FEVr
- low (<75%)
- very low (<75%)
. Exercise tolerance
- limited (able to walk <300m unaided)
- very limited (able to walk < 100m unaided)
. >3 courses of prednisolone in the last 2 years
. High doses of inhaled corticosteroids (>1.5 mg beclomethasone or
equivalent) daily for at least 2 years




















3.4 Exclusion criteria for patients to have screening DXA
ndications for
a Unable to lie on BMD table
s for alendronate t
(Developed from the MIMS annual2o3¡
Unable to sit upright for 30 mins or more
Not be pregnant or likely to become pregnant for 12 months
Moderate to severe renal impairment
Symptomatic oesophageal reflux
Active gastritis or ulcers of stomach or oesophagus, or oesophageal
achalasia, dysphagia, oesophageal stricture
Taking Losec, Somac or Zoton for gastro-oesophageal reflux
Ever diagnosed with Paget's disease
3.4.3 Contraindications for randomised controlled trial
Previously taken alendronate or etidronate
lnability to give informed consent
Life expectancy not exceeding 2 years








3.5 Sampling frame for patients receiving screening questionnaire
The patients who were interviewed were a convenience sample of patients
presenting for densitometry. We interviewed patients attending every second or third
weekly densitometry clinic from 19/6/1999 lo 41512000 and then every patient where
possible from 1 0l5l2OOO lo 2410112001. Overall, the sample included 239 patients
with bone density tests dating from 19 June 1999 lo 24 January 2001 .
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3.6 Screening questionnaire study factors
The questions asked as part of the investigation of Hypothesis 1 are listed in Table
33, and in their context on the original questionnaire in Appendix 3 - Screening
questionnaire.
The screening questionnaire was a composite of the baseline RCT questionnaire and
the pre-screening questionnaire (See Figure 2), and was designed to gain maximum
information in the limited period of time that patients were waiting for densitometry.
There was some overlap of patients completing the baseline RCT questionnaire and
the screening questionnaire, but there were many patients who completed a
screening questionnaire who had normal bone density who were not eligible for the
randomised controlled trial of alendronate.

























Daily use of inhaled corticosteroids (lCS)
Daily ICS dose (raw dose)
Daily ICS dose (categories of doses)
Daily use of oral corticosteroids
Current use:Current use:
Courses of OCS in last 2 years - any/none
Number of OCS courses in last 2 years
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3.7 Methodology of measurement of study factors
3.7.1 lntroduction
Responses to study factors 1 lo 4,8-25 and 27-31 were determined from a
questionnaire-based interview of the patient plus individual spirometry (Study factor
26). No attempt was made to objectively verify patient information eg medication
dosage or name, patient compliance of medications etc. This was because the
purpose of this study was to develop a screening tool for use by clinicians to aid in
identifying patients who would benefit from bone densitometry rather than quantifying
the exact nature of relationships between bone density and epidemiological risk
factors for low bone density.
Study factors 5-7 consisted of data routinely collected by the bone density operator.
The interview was conducted primarily at the time of the bone density test. Results
from questionnaire-based interviews from the first visit for the randomised controlled
trial were also utilised provided the time of the bone density test was within the time
window described in the sampling frame (Section 2.2), and there was not more than
12 weeks between bone density test and interview. Additional patients who had
completed a bone density test during the time window described in the sampling
frame were interviewed up to 6 months following the bone density test. Follow-up
telephone calls were made to participants if any missing data was identified during
the data entry phase of the studY.
Further discussion of the methodology of measuring study factors 5-7,9-19,24-26,
and 28-31 is as follows:
3 7 2 Studv 5-7 - heioht. weioht. and bodv mass index
Standing height was measured without shoes, and weight was calculated with the
subject wearing regular outdoor clothes. The bone density operator used the same
equipment to measure each patient's height and weight.
Body mass index (BMl) was calculated using Quetelet's index:116
BMI= Weioht (ko)
tH"iiht(rÐÏ'
Quetelet's index is a reliable and valid indicator of obesity that was developed in a
hospital obesity outpatient clinic, and is widely used as an indicator of obesity.
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The categories developed by Garrow & Webster, ''!98511u were used for normal
weight and obesity. "Underweight" is classified as <1 8.5.204 However, in our actual
analysis we used a more conservative cutoff for "underweight" of <2O glcm2 which we
obtained from receiver operator characteristic curves in the multivariate analysis (See
Chapter 4.6.6 on page 117 and Table 34).
Table 34 - Number of artici nts in BMI
3.7.3 Studv factors I - cioarette consumotion lamount and duration) in "pack
VEATS,,
Cigarette consumption was calculated using "pack years". lt was assumed that 20
cigarettes equalled one pack. This was calculated as follows:
Pack years has been used by other authors to assess smoking consumption,sT and
we consider this technique to be more informative than using "current", "former" or
,, evef', SmOked. 60,7 4,205,88,72,66,65,62.
3.7 .4 Studv factor 10 - Maternal fractures
"Maternal fractures" was defined as any fracture the participants' mother sustained
after age 40 obtained under any circumstance. Responses were coded as "yes" or
"no" or "don't know". Participants were encouraged to answer "rìo" if they did not
recall any fractures in their mother after age 4O rather than list responses as "Don't
knov/'. These were reserved for instances in which participants genuinely could not
or did not know whether their mother sustained a fracture after age 40, such as if
patients were adopted and did not know their birth family.
3.7.5 Studv factor 11 -Fraclures since aqe 40
The site at which the fracture occurred was recorded, as reported by the patient.






















BMI Number of patients in our sample with this BMI
(N=239)
Label
ack Number of c smoked rda x Number of rS SMOrs=
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3.7.6 Studv factors 12-17 and28-31- Current medications
Participants were asked to bring a list of current medications as a memory aid. Use
of listed medications was recorded and for analysis purposes was collected as a
binary yes/no variable (without taking into account daily dosage).
3.7.7 Studv factors 18-19 - Ever use of diuretics
Diuretics were separated into two categories - "loop" eg frusemide and "thiazides" eg
hydrene. These types of diuretics are known to have different effects on bone
density. Low dose hydrochlorothiazides have been shown to preserve BMD even in
normotensive adults.'ou Ever use of loop and thiazide diuretics was determined from
patient recall of any diuretics ("fluid tablets") ever regularly prescribed for the patient
in question. Reasonable efforts were made to determine the identity of tablets where
the patient was unsure by cross-referencing with MIMS'o" for tablet colour, shape, or
recalled fragment of drug name.
3.7.8 Studv factor 20-22 - Number of of oral corticosteroids in the last 2
VEATS
When the number of courses of oral corticosteroids taken in the last two years was
transformed into categorical data, the categories used were: O', 1-4;5-8; >9 courses.
We only asked about corticosteroid usage in the last two years. Therefore, if
participants have changed their OCS usage over time, this will be missed. This could
be important, as bone loss occurs most when use of corticosteroids in high doses
begins.207 However, collecting more detailed information about past corticosteroid
intake does not predict low BMD,208 and therefore we have elected to ask about
booster courses of OCS in the last two years only.
3.7.9 Studv factor 24 - Exercise tolerance
Three levels of exercise tolerance (unaided on a flat surface)were created using this
variable - either <100 m, 100-300m, or >300m. This was estimated by the
participant and was not externally validated.
3.7 .10 Studv factor 25 - Baecke Leisure Score
The questionnaire by Baecke et al.20e was considered suitable for measuring activity
in leisure time in this study. It is reliable, as assessed by good test-retest correlations
of 0.74 for leisure-time activity in the original study;20e and has previously been used
in a cross-sectional study of community dwelling asthmatics which investigated the
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association of beclomethasone dipropionate and other lifestyle factors with bone
density eg physical activity.2oo
Leisure score was calculated from non-sport leisure questions as per Baecke et al.2oe
and referred to current activity only (last 5 years). Non-sport leisure questions were
chosen above the other indices in Baecke et al.2oe (occupational activity and sport
leisure index) as non-sport leisure had the highest association with bone density in
the cross sectional study mentioned above.200
Slight modifications were made to the original non-sport leisure questions for use in
this study.
ln asking the questions we changed the subject of the sentences because we were
administering the questionnaire to patients rather than them completing the
questionnaire themselves, eg:
"During leisure time / walk"
to
"During leisure time do you walk?"
We changed the wording in the questions:
"During leisure time I cycle"
and
"How many minutes do you walk and/or cycle per day to and from work, school and
shopping"
to
"During leisure time do you ride a bike"
and also
"How many minutes did you walk and/or ride a bike per day to and from work, or
shopping".
This was done to reflect Australian wordings for the action of bicycle riding.
We asked one question about sport activity in leisure time "During leisure time do you
play sport". We did not use this question in the analysis as the heterogeneity of




We also omitted references to "school" in the question "How many minutes do you
walk and/or ride a bike to and from work, school and shopping". Our cohort had
mean age of 6518 years (older than the Dutch cohort on which the original study was
based in which participants' ranged from 19-31 ). Therefore the vast majority of our
subjects were middle aged or elderly people who were too old to attend school.
Some may question whether the reliability and validity of the Baecke instrument can
be appropriately extrapolated to this study since our study population is significarrtly
older than the original Dutch cohort in which the Baecke questionnaire was
developed. Our cohort is also older than the study of community-dwelling asthmatics
where the average age of respondents is 45+14 years (110 female and 63 male),
compared to 65+7 for our study (139 women, 100 men). The advantage of the
Baecke questionnaire is that it has three indices that can be used separately. The
work, and particularly the sport index have limited relevance to this population, and in
the previous study of asthmatics they were not significantly associated with low
BMD.208 The non-sport leisure index included regular activities which should not be
limited by age per se, such as watching TV or walking, and as the questionnaire was
very short and therefore had the advantage of limited respondent burden.
3.7.11 Studv factor 26 -FEV j
Lung function was measured objectively using FEVr (forced expiratory volume in one
second), standardised to percent predicted for a patients age, gender and height.
The algorithms used for the study were the E.C.C.S210 which were pre-programmed
into the Microlab 3300 spirometer used for the study (Micro Medical Ltd, Kent,
England). The Microlab 3300 complies with the American Thoracic Society
recommendations for spirometer in terms of accuracy (+3o/o), manner of test
procedure (best of 3 reproducible tests with patient in a seated position),211 except
nose pegs were not used.
FEVr was preferred over other methods of assessing breathing restriction eg forced
vital capacity as FEVr is the best measure of disease stage and symptom severiTy."'
The same spirometer was used in 2221239 study participants. The remaining 17
people did not have spirometry tests done at the same time as the questionnaire.
Their FEVr scores were obtained from a variety of sources, and were not
administered by staff in our research team. These sources included The Queen
Elizabeth Hospital pulmonary function laboratory, and also various spirometry
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devices in outpatients at The Queen Elizabeth Hospital, the Lyell McEwin Health
Service, or the Royal Adelaide Hospital as recorded in the patient's hospital case
notes. FEVI values were only accepted for use in this analysis if the sourced values
were within t6 months of the screening questionnaire to minimise any change in the
lung function of study participants due to a change in the severity of their underlying
lung disease. The reproducibility of FEVr data obtained from spirometers in hospital
outpatient departments is unknown, and may not comply with ATS recommendations.
We expect that some inter-operator variation will have been present, as there were 5
spírometry operators as part of our research team, and numerous others not part of
our team (who performed lhe 17 tests we were able to obtain from other sources).
Whilst one investigator (myself, LL) trained the other four operators who were part of
our team, and observed their technique whilst they were first learning, to ensure that
our techniques were as similar as possible, we did not statistically analyse the
spirometry by operator to assess if there were any systematic differences in FEVl by
operator. However, in the final statistical analysis, we used FEVr only as a
categorical rather than continuous variable, and therefore the FEVr data would have
to have been misclassified in order to affect the final results.
3.7.12 Studv factor 28-30 - lnhaled corticosteroids
Daily dose of inhaled corticosteroids was recorded, and determined from dosage per
puff from metered dose inhalers and prescribed number of inhalations per day.
When the dose of inhaled corticosteroid was transformed into categorical data, the
categories used were 0; <1000 ¡rg; <2000 pg; >2000 pg. As seen in Table 35, of the
80% of our population taking inhaled corticosteroids, nearly half were taking FP
(46%), a third BDP (30%), and the remaining quarter BUD (23%).
Table 35 - lnhaled corticosteroid u name in our population
*80% of patients used inhaled codicosteroids (192/239)
Different ICS are known to have different effects - both in terms of altering








UsaqeName of inhaled corticosteroid
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systemic effects, such as suppression of bone turnover or adrenal-cortical function.
The following comparisons are available from the literature.
ln terms of clinical efficacy, FP is twice as potent as BUD in changing morning peak
flow,213 and is also more potent than BDP, although there is insufficient evidence to
determine the potency ralio.21a
ln terms of systemic effects, BDP is twice as potent as BUD in suppressing adreno-
cortical function,2lt but there is insufficient evidence to decide if there are differences
in the systemic effects of FP and BDP.21a There are differences not only between
different lCS, and also the method of delivery, with the FP Diskhaler more potent
than BUD Turbuhaler with a potency ratio of 1.7:1.0.216 The potency ratio between
FP and BUD measured dose inhalers is 3:1214 and the potency ratio between FP &
BUD dry powder inhalers is 1 .5:1 in adults. There is inadequate information to
calculate an accurate systemic effect ratio for BDP measured dose inhalers versus
BUD or FP.214
Therefore, we can conclude that the effects of ICS on the body vary both by ICS type
and dose, and by method of delivery eg measured dose inhaler versus dry powder
inhaler, and also by numerous other factors, such as spacer usage.'14 We did not
record the method of delivery or duration of use of the current or previous lCS, and
thus would have been unable to correctly calculate any potency ratios to give
different weighting to individual lCS. Also, many patients would have used other
types of ICS or different methods of delivery over the course of their disease, and so
to calculate any potency ratios accurately we would have needed to take these into
account also - leading to an immensely complex potency ratio which would be of
limited applicability to clinical practice.
Therefore, we have pooled all three ICS types used by our study subjects (FP, BUD
and BDP) for use in study factors 23-30.
3.8 Outcome factors
3.8.1 Bone densitv measurement bv DXA
Bone density was measured by a DXA (dual X-ray absorptiometry) using a Lunar
DPXprus machine (Lunar Radiation, Madison, Wl, U.S.A.) by trained bone density
technicians using the recommended methods of operations.2lT Scans were analysed
using Lunar DPX-lQ version 4.6b software and were undertaken at The Queen
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Elizabeth Hospital Department of Endocrinology. Daily quality assurance tests and
weekly scans of aluminium spine phantoms as supplied by the manufacturer were
performed to monitor system bias and precision. During a 51 week period in 2000,
the average of 51 weekly measurements from the densitometer used for our study
(using the Lunar spine phantom) gave a mean value of 1249.4t4.6 mg/cm2.21u This
standard deviation represents 0.36% of the mean value. No reference standard is
currently available for DXA.
3.8.2 Bone densitv sites
Bone density values at the lumbar spine (L2-L4),21e total femur, and neck of femur22o
were used. Bone density was standardised for age, race and gender to Z-scores. Z-
scores were then categorised as low (2.-1.5) or not low (Zr-1.5) bone density at any
one of the three sites measured. lf low bone density could not be accurately
assessed at a particular site for any reason, patients were allocated to either the
"low" (Z<-1.5) or "not low" (Zr-1.5) bone density groups based on the available data
at other sites. Fractures are best predicted by site-specific measurements,la ln
addition, hip BMD does predict "all" fractures a little better than spine BMD (RR of 1.6
(95% Cl 1.4 - 1.8) compared to 1.5 (95% Cl 1.4 - 1 7)) for 1SD decrease in BMD at
this site.la
Risk factors for low BMD may differ between sites, reflecting the structure of the bone
(cortical vs trabecular), and different types of mechanical loading on the bone, such
as physical activity. Therefore, it is possible that different risk factors will predict low
BMD at the spine and hip in our population. However, we have elected to pool the
sites in the first instance as we were aiming for a set of risk factors that could be used
as a clinical tool such as that in Figure 18 on page 1B2lo help physicians decide who
should be sent to, or excluded from densitometry. Additional analyses by site and
gender have also been provided following the analysis using data pooled by site and
gender.
n a bone den
Fracture risk increases exponentially with decreasing BMD,r5'18 and there is
considerable overlap in BMD values of groups with and without fractures.22l The
WHO definition of osteoporosis222 defines an arbitrary threshold defined primarily for
epidemiological purposes which includes the majority of people with osteoporotic
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fractures, and is confounded by such factors as variability between equipment, and
differing reference ranges between different skeletal sites and ethic groups. Given
that the WHO definition defines osteoporosis in terms of absolute risk relative to
young adults, it has become regular clinical practice to use l-scores to decide
whether to treat, with ß-2.5 the BMD cutoff below which treatment should begin, and
ß-1 the BMD cutoff below which prevention of future fractures should begin.223'224 Z-
scores are another method of assessing BMD, and are used primarily to assess age-
matched BMD, and thereby identify non age-related deficits in bone density. There is
less consensus about the best cutoff to use, as different guidelines,22a
bureaucracies,22s and authors226 use diflerent cutoffs (2.-1, Z <-1.5 and Z .-2).
There is no evidence base for the use of one cutoff over others.
We have chosen to use the cutoff o'n Z<-1.5 for further analysis.
There were two reasons for this'
1) Z<-1.5 is the bone density cutoff at which subsequent DXA's are subsidised by
Medicare every 24 months, at no cost to the consumer.l3
2) For pragmatic purposes, we required the best mix of low bone density with
sufficient numbers to run useful analyses. There were insufficient subjects who
had bone density of Z<-2.0 for further analysis (181239 - 8o/o), whereas 2Oo/" of
our sample had bone density of Z<-1.5 (491239). 6.68% of the reference
population have a Z-score of <-1.5.10
3.8.4 Other considerations reqardinq observed BMD in individual cases
Densitometry results could have been affected by unidentified crush fractures, and
spinal osteophytosis, both of which artificially elevate spine BMD, potentially
misclassifying the patient as non-osteoporotic. Therefore, the densitometry results of
all patients were manually double-checked to identify any scans that may have
contained undetected anomalies or discrepancies, and we further investigated
individual cases where patients Z-scores at spine, neck of femur or total femur
differed by two standard deviations or more (N=28).
Of these 28 patients, 4 patients had BMD Z-scores of >3 at the neck of femur, total
femur, or lumbar spine. Three of these patients had accessible case-notes at either
The Queen Elizabeth Hospital, Lyell McEwin Health Service, or the Royal Adelaide
Hospital. Casenotes of these three patients were read to ascertain if any diagnosis
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had been made which could explain their high Z-scores, particularly diagnoses
relating to study exclusion criteria that may have been overlooked when the patient
was recruited.
Following casenote inspection, no anomalies were found in two of the three patients
whose case notes could be sourced. The other patient (Unique lD 777) was
subsequently dropped from the analysis. His Z-scores were 5.61, 1.73,2.9 for the
lumbar spine, neck of femur and total femur respectively. We could find no diagnosis
which would explain his high Z-scores, especially that of his spine, which had a Z-
score of 5.61. We considered that such an event was unlikely to have occurred by
chance (p<0.00001) and therefore explainable by diffuse idiopathic skeletal
hyperostosis (DISH), or some other pathology unknown to us.
Spine densitometry results are routinely assessed to identify "crush" fractures (on the
basis of the scan), and suspicious vertebrae are omitted from the calculation of the
bone mineral density of the spine. Spinal osteophytosis is reported to affect up to
70% of the populalion,z2T but we were unable to assess the results or adjust for this
phenomenon, as we did not take X-rays as part of this study. Overall, Z-scores are
higher in the spine than either femur site in both sexes (Table 38), although the
shape of the curve was not significantly skewed, or the mean significantly different to
zero (Table 36). We would have expected BMD at the spine to be lower than the hip
due to preferential thinning of trabecular bone by corticosteroids, as the spine is
mostly trabecular bone whereas the hip has more cortical bone. However, despite
the above, diagnoses of "low BMD' is made in more cases by spinal BMD than
femoral BMD in women, with spine and femur equally good in men (See Table 37).
This is contrary to what would have been expected if spinal osteophytosis was
adversely affecting our results.
Conclusion
People with moderate to severe asthma, emphysema, COPD or chronic bronchitis
who had attended respiratory outpatients or had been hospitalised for their ainruays
disease at The Queen Elizabeth Hospital, the Lyell McEwin Health Service, or the
Royal Adelaide Hospital over 1999-2OO2 were targeted for the study. ln addition,
patients were sourced from a number of general practices in the Adelaide Western
Division of General Practice as well as a number of other sources. Patients who
scored more than 5 points on our pre-screening questionnaire and satisfied other
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inclusion and exclusion criteria were invited for densitometry, and completed a more
detailed questionnaire on their health (screening questionnaire). This data was used
to test Hypothesiê 1: that patients with "loÛ" (2.-1.5) or "not loW' (Zr-1.5) age- and
gender-matched BMD at either the neck of femur, total femur or lumbar spine differed
significantly for one or more risk factors for low BMD using a 12 test for categorical
variables, or logistic regression for continuous variables.
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Chapter 4 - Results of a r¡sk factor analys¡s to develop a screening
tool to identify patients with respiratory disease who are at
increased risk of low bone densit
Data collected using the screening questionnaire was analysed using logistic
regression, first one factor at a time (univariate), then a number of factors together
(multivariate) to generate a risk factor model to identify a high risk group for low BMD
4.1 Analyses
This analysis relates to Hypothesis 1 (Section 1.5, page 16) which is:
That patients with "low" (Z<-1.5) or "not low" (Zr-1.5) BMD (matched for age and
gender) at either total femur or neck of femur or lumbar spine differ significantly for
one or more risk factors for low bone density using an "1"2 test for categorical
variables, or logistic regression for continuous variables.
Analysis was performed using Stata 6.0 (Stata Corporation, USA).
4.1.1 Univariateanalvsis
Each risk factor was tested for association with the outcome factor using logistic
regression (variables with continuous data) o, x.' tests (variables with categorical or
binary data) at the significance level of a=O.25. This approach has been used in
studies that developed screening tools to identify patients with low BMD,1s0 with
similar cr levels. Variables found to be significantly associated with low BMD at
univariate level could therefore be considered to be independently associated with
low BMD.
4.1.2 Multivariateanalvsis
Risk factors which were significantly associated with the outcome variable at
univariate level were placed into a multiple stepwise regression model using forward
selection at the a=0.10 level. Goodness of fit of the model was calculated using the
Hosmer-Lemeshow 12 statistic. Sensitivity, specificity, positive predictive value,




were calculated at the probability level which corresponded most closely to a
sensitivity of 90% (86%). The logistic model was calculated for this probability cutoff,
thus generating the final screening model.
The number of patients in the final analysis was 239.
4.2 Patients with missing data at skeletal regions of interest
Seven of the 239 subjects did not have completed scans of the lumbar spine. One
patient did not have completed scans of the femur.
The 7 patients who did not have spine scans had girth of >28cm, and were therefore
unable to fit underneath the arm of the DXA machine. These seven patients were all
obese, with an average weight of 1 16t6kg and BMI of 41+ 2, compared to the
average BMI for the whole population of 27!ß. They had average femur Z-scores of
0.3t0.4 for neck of femur and 0.7+0.3 for the total femur.
The one patient who did not have a femur result had polio and was unable to be
appropriately positioned for the DXA scan. His spine Z-score was 2.5.
ln these 8 subjects low bone density could not be assessed at either the hip or spine.
Therefore, these patients were allocated to either the low (2.-1.5) or not low (Z>-1.5)




4.3 Bone density distribution of the sample
4.3.1 Shaoe and oosition of the bone dens itv distribution of our oooulation
As seen in Table 36, Z-scores for the sample of patient data studied in this research
were Normally distributed - in 3 out of 3 sites in men and 2 out of 3 sites measured in
women (skewed slightly to the left at the neck of femur). The mean was not
significantly dissimilar to zero for women, but the bone density of the men was
significantly different to zero in 2 out of 3 sites measured, with the mean BMD nearly
half a standard deviation below zero al the neck of femur.
Table 36 - Normal and ition of bone densi distribution in our sam le
f using the Shapiro-Wilk test for normality, using p<0.05
f using the one-sample t-test for x=0
Given the selection factors (Table 32 - Pre-screening questionnaire on page 84), we
expected that the mean BMD would be significantly less than zero in most of the
sites and both genders, whereas only one site is below zero, and this mean BMD is
higher than the 1SD decrease reported in earlier studies .22e Explanation for this
discrepancy include higher risk individuals not responding or being unwilling to
participate in the study (See section 3.2.3 Generalisability of results on page
82), overly generous weighting for some items, such as giving post-menopausal
women two points; and including risk factors which selected more for low l-scores
than low Z-scores, such as exercise tolerance. Factors such as these resulted in the
women in our sample having higher BMD than the men, and younger women having
lower Z-scores than older women. Another explanation is that the estimate of mean
BMD of Z=-1 overestimates deficits in BMD for people with moderate to severe
disease due to biases in study design such as over-sampling of higher-risk patients.
Conclusion
The bone density of women is Normally distributed at two sites, and is slightly
skewed to the left at the neck of femur, and the mean is below zero for men in only
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one the sites measured, and is approximately zero for men and women at the other
sites measured. Bone density of the men is Normally distributed at all three sites,
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4.3.2 Breakdown of patients with a diaqnosts of low bone densitv bv site
For the purposes of this study, we assessed whether our study patients had low BMD
(2.-1.5) at one or more of three anatomical sites (lumbar spine, neck of femur, and
total femur). Some patients will have low BMD at one site only, and others at more
than one site. The number of patients who have BMD below three Z-score cutoffs
(2.-1, Z<-1.5, Z<-2.O) at each anatomical site, by gender, are illustrated in the Venn
diagrams in Chapter 4.3.
These diagrams concur with the finding of Phillipov et al.23o - that measurement of
bone density at the lumbar spine is the best site for identifying women with low bone
density at the neck of femur or lumbar spine (87 .1% compared to 45. 1o/o al the neck
of femur), using T<-2.5 as the definition of low bone density. ln men, the lumbar
spine and the neck of femur are equally useful for detecting low bone density (69.3%
and 67 5% for the lumbar spine and neck of femur, respectively). While we used Z-
scores, we obtained similar results.
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LS (%) NoF (%)LS (%) NoF (%) rF (%)Bone
density
Women - measure two sites onlYWomen - measure three sites
LS = lumbar spine, NOF = neck of femur, TF = total femur
These findings are different to studies investigating site-specific BMD for fracture
prediction, where hip BMD was slightly better at predicting all fractures than spinal
BMD.14 However, these studies provide no ¡nformation on where these people have
low BMD - whether hip or spine or both.
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Includinq total femur - 48 PeoPle
with osteoporosis
31148 al spine=65%
18148 al neck of femur=37o/o
29148 al totalfemul=60%
Excludinq total femur - 39
people with osteoporosis
31/39 at sPine=79%
18/39 at neck of femur-46o/"
lncludinq total femur - 46 PeoPle
with osteoporosis
23146 al spine=50%
20146 al neck of femur=65%
2O146 al totalfemup65%
Excludinq total femur - 40
people with osteoPorosis
13140 al spine=58%
20140 al neck of femue75o/o



















lncludinq total femur - 23
people with osteoPorosis
15123 at sPine=65%
6l23al neck of femur26o/o
1 1 123 al lolal f emur= 47 o/o
Excludinq total femur - 17
people with osteoPorosis
15117 al spine=88%
6117 al neck of femur=3S7o
lncludinq total femur -26
people with osteoPorosis
14/26 al. sPine=53%
12126 al neck of femup46%
I 5126 al total femu r=57%
Excludinq total femur - 22
with osteoporosis
14122 al sPine=64%
12122 al neck of femur55%
Figure 13 - Diagnos¡s of low BMD (Z<'1'5) by site in men
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lncludinq total femur - 6
people with osteoporosis
5/6 at spine=Ù3o/o
1/6 at neck of femur=16%
2/6 at total femur=O%
Excludinq total femur - 6
people with osteoPorosis
(as above)
lncludinq total femur -12
people with osteoporosis
6112 al spine=50%
4112 aI neck of femur=33%
6112 al totalfemur50%
Excludinq total femur - 22
people with osteoPorosis
6/9 at spine=66%
4/9 at neck of femur=44o/o
Figure 15 - Diagnos¡s of low BMD lZ<-2.O1by site in men
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4.4 Baseline characteristics of study population
The baseline characteristics of our study population are listed in Table 38
441 Com oarison to "normal" pooulationsS
Our sample is middle aged, with more women than men (p<0.05), with similar BMD
to reference populations when matched for age and gender in the women, but lower
BMD in men (spine p=0.05, neck of femur p<0.0001, total femur p<0.01), compared
to reference populations.lo Both men and women were overweight for their height
(p<0.0001)116 and sedentary in their leisure time (p<0.001)20e compared to reference
populations.
442 Co sons between men and women
Men and women had different patterns of risk factors. We considered this to be an
artefact of the pre-screening questionnaire (See Table 32 on page 84, and Appendix
2), where men needed more risk factors to be eligible for the study. Men had lower
age- and gender-standardised BMD at the spine (p<0.05), neck of femur (p<0.01)
and total femur (p<0.01) than women. Men had poorer lung function (as measured
by FEVr % predicted) than women (p<0.001), and different underlying respiratory
illnesses. More women were asthmatics (p<0.001), and more men had emphysema
(p<0.001). No difference was found in the proportion of men and women with COPD
and chronic bronchitis (Note. respiratory illness was self-reported, and respondents
could choose more than one underlying illness). There were no significant
differences in the proportion of men and women taking daily oral corticosteroids,
theophylline, loop diuretics, calcitriol, warfarin, or daily dose of inhaled
corticosteroids. There were more women than men taking hormone replacement
therapy (p<0.001), calcium supplements (p<0.05), ever having used thiazide diuretics
(p<0.01), or daily thyroxine (p<0.01). Women were shorter (p<0.001) but heavier
(p<0.01), and had higher body mass index (p<0.05) than men. More men had ever
smoked cigarettes (p<0.0001), and men had higher overall cigarette consumption (in
pack years) (p<0.0001) than women.
s All comparisons in this section are one-sample t-tests
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Neck of femur BMD (mg/cm')
- neck of femur
- total femur
I-score - lumbar spine
- neck of femur
- totalfemur
% post-menopausal
Proportion with BMD Z<-1
Proportion with BMD Z<-1.5
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Table 38 - Baseline characteristics of stu o lation
British Thoracic Society guid
82.232 Mean
elines (FEV1 % pred
fBaecke et a\.19 activity levels 2.8+0.1 (women), 3.1+0.0 (men), p<0.01 for our
population. s "Normal" BMI22.5 116, p<0.001 for our population
Chapter 4
" lncludes use of testosterone replacementtherapy
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4.5 Association between low bone density and individual risk factors
We used logistic regression for testing the association between low BMD and
individual risk factors, because our outcome variable (low or not low BMD) was
binary.
While men and women in our study had slightly different patterns of risk factors at
baseline (See Chapter 4.4 and Table 38), we chose not to analyse male and female
cohorts separately, because we did not expect our sample size to be large enough to
enable us to investigate all of the factors in which we were interested.
Advancing age was associated with higher age-standardised BMD. We consider this
to be an artefact of the selection of patients via the pre-screening questionnaire. To
be eligible for the study, younger people needed to have more severe disease than
older patients. As discussed in the previous section, women had higher Z-scores
than men. Therefore, female gender as associated with decreased incidence of low
BMD at all three cutoffs listed (2.-1.O, Z<-1.5, Z<-2.O). As expected, decreasing
weight and low body mass index were significantly associated with low BMD.
Ever smoking was not associated with low BMD (the prevalence of ever-smoking was
high in both groups), but increasing amount of pack years smoked was associated
with low BMD in lhe Z<-1.0 and Z<-1.5 groups.
Use of medications for preventing or slowing bone loss, such as hormone
replacement therapy, calcitriol, and calcium supplements were associated with low
BMD in some Z-score groups. We observed that these medications were often
prescribed to people who had a prior diagnosis of low BMD or were considered to be
high risk of developing low BMD by their physicians, although we did not record
whether or not people had a prior diagnosis of low bone density or not.
The number of booster courses of OCS was also related to low BMD - whether they
had any or no courses of OCS with BMD Z<-2.O, the total number of courses with Z<-
1.0 and the number of courses (split into categories) with Z<2.O. The direction of
effect for two of the three variables with low BMD at Z<-2.O, is the opposite of what
would be expected from previous research, with higher number of OCS courses
associated with high BMD. The best explanation for this is that there were very few
numbers of people wllh Z<-2.0, so a few spurious results related to the small sample
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size are to be expected, and that the association of total number of courses with
bone density Z<-1.0 is only just significant according to our criteria (p<0.25).
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Table 3g - Univariate associations between low BMD and selected risk factors
in men and womens
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S Positive (+) eflect direction indicates that the presence of the factor is associated with low BMD eg
people who smoked cigarettes for a large number of pack years are more likely to have BMD Z<-1.5
than those who smoked for fewer pack years. Negative (-) effect direction indicates that the absence
of the factor is associated with low BMD eg patients NOT taking thiazides are more likely to have BMD
Z<-1.5 than those who have taken thiazides.
. 
Females had higher BMD
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4.6 Muttívariate analysis for bone density cutoff of Z<-1-5
Knowing that an individual risk factor is associated with low BMD has merit-
However, some risk factors will be more strongly associated with low BMD than
others, and some risk factors will measure similar things - and therefore will be co-
linear. Therefore, identifying a group of risk factors that will predict low BMD when
considered together will predict low BMD more accurately than individual risk factors,
and will use the least number of risk factors by adjusting for strength of association
and co-linearity. This requires multivariate analysis, and the process and results of
the multiple logistic regression are discussed next.
4.6.1 Itivariate looistic reqression
Variables that had an association with low BMD (2.-1.5) of p<O.25 ("ticked" (/) in
Table 39) were included in the multivariate model. This approach was used because
it reduced the number of factors entering the multivariate analysis, whilst still
including factors with some association with low BMD into the analysis.




"Current use of calcitriol"
"ever use of thiazide diuretics"
. "weight"
This leaves the variables gender, BMI<20, >80 pack years smoked, maintenance
OCS usage, ICS daily dosage, exercise tolerance, Baecke Leisure score, FEVI %
predicted (separated into BTS groups), current use of hormone replacement therapy,
current use of warfarin, fractures of the ribs or spine.
The reasons why these variables were not included are described as follows:
4.6.2 Current use of calcitriol
We chose not to include "Current use of calcitriol" in the multivariate analysis as it
indicaied that a patient was already being treated for low bone density. This
argument is also appropriate for current use of hormone replacement therapy and
calcium tablets, but not thiazide diuretics because thiazides are not used as a
therapy for osteoporosis, nor was their effect on BMD widely recognised at the time
this study was undertaken.
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While we did not specifically ask whether or not individual patients had already been
diagnosed as having low BMD, people are only able to obtain calcitriol via an
authority prescription if the person has a demonstrated osteoporotic fracture.203
While patients who have already had an osteoporotic fracture probably have low
BMD, the purpose of our analysis was to develop a screening tool to find people at
risk of having undiagnosed low bone density rather than finding patients already
known to have low BMD.
4 6 3 Ever use of thiazide diuretics
Thiazides are medications prescribed primarily for hypertension. "Ever use" of
thiazide diuretics was significantly associated with low BMD in the univariate
analysis, but was omitted from the multivariate analysis due to "estimability". This is
because patients who had "eve/' taken thiazide diuretics or when ever-consumption
of thiazides were "unknown" were all in the non-osteoporotic group at Z<-1.5 (See
Table 40), and therefore Stata was unable to utilise this factor in the multivariate
model. This was unfortunate, because thiazides are known to preserve low BMD in
normotensive subjects randomised to thiazide treatment,206 and to reduce hip
fracture risk by around 30% in cohort studies of thiazide users.2tt''34
Table 40 - Ever use of thiazide diuretics for pañicipants with low (Z<-1.5) and
not-low -1.5 bone dens
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4.6.4 Bodv size parameters
BMI was chosen in preference to weight as we considered that it provided more
information on body build than weight alone.
However, there are additional considerations of interest surrounding the risk factor
"weight" which will also be discussed.
4 6 5 Further considerations reoardinq "weiqht"
Adjustment for weight is made in the Z-score calculations for DXA to correct for
technical errors in the calculation of the BMD values related to soft tissue effects in
the reference population (higher weight is associated with higher BMD and vice
versa). These equations are as follows and are applied for weights 25-100 kg.
N.B. No-one in our sample had weight below 25k9, and 13 patients had weight above
1OOkg (13/39=5.4%), with the heaviest weight of any subject being 135k9.
Table 41 - tre ression for reference femalesro
Evidently the adjustment made to Z-scores to standardise weight is only slight.
However, weight must have an effect over and above technical considerations
because weight survived to the multivariate analysis in our study population.
One possible reason for this is that the population studied by us is sufficiently
dissimilar to the reference population.
The reference population were white ambulatory subjects from the general
population who were free from chronic diseases affecting bone (like asthma), and
were not taking rnedications known to influence bone density (eg corticosteroids,
thyroxine, estrogen). This would have excluded the vast majority of participants in
our study sample. Therefore, our sample is likely to differ in a number of ways.
Examples include:
. 80% of sample were currently taking corticosteroids
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Neck of femur o.28BMD=0.670 + (0.003x Weight)
Anterior-posterior spi ne BMD=0.845 + (0.004 x Weight) 0.14
Site rReoression equation
a 8.8% of sample were currently taking thyroxine
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. Mean BMI significantly differentfrom "normal" BMI as per original researchll6
(See Table 42)
. Mean leisure scores were significantly different from the original cohort2oe (See
Table 43), although the original cohort were young Dutch men and women aged
19-31, not older Australians (mean age of our sample 65+8 years).
The weight and activity levels of people in the general population of all ages may
have changed since the early 1980's when the research by Garrow et al and Baecke
ef a/ were published .116'2oe This has not been taken into account when comparing
our population to.the reference population.
Tabf e 42 - Mean BMI for our sam eco red to "normal" BMI
Table 43 - Baecke leisure scores for nal cohort and our s e
Other factors may also explain this phenomena. Weight and physical build may have
an effect on bone density in addition to the technical readings by the DXA machine,
and these must be independent of age (as comparisons are standardised for age in
Z-score calculations). Such factors could include increased skeletal loading (and
hence increased BMD)with increased weight. Further considerations about weight
and true BMD as measured by DXA are discussed in Chapter 3.9 on page 59.
4.6.6 Dichotomisinqcontinuousvariables
Receiver operating characteristic (ROC) curves were constructed for continuous
variables that had survived the univariate analysis (BMl, pack years, FEVr %
predicted) to determine cut-off points at which the continuous variable could be
dichotomised. The cutoff points chosen were BMI=20 and pack years=8O. There
was no useful cutoff point for FEVr, which would have enabled the variable to be
dichotomised, therefore the variable was left grouped into the four categories used in








p-value (one samPle t-test)
0.9+0.13.1+0.0Women <0.001
2.8+0.1Men 1.0r0.7 <0.001
Our sampleOriqinal cohort"' p-value (one sample t-test)
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The leisure score variable was set to choose the most important category of this
variable should it exist by using the "indicato/'function of Stata. P-value for entry
was set at p=9.1 for the multiple stepwise logistic regression'




. Current use of warfarin
. FEVr group (grouped according to British Thoracic Society criteria2l2)
These four factors, when considered together, were a good fit to the model
(assessed using Mantel Haensel 12 test for goodness of fit). These factors and
associated odds ratios are listed in Table 44.
Factors surviving multiple logistic regression
Table 44 -Factors survivin multi e istic re ression
Goodness of fìt 4)=11.9S, p=0.65 (reject good fìt if p<0.05)
Area under the ROC curve 0.7
s Grouped according to British Thoracic Guidelines2l2
Therefore, having a BMI <20 increased the odds of having BMD Z<-1.5 by -3.5x ,
smoking more than 80 pack years increased the odds by -2.5x, and currently using
warfarin increased the odds by 5.1x. Having FEVr 60-80% of predicted increased
the odds of having BMD Z<-1.5 by 1.35x; having FEVr 40-600/o predicted by 1.82x



























95% confidence interval (Cl)p-value
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4.7 Sensitivity and specificity
We calculated the sensitivity and specificity of the use of four risk factors to predict
patients who had BMD of Z<-1.5. The sensitivity-specificity curves are illustrated in







































Figure 17 - Receiver operating characteristic (ROC) curve for factors surviving
multivariate model with probability cutoff p=0.13 (Table 44)
There was no probability cutoff that corresponded to the target of 90% sensitivity in our
data (see two dots indicated by arrows in Figure , either side of the line indicating 90%
sensitivity). Therefore, the closest approximations to 90% sensitivity in our data was
p=0.13 with a corresponding sensitivity of 85.71% (See Table 45).
This mix of sensitivity and specificity corresponds to a probability level of 0.1 3 and
sensitivity of 86% (See Table 46) is preferable to the mix which corresponds to a higher
probability level of 0.12 with sensitivity of 96% (See Table 46). With the higher
sensitivity level, patients identified by the test as having low BMD are more likely to
actually have low BMD. However, the specificity is poorer (21o/o compared lo 41o/o), and
only 36% (compared to 5O%) of patients are correctly classified as either haVing low
BMD, or not having low BMD. These high values of sensitivity also result in high rates of
false positive results - 60% with p=g 13, and 80% with p=O.12.
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Table 45 - Logistic modelfor Z<-1.5 at cutoff level p=0'13, yielding sensitivity
of 86% and specificity oÍ 45o/o
True
Classifiedl D -D TotaL
---+---- ------+-
+l42Lr3l1s5
- | 1 11 | 84
---+---- ------+-
Total | 49 190 | 239
Cl-assified + if predicted Pr(D) >































* rate for true -D
- rate for true D
* rate for cl-assified *












Correctl-y cJ-assified 49 .1 9%
Table 46 - Logistic model for Z<-1.5 at cutoff level p=O.12, yielding sensitivity of
96% and spec¡fic¡ty of 21%
True





Total- | 49 1-90 | 239
Cfassified + if predicted Pr (D) >




















































4.8 Summary of selected model
The logistic model finally selected as a fit to this data has characteristics as seen in
Table 45 - sensitivity of 86Vo, specificity of 41Vo, positive predictive value =27o/o,
negative predictive value =92o/o, with 50% of patients correctly classified
((42+77)1239=50%).
This model was chosen in preference to a logistic model fitting this data that had
sensitivity over 90%. This model had sensitivity of 96o/o, specificity of 21o/o, positive
predictive value of 24o/o, negative predictive value of 95o/o, and correctly classified
only 36% of patients. Patients that the model labelled as having Z>-1.5 had a 12%
chance of having low BMD. Whilst this model missed less people who had BMD Z-
score of Z<-1.5 at the lumbar spine, neck of femur or total femur, it misclassified
many more as having low BMD who in reality had normal BMD.
Participants who had a likelihood of having low BMD of more than the cutoff value of
p=0.13, corresponding to the sensitivity and specificity parameters shown in Figure
17 could be recommended to have a screening DXA. This applies to participants
who had any of.
. BMI<20
. Smoked for >80 pack years
. Currently using warfarin
. FEVr <60% predicted
This corresponds to 65% of our sample (155/239).
However, a more useful approach is to recommend that patients who do not have the
criteria above are not recommended for screening DXA. There are two combinations
of risk factors to which this probability applies (See Table 47).
The best use of this screening tool would be as a pre-DXA tool to identifying those
who do NOT require screening with DXA. This would apply to the subjects who do
NOT have any of the risk factors listed above and who therefore have less than '13%




Table 47 - Gombinations of risk factors with 13
Therefore, the use of our pre-screening tool would reduce the use of DXA by around
35o/o.
Therefore, of the patients recommended for DXA, 27o/o would have low BMD (Z<-1.5)
(positive predictive value), and of the patients NOT recommended for DXA,92o/o
would NOT have Z<-1.5 (negative predictive value). Eight percent of patients were
not recommended for DXA but did have BMD Z<-1.5 (false negatives) - these
patients would miss being identified as having low BMD in the first instance, although
they may be able to be identified and re-screened at later visits to their general


























4 8 1 Comment on confidence intervals in Table 44
Of the four factors which survived multiple logistic regression (listed in Table 44), the
risk factor "Pack years >80" has a 95% confidence interval which touches 1 (1 .00 )
6.08), and "FEV1 % predicted, grouped" crosses over 1 (0.97 ) 1.88). Therefore it is
possible that these two factors have odds ratios that are not statistically significant as
the "true" odds ratio may be 1 or close to 1 (where 1 is "no effect" or the Same aS
"controls").
To be more sure that all the risk factors used to predict whether or not patients will
have low BMD are statistically significant, the p-value for entry to the multiple logistic
regression could be reduced from p=0.1 to p=9.95. This results in the reduction of
the number of risk factors from 4 to 3 (FEV1o/o predicted, grouped drops out), and the
95% confidence intervals do not cross 1, and the odds ratios and standard errors
adjust slightly (See Table 48).
Table 48 - Factors surviving multiple logistic regression when p-value for entry
to the lo istic model is 05
Goodness of fìt (2)=0.0t, p=0.9971 (reject good fit if p<0.05)
Area under the ROC curve 0.65
However, the logistic models resulting from the analysis in Table 48 which are close
to 90% sensitivity are:
Analysis from Table 48 - Model '1: Sensitivity=41o/o, specificity=14o/o, positive
predictive value=41%, negative predictive value =85o/o, correctly classifying 75% of
patients.
Analysis from Table 48 - Model 2. Sensitivity=1OOo/o, specificity=Oo/o, positive
predictive value=21%, negative predictive value null, correctly classifying2l% of
patients.
Either Model 1 or Model 2 above would be poor screening tests. Model 1 would miss
half the patients who had low BMD (false negative rate of 55%), and Model 2 would




























Therefore, I consider that the logistic model described in Table 44 and Table 45 with
sensitivity of 86% and specificity of 41% is better than either Model 1 or Model 2
resulting from the analysis in Table 48.
I also consider that the risk that some of the risk factors described in Table 44 may
not be statistically significant is less than the inefficiencies that would result from
using either Model 1 or Model 2 resulting from the analysis in Table 48 as a tool for
selecting who should receive a DXA.
4.9 Further ahalysis by site and gender
Despite reservations about the limited power to detect differences with these sample
sizes, analyses for associations between study factors and individual anatomical
sites (spine and femur separately) by gender have been presented over the following
pages in Table 49 to Table 54 on pages 125-130, except treatments for low BMD
(HRT, calcitriol and calcium tablets but not thiazides) using the rationale already
described in 4.6.2 Current use of calcitriol on page 113. As per the previous
analyses, risk factors that were associated with low BMD (p<0.25) at the particular
site and gender in question were used in the multivariate logistic regressions (See
Table 55 to Table 58 on pages 131 to 134). Stepwise (multiple) logistic regression
with a p-value for. entry to the model of p=g' 1 was used' Surviving continuos
variables were dichotomised using the same cut-off points as in the earlier analyses
(See 4.6.6 Dichotomising continuous variables on page 116), as long as
dichotomising the variable did not alter the model such that the pseudo R2 was
greatly reduced, or the goodness of fit was poor. ln these cases, the continuous
variable was retained. Any risk factors that the model could not use for reasons such
as "estimability" were excluded from the multivariate analysis for the reasons
previously described (See 4.6.3 Ever use of thiazide diuretics on page 1 14).
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Courses of OCS in last two years -
any/none
Number of OCS courses in last two
years

































Fractures since age 40























































































Daily ICS dose (raw)



















































Table 49 - Univariate associat¡ons between low sp¡ne BMD and selected risk
factors in men and women$
// p<0.051./.// p<0.01x p>0.25 l' P<o'25Legend
s Positive (+) effect direction indicates that the presence of the factor is associated with low BMD eg
people who smoked cigarettes for a large number of pack years are more likely to have BMD Z<-1.5
than those who smoked for fewer pack years. Negative (-) effect direction indicates that the absence
of the factor is associated with low BMD eg patients NOT taking thiazides are more likely to have BMD
Z<-1.5 than those who have taken thiazides.
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Courses of OCS in last two years -
any/none
Number of OCS courses in last two
years





















Fractures since age 40












































































Daily ICS dose (raw)











































Table 50 - Univariate associations between low spine BMD and selected risk
factors in women
r'/ p<o.OSlttt p<0.o1/ p<0.25r p>0.25Legend
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Courses of OCS in last two years -
any/none
Number of OCS courses in last two
years






























Fractures since age 40


































































Daily ICS dose (raw)





































Table 51 - Univar¡ate assoc¡at¡ons between low sp¡ne BMD and selected risk
factors in men
































Courses of OCS in last two Years -
any/none
Number of OCS courses in last two
years


















Fractures since age 40










































































Daily ICS dose (raw)
















































Table 52 - Univar¡ate assoc¡ations between low femur BMD and selected risk
factors in men and women





































Courses of OCS in last two years -
any/none
Number of OCS courses in last two
years
























Fractures since age 40















































































Daily ICS dose (raw)











































Table 53 - Univar¡ate assoc¡at¡ons between low femur BMD and selected risk
factors in women
x BMI<=17.2248fits data perfectly
r Using no courses of OCS in last 2 years predicts Z<-2.0 perfectly
* FEV, <40% predicted predicts Z<-2.0 perfectly
/{/ p<0.01// p<0.05,/ p<0.25x p>0.25Legend
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,.Courses of OCS in last two years -
any/none
Number of OCS courses in last two
years














Fractures since age 40

















































































Daily ICS dose (raw)

































Table 54 - Univar¡ate assoc¡at¡ons between low femur BMD and selected risk
factors in men
,t// p<0.01// p<0.05./ p<0.25x p>0.25Legend:
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FEVI grouped [3.9 (2.4)]




age (groups) t0.7 (0.09)l
theophylline Í1 17 (1 16)l
WOMEN
FEVI grouped [2.8 (1.2)]





used OCS in >2yrs 1112.2 (115.1)l
BMr<20 Í6.7 (3.2)l
age (groups) 1111.3 (1114)l
warfarin 14 (2.8)l
Variables included tOR (SE)l
Men and women
Thyroxine [28 (43)]
Rib fractures t7 (7)l
Ase (grouped) l2l3 (118)
Current use of thyroxine [19.6 (30)]
Spine fractures t12 (18)l
Ase (srouped) 11l8 (1/3)l
Current use of warfarin t6 (5.7)l
0.15 83 37 28 88 47 0.61 9% 0.7 32%
Prob- Sens- Spec- PPV NPV Correctly Model Variation
ability of itivity ificity classifìes goodness Explained





0.08 86 44 20 95 50 0.73 40Yo0.47 11To
0.15 78 47 31 88 54 0.67 41o/o0.53 7'/o
0.05 80 84 16 99 84 0.92 24% 0.9 82%
0.07 93 21 13 96 30 0.60 4% 0.61 18o/o
0.095 90 26 26 90 40 0.76 22o/o0.89 20o/o
0.022 91 49 8 99 51 0.80 47%0.74 16To
0.71 29%0.065 90 31 15 96 38 0.53 9o/o
no model better than chance
*FEV1>60% predicted
"age >65 & BMI>20,
not using warfarin &
have taken OGS in
last 2 years
*age 65+ & BMI>20
& not using warfarin
Don't need DXA
*Aged over 70 years and
not taking thyroxine,
no spine #
"Aged over 70 years and
not takinq wafarin
*FEV1>40 predicted
& >1 courses OCS in 2 yrs
BMt>33





















Smoked >80 pack years [4.2 (3.2)]
Daily dose ICS (us) t0.99 (0.0006)l
BMr>20 14 (2.3)l
FEVI srouped 12 (112))
rib fracture since age 40 [3.4 (1.9)]
Pack years>80 [3.4 (1.9)]
Current use of theophylline 1118 (117)l
BMr>20 t1o (s.6)l
Baecke leisure score (grouped) 1112
(1/8)l
rib fracture since age 40 [3.6 (2.0)]
gender Í112 (115)l (female=1, male=O)
respiratory admissions in Syrs [1.3
(1.Ðì
Model includes
0.02 80 53 7 98 54 0.74 51%0.1025 11%
0.08 90 51 21 97 56 0.1018 21Yo 0.79 45%
0.76 24o/o0.15 91 31 35 90 49 0.0043 17
Prob- Sens- Spec- PPV
ability of itivity ifìcity
"low
BMD"
NPV % Model Variation
Correctly goodness Explained



































BMI<=17 .2248, F EV 1 <40%
predicted, 0 courses OCS in last 2
years all predict BMD of Z<-2.0
perfectly
BMr>20 t10.8 (e.8)l
FEVI (sroupeQ þ.2 (2.1)l
Baecke leisure score (grouped) [1/3
(1/5)I
Age (srouped) t1.6 (112.3)l
BMr>20 t50.7 (48)I
Baecke leisure score (grouped) [1/3
(1/8)I
respiratory admissions in Syrs [1.8
(0.5)l
ICS dose (grouped) 11.9 (213)l
Model includes
0.94 43o/o0.1 92 83 36 99 84 1.000 42o/o





NPV Correctly Model Variation
classifies goodness Explained









*Leisure score low &
BMI>20 & ICS <1000 pg/day
*Leisure score very low
& BMI>20 & no respiratory
admissions & not using ICS
Don't need DXA
*BMl>20 & Baecke leisure
score medium or high
& FEVI >40 % predicted
*BMl>20 & low Baecke
leisure score & FEVI>60%
*BMl>20 & very low Baecke























Pack years [(1 .02 (1/100)]
Daily ocS ts.3 (7.7)I
Baecke leisure score (grouped) [3
(1.7)l





NPV Correctly Model Variation
classifies goodness Explained







0.86 57%0.1 89 60 33 96 65 0.74 28Yo
0.24 92 34 44 88 55 0'3 14Yo 0.72 25Vo "No rib fractures, weight
>85 kq
Don't need DXA
*Leisure score medium &
not taking daily OCS, no rib
# & not taking theophylline
*Leisure score medium &
25 pack years smoked, not
taking daily OCS
*Low leisure score, <1 l0
PY, & not taking
theophylline
*Very low leisure score, no
rib # & not taking daily OCS












Analysing the data in this manner shows the difference in selection factors between
males and females and between spine and femur. The following risk factors survive
multivariate analyses (as listed in Table 55 to Table 58 on pages 131-134.)
Table 59 -
and
Risk factors surviving multivariate analysis: data subgrouped by
nder$
$ See Table 55 to Table 58 on pages 131 to 134for actual odds ratios
ln addition, low BMD appears to be better predicted by risk factors than low spine
BMD. From this data, we are not able to assess whether this is because spine BMD
is more difficult to predict in general, or due to technical difficulties with measurement
of BMD at the spine. The results above are consistent with current literature and
understanding except for the increased risk in younger age groups. This is most
likely an artefact of our sampling frame as discussed earlier - as younger people had
to be at higher risk overall than older people to meet the study entry criteria.
Theophylline has been used to treat respiratory diseases in the past, although it has
fallen out of clinical usage. Theophylline use has been associated with low BMD in
animat models.23s
Where both men and women are included in the analysis together (see Table 55 to
Table 58 - not listed in Table 58 above), the risk factors become "mixed", blurring the
differences between genders. Overall, different mixes of risk factors predict low BMD
in men and women, providing evidence that there are different factors contributing to
low BMD in the different genders. While this is certainly interesting, at the practical
level, physicians need to decide whether or not they should be referring their patients
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. rib fractures. BMI>20
r lourlQel age group
¡ OCS use (or OCS dosage) in the
last two years





. low Baecke leisure
index
. low weight
. daily use of OCS
. low Baecke leisure scores




r loun$el age group
. low Baecke leisure scores
. higher number of respiratory
admissions in the last 5 years
. OCS dose in the last 2 years
. lower FEVI (grouped)
. hiqher dailv ICS dose
Femur
r lounQêr age group. current use of warfarin




r lourìQer age group
. current non-use of theophylline




with respiratory disease for densitometry, and considering different risk faciors for
different genders and anatomical sites (or even different bone density cutoffs or
definitions) can unduly add a level of complexity to this decision. Therefore, if one
set of risk factors for this one group of people with respiratory disease could be found
which predicts who would benefit from densitometry, this would benefit patients-
Therefore we return to discussion of the analysis for predicting BMD of Z<-1.5 at the
spine or femur, in both men and women.
4.9 Discussíon
Three of the four clinical risk factors constituting the final screening tool have
previously been associated with low BMD in respiratory patients (low BMl,71'70 poor
lung function,se smoking65'tt¡. Warfarin has been associated with low BMD in post-
menopausal women only,236 with warfarin use identified as a marker for other risk
factors associated with low BMD eg poor health rather than low BMD alone.236
The specificity of our algorithm is poor (41%) at selected sensitivity of 860/o.
However, the specificity of other screening algorithms is also poor at the sensitivity
they used. At sensitivity equal or greater than our target sensitivity of 9Oo/o, specificity
was 13-51o/o, and area under the ROC curve was 0.7-0.81 in studies using
SCORE,1s0-1es and specificity was 25-48Vo and area under the ROC curve O.73-O.79
for studies using non-SCORE prediction models.60'73'85"1e8'1s6'1ss Using "SCORE" to
identify patients likely to have low BMD prior to DXA reduces the costs of screening
programs by -2O% by identifying people with normal BMD not requiring bone
densitomelry."' This has significant cost-effectiveness implications. For further
discussion of combining this risk factor analysis with other research, see Chapter 6
on page 178.
We did not collect all the information required to reliably estimate SCOREIs0 or
ORA¡238 in our patients eg rheumatoid arthritis status, current use of estrogen (as
compared to HRT in a generic sense). Therefore, we have not generated estimates
of SCORE or ORAI estimates for our cohort.
We would have liked to use half our data as a development and the second half as a
validation cohort, much as Some other authors have done.238'23e However, these
were much larger studies than ours (1279 and 1376 women) using nation-wide or
multiple centres from which the sample was drawn. Therefore, we did not have a
large enough sample size to attempt to validate the screening tool with our data
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However, our research group is in the process of preparing and submitting a
manuscript to peer-reviewed journals using data collected in Newcastle, New South
Wales in 1991-1993 by one of the study investigators2ou as a development cohort
and using the data from this thesis as the validation cohort.
4I I Discussion whv corticosteroid use and orevious fractures did not feature
prominentlv in analvses for predictinq low BMD
It may also seem surprising that corticosteroid use and previous fractures did not
appear to be good predictors of low BMD in this group. Corticosteroid usage may not
be predictive of low BMD in this group if the participant had bone loss from
corticosteroid usage prior to the last 2 years, as this would not have been picked up
the questions used in the questionnaire if corticosteroid usage has varied over time
(See discussion on page 89 in section 3.7.8 Study factor 20-22 - Number of
courses of oral corticosteroids in the last 2 years.) However we did ask about
fractures since age 40.
Fractures at the spine or ribs were of most interest to us given their high background
prevalence in this patient group. Around 20% oÍ the sample had experienced a bone
fracture since age 40 (491239), but the sites where participants sustained fractures
varied. The total number of participants sustaining spine fractures was very small
(N=4 - see Table 60), and may explain why spine fractures are so infrequently
associated with low BMD in the previous analyses; whereas rib fractures are more
common (N=20, see Table 61) and demonstrated better associations with low Bl/D
in the previous analyses. The selection criteria used for this study was intended to
select a higher risk group of participants for the study. However, as seen in Table
36, this group was not as high-risk as had been anticipated, with the mean BMD of all
but one site was not significantly different to zero. Having a sample which was not as
high risk as expected could explain why the number of fractures (particularly spine
fractures) was so small.
Another possible explanation for the low numbers of spine fractures is that people
with spine fractures would have been otherwise eligible for the study would also have
been eligible to receive authority scripts for alendronate and therefore may have
been excluded from the study because they were already taking alendronate, We
recorded 25 people being unsuitable for the study for this reason. This represents
10% of the people excluded from the study who were alive. At the time this study
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was recruiting alendronate was not widely prescribed and men were unable to obtain
authority scripts for PBS-subsidised alendronate.
Table 60 - S ne fractures in cl with BMD o1 Z<-1.O Z <-1.5 or Z <-2.O
Table 61 - R¡b fractures in rtici nts with BMD of Z<-1, Z<-1.5 or Z<-2.0
4.10 Study limitations
Case notes were used as the initial source of data. Therefore data on the initial
eligibility of patients to participate in the study may be inaccurate. This may have
resulted in patients who were eligible to participate in the study being excluded,
although patients.who were included in the first instance but in reality were not
eligible to participate would have been excluded at a later stage in the recruiting.
Our exclusion criteria relating to alendronate contraindications (excluding patients
with existing gastrointestinal disease) excluded more patients from the study than
initially expected. The patients whom we excluded were in quite poor health, with
numerous co-morbidities and risk factors for low BMD, and were therefore a high-risk
group for low BMD.
We excluded patients who had been treated with alendronate or etidronate, because
we intended to randomise patients subsequently found to have low BMD to daily
alendronate in a randomised controlled trial. The active components of these drugs
are retained in the body, changing BMD even after the tablets are discontinued,2a0
and may therefore confound the results of the future randomised controlled trial.
However, this also means that a high-risk group of patients has been excluded from
the study, as many people already taking these drugs had vertebral fractures (which

























N- z<-'l.o z<-1.5 z<-2.0 z<-1.0 z<-1.5 Z<-2.0 z<-1.0 z<-1.5 z<-2.o
Totalspine
fractures
Spine BMD Femur BMD Spine or femur
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patients to which this applies is small (1O% of live subjects who did not meet all the
criteria for entry to the study), but is still worthy of consideration
Our inclusion criteria were generous, resulting in the inclusion of larger numbers of
participants than expected who were unlikely to have low BMD. ln particular,
allocating women two points if they were postmenopausal on the pre-screening
questionnaire (Table 32 and Appendix 2) meant they needed few other risk factors
for low BMD to be eligible for the study. Therefore the females on our study were at
lower risk of having low BMD for their age than the men.
Our modest sample size makes drawing any conclusions from analyses of risk
factors by gender or individual skeletal sites somewhat tenuous, although these have
been presented for completeness.
Page 139
Chapter 4
4.11 Directions for future research
Future research could include studying risk factors on a larger sample size of
participants, allowing more definitive conclusions to be drawn from analyses of
relationships between low BMD and individual skeletal sites and genders, and
investigation of the predictive value of these risk factors in other COPD populations.
It would be useful to collect information on how many people had undergone
densitometry prior to study entry, and to select higher-risk women, by not giving them
additional points for being post-menopausal. Markers for co-morbidity other than
warfarin could be considered.
Conclusion
Our sample was middle aged, with more men than women. Both men and women
were ovenrveight and sedentary compared to reference populations. Men and
women had different patterns of risk factors, and the men had poorer health and
lower age- and gender-matched BMD than the women. lndividual risk factors that
were associated with low BMD (with genders pooled) (p<0.25) were included in the
multivariate analysis. At a p value of entry of 0.1 , the multiple logistic regression
"model" comprised three factors - having a body mass index <20, smoking >80 pack
years of cigarettes, FEV1 <60% predicted, and current use of warfarin. The
combination of these four risk factors corresponded to a sensitivity of 86% and
specificity of 41% and correctly classified 50% of patients. This was chosen in
preference to an alternative model comprising 96% sensitivity and 21% specificity,
which had a higher sensitivity but a poorer overall mix of sensitivity and specificity,
correctly classifying only 36% of patients. The chosen model had a positive
predictive value of 27o/o, and a negative predictive value of 92o/o, and had an area
under the ROC curve (AUC) of 0.7. People who did not have any of the four risk
factors in the multivariate logistic regression (comprising 65% of our sample ) who
had a risk of having Z<-1.5 of 13% or less would not be recommended for
densitometry. The use of pre-screening questionnaires has the potential to reduce
the cost of screening programs by -20o/o by identifying subgroups who would not
benefit from densitometry.
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Chapter 5 - Methods and results for modelled estimates of number
needed to screen and number needed to treat to prevent hip
fractures over one and ten years with daily alendronate
This chapter investigates Aim2- Number needed to screen and number needed to
treat
"Determine the number needed to treat (NNT) and number needed to screen for
preventing hip fractures in nominated subgroups of the general population and the
chronic obstructive airways population by treating with alendronate for one and ten
years."
5.1 Number needed to treat
NNT was first described by Laupacis et al.2a1 as a more meaningful tool for use in
clinical practice than relative risks or odds ratios because it incorporates both the
base-line level of risk and also the magnitude of the risk reduction. lt is defined as
"the number of people who need to be treated for a given duration to prevent one
death or adverse event". NNT is the reciprocal of the absolute risk reduction (ARR),
which is the difference between rates of adverse events, such as a fracture, in the
control and intervention groups of randomised controlled trials. This is illustrated
below:
1 t1
NNT= number of events in control qroup
number of people in control group
number of events in intervention qroup
number of people in intervention group
ARR
1 l2l
control- intervention event rate
NNT is calculated for a specific patient group and for a particular period of time, and
must always be considered within that context. NNT gives clinicians a tangible grasp
of how effective the intervention is within these parameters.
NNT can easily be calculated by clinicians from information provided by drug
companies such as the ARR. NNT is therefore a very useful toolfor assisting
clinicians to conceptualise the absolute risk of an adverse event that may occur if
they do nothing, and the change in absolute risk that may be obtained by providing
the patient with a particular intervention.
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5 1 .1 Clinical shortcominqs of NNT
Laupacis et al.2a1 summarised the clinical shortcomings of NNT, which result both
from the properties of the measure and from the data used. NNT is an average of
the number of patients requiring treatment in order to prevent one event. NNT gives
no information regarding the fate of other patients who are treated in whom an
adverse effect is not prevented. NNT estimates are developed from randomised
controlled trials in which patients and conditions of treatment, levels of baseline risk,
patient compliance, differ from regular clinical practice.
5.2 Number needed to screen
NNS was first described by Rembold et al.2a2 as an extension to NNT, and is defined
as the number of people needing to be screened to prevent one death or adverse




where "prevalence" is the rate of people with the disease of interest (using a
designated definition) in a specified population at a specified time. The use of NNS
also takes into account baseline risk, and allows more fair comparisons of screening
strategies for diseases with different levels of baseline event rales.2a2 NNS can also
be calculated from clinical trials that directly test the benefit of a screening strategy
(such as mammography for the prevention of breast cancer, or fecal occult blood
testing for prevention of colon cancer), where the intervention is not a drug treatment
but the screening strategy itself (See Table 70). The calculation of NNS in these
trials is the same as the NNT formula (NNS=1/ARR). No such trials exist for
preventing fractures with alendronate, therefore the use of the equation
NNS=NNT/prevalence of disease will be used in the investigations presented in this
thesis.
5 2.1 Clinical shortcominqs of NNS
Additional errors are introduced into the NNS estimate by using prevalence estimates
whlch do not come from the population from which the trial participants come, but
use an estimates from a separate source eg data from another trial, or prevalertce
estimates from another setting or country. Limitations of applying trial data to actual
clinical practice for NNT discussed above also apply to NNS regarding compliance
with screening and treatment.
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Providing that screening is useful, NNS provides a tangible guideline for busy
clinicians to conceptualise the number of patients that need to be screened to
prevent a fracture in patients that they see.
NNS will be further considered as part of the original research for this thesis.
5.3 From trial data to modelling
Data collected from randomised controlled trials provide us with useful information on
the relative effectiveness of the treatment studied in the RCT, and on the safety and
tolerability of the intervention (See Table 62). However, there are limitations in
obtaining NNS and NNT estimates from RCT data. Long term studies on adverse
events (eg fractures) are difficult to conduct, and results may not be available for a
number of years. These trials may not include the sickest or least compliant patients
who may have a different risk of hip fracture, death or institutionalisation. Thus, the
effectiveness of the treatment in non-trial situations may be overestimated, thus
altering NNS, NNT and cost-effectiveness estimates, and limiting generalisability of
the findings of the study to other populations. The published reports of the RCT may
often not include sufficient data regarding the population from which the study
subjects were chosen to estimate NNS except in a very broad sense, which may be
so broad that the estimate is useless.
The sample of patients in the RCT's may not be representative of the underlying
population. This inay be related to differences in inclusion and exclusion criteria, and
different definitions of low bone density - such as the World Health Organisation
definition (I-score .-2.5), or "established osteoporosis" (presence of existing
fractures) or the Medicare definition (Z-score of <-1.5), or even a novel definition
used for the purpose of the individual trial. Therefore, the shape of the underlying
statistical distribution of the trial population may be unknown, although likely to be
significantly different from normal, with sections of the normal population under- and
over-represented. This means that individual trials may not be able to be sensibly
compared to each other.
However, modelling these scenarios provides information for today, and allows the
possibility of exploring scenarios such as what happens when different subgroups of
the population are screened and treated, using simulated populations with known
characteristics.
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5.4 Methods - modelled estimates of NNS and NNf
Aim2 will be investigated by the development of a spreadsheet-based "model" to
simulate the NNS and NNS for treating subgroups of the general population and
people with moderate to severe respiratory disease with alendronate for a specified
period of time. Since some authors have proposed that treatment for reduced bone
density should begin at Z-scores other than <-1 .5247'226, modelling estimates for Z<-
1.0 and Z<-2.0 as well as <-1.5 have been included.
5.4 Model inputs
. Lunar reference data for the mean BMD and standard deviations for age and
gender217 (See Table 77 in Appendix 4 on page 197).
. Reducing BMD by 1 SD increases the relative risk of a hip fracture by 2.6x.57
. Australian population hip fracture rates, derived from fracture incidence data; and
Australian population estimates from the 1996 Census of Population and
Housing.so Hip fracture incidence data by age and gender was obtained by
request from the Australian lnstitute of Health and Welfare (see Appendix 5 - Hip
fracture incidence in Table 78, page 198).
. Hip fracture rates for treated and non-treated groups - developed from equations
in Kanis et al.1 See Equation '1 and Equation 2.
Equation 1 and Equation 2 calculate the rate of hip fracture below (Equation 1) or at
(Equation 2) a stationary point on the Normal distribution, defined by the mean and
standard deviation of a given age and gender group. These pre and post hip fracture
rates are used to calculate the effect of treatment for the NNT and NNS.
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Equation I - The pre-treatment fracture rate for the risk of fracture in the short
perspective (not accounting for deaths) for those BELOW the threshold for
BMD
Equation 2 - The pre-treatment fracture rate for the risk of fracture in the short
e ective not accounti for deaths for those AT the threshold for BMD
where
For worked examples see Appendix 6 on page 199
= Yearly incidence (of fracture) of the age group x
o((g - p)/o) + los(RR)/ (( g - p)/o)
= Yearly incidence (of fracture) of the age group x
exp(-loq(RR) (x - u)/o - (loq(RR))2
2
Threshold BMD (BMD below where treatment begins)g
normal distribution function (mean=O, SD=1)o
ls the e-log of the risk ratio of an individual with BMD 1 SD
below another individual
los (RR)
Relative risk of (hip) fracture for decreasing BMD by 1SD (= 2.6)RR




5,6 Creating the simulation model
We used Microsoft Excel 97 (Microsoft Corporation) to calculate the hip fracture rates
using Equation 1 and Equation 2 (from Kanis et at.1). This method of obtaining pre-
treatment hip fracture rates was validated with the data in the original paper using the
NHANES reference data,11 and the Australian hip fracture data (from Australian
lnstitute of Health and Welfare hip fracture data (Table 78), and from ABS Census
datasa) to ensure that no errors had been made in the transfer of the formula to
Microsoft Excel 97.
5.7 Modelling effect of COPD
To model the effect of COPD, the shape and distribution of the COPD population,
and the position of the curve of the COPD population relative to the general
population needs to be able to be described.
5.7.1 Position of the COPD oooulation relative to the normal population
Patients with COPD have a lower mean BMD than the general population, with an
estimated average 10% reduction in mean BMD compared to controls.a
To simulate the effect of having COPD, the shape of the curve and the placement of
the mean BMD for the COPD population need to be determined.
The standard deviation of the COPD population is assumed to be identical to that
used for the general population pre-treatment (O.12 glcm2 in women, and 0.13 g/cm2
in men) in the absence of data to the contrary.
5.7.2 of the curve for the COPD distribution
Data on the distribution of the COPD population was required to estimate hip fracture
rates in this population, however no published data is available on the shape of the
distribution of the COPD population.
Data from the cohort of patients studied by us to develop a screening tool for
identifying patients who did not require bone densitometry (investigated as part of
this thesis) are described in Chapter 4.3.1 - Table 36 on page 100). The patient data
from this cohort was assessed by gender, and anatomical site (lumbar spine (L2-L4),
neck of femur, and total femur) to determine if the distributions were significantly non-




5 7.3 Esti n of the mean BMD for the COPD pooulation
Literature estimates of BMD reduction conferred by having COPD are aroun d 1O'/o4
(approximately one standard deviation). A sensitivity analysis on varying this by up
to t100% is shown in Table 63.
lf the COPD effect is underestimated, the prevalence of low BMD and the fracture
rate in lhe Z<-1.5 group will also be underestimated, and the NNS estimates after
one and ten years and the NNT estimates after one year of daily alendronate
treatment will be less. The NNT after ten years of daily alendronate treatment will
remain unchanged.
lf the COPD effect is overestimated, the prevalence of low BMD and the fracture rate
in the Z<-1.5 group will also be overestimated, and the NNS estimates after one and
ten years, and the NNT estimates after one year of daily alendronate treatment will
be higher, having moved closer to NNS and NNT estimates for the general




Table 63 - Effect of changing the COPD effect from 1O% in women aged 55-75
with COPD and bone density of Z<-1.5 on number needed to screen and
number needed to treat estimates for I and '10 ars
Therefore. the COPD population will be simulated bv
. reducing the mean BMD to 10% below that of the general population for age and
gender
. maintaining the standard deviation equal to that of the pre-treated general
population
o âSSUrTling a Normal distribution
g (threshold BMD, the BMD value below which people receive treatment) will remain
constant but the proportion of the COPD population below g will be larger than the
proportion of the general population below g.
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NNS for treating women with COPD and Z<-'1.5 with alendronate for 1 year
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5.8 Modelling the effect of treatment
Alendronate treatment increases BMD of the neck of femur by approximately 5% in
postmenopausal women (See Table 62). The model assumes that the effect of
treatment is the same regardless of initial bone density (See Chapter 5.9). A
sensitivity analysis on varying the 5% change in BMD by +1OOo/o are listed in Table
64.
lf the "true" effectiveness of daily alendronate treatment is greater than 5%, then
fracture rates will be even more reduced in people receiving treatment, and NNS and
NNT estimates after one and ten years will be reduced.
Conversely, if the "true' effectiveness of daily alendronate is less than 5%, then
treatment will have little effect, as fracture rates in the people receiving treatment will
become similar to fracture rates in people receiving placebo. Therefore, NNS and
NNT estimates after one and ten years of treatment will increase.
Table 64 - Effect of changing treatment effect from 5o/o in women in the general






































































































































NNS fortreating women in the general population alZ<-1.5 with alendronate for 1 year
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Therefore, the size of the treatment effect is important, and data on the effect of
alendronate on BMD over longer periods of time will enable the treatment effect to be
estimated more accurately.
The effect of treatment will be simulated by
. lncreasing the population mean BMD by 5%
o maintaining the standard deviation equal to that of the pre-treated population
The same position on the Normal curve will be associated with a lower hip fracture
rate post-treatment.
lf the "true" effect of treatment is different to 5%, the NNS and NNT estimates for one
and ten years of treatment with daily alendronate will be over- or under-estimated.
5.9 Other model assumptions:
. All persons are screened (the model uses N=1000forthe size of the screened
population for each age)
. All persons in assigned treatment group are treated, with levels of compliance
assumed to be equal to that in the RCT's of alendronate from which the effect of
treatment is derived (See the list of trials in Table 62).
. All persons at any point in the normal distribution receive the same increase in
BMD due to treatment
. For comparative purposes, the population mean is used regardless of whether
the general population or the COPD population is being considered.
. The prevalence of low bone density in the group treated (eg Z =-1 to Z=-2) is
equivalent to the probability assigned to each Z-score group by the use of normal
distributions.
Therefore, out of the 1000 patients screened, 158.7 patients in the general
population are treated in the treatment group Z<-1.0 (15.87%),66.8 in Z<-1.5
(6 68%), and 22.8 in Z<-2.O (2.28%) (See Table 65). For the COPD population, the
numbers are as follows, depending on gender and age: 359 - 396 for Z<-1.O (35.9 -
39.6%), 195- 222for Z<-1.5 (19.5 -22.2%), and 87 - 103 for Z<-2.O (87 -10.3%)
(See Table 66). This is the proportion of people with the corresponding Z-scores in
the general and COPD populations. The number treated in a particular Z-score
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group is constant in the general population (See Table 65), but changes in the COPD
population (See Table 65). See Chapter Chapter 6.1.4 on page 168 for further
discussion of this phenomena.
Therefore, as the population ages, hip fracture rates increase - for the whole
population and for each Z-score group described. As the hip fracture rate increases,
so do the number of hip fractures prevented.
The validity of these assumptions are discussed further in Chapter 6.
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Table 65 - Hip fracture rates and number of hip fractures prevented after one year for men and women in the general population, for
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Table 66 - Hip fracture rates and number of hip fractures prevented after one year for men and women in the COPD population, for
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5.10 Extension of model beyond the short term
The equations for the risk of hip fracture used in this modell calculate hip fracture risk
for the short term only. However, treatment with alendronate continues to increase
BMD and reduce fracture risk over time with treatment up to 7 years in post-
menopausal women ,24o and few people would take alendronate for only one year.
Therefore, we incorporated a Markov model as an extension to the 1-year model,
which allowed us to calculate risk of hip fracture over time, and therefore NNS and
NNT over a longer period of time.
5.11 Markov model
A Markov model was developed concerning the specification of relationships
between the probability of hip fracture, death and institutionalisation for different
gender, age, BMD, BMD threshold for treatment, patients'treatment status (general
population or COPD) to enable estimates of cost-effectiveness to be made, including
estimates of NNS and NNT beyond one year. The Markov model begins with
probabilities that an individual will sustain a hip fracture, die, be institutionalised, or
remain healthy over that year. The model "iterates" for every year, beginning with the
likelihood of the event from the end of the previous year.
The assumptions for the Markov section of the model are as follows and are obtained
from literature data, or from expert opinion where no literature data is available.
Events occur at the end of each year, and each person has a defined risk of
experiencing the following each year:
hip fracture
admittance to an institution (nursing home)a
a death
After a hip fracture, an individual has a higher risk of being admitted to an institution
or dying.aT'ou Patients admitted to a nursing home cease being allocated to a
treatment group (and are no longer prescribed tablets), because there are too many
uncertainties about the risk of hip fracture once a patient is institutionalised to allow
hip fracture risk to be accurately estimated. This is discussed further in Chapter 6.1.3
on page 168. Therefore, as far as treatment is concerned, people drop out of the




Extending the model beyond one year requires additional data on rates of institution
and death,2Æ'46'202 and prevalence of COPD in the general population,56 The rates of
mortality and institutionalisation (both in general and following hip fractures) are listed
in Table 67. We have assumed that the mortality rates (in general and after hip
fracture), and institutionalisation rates in people with COPD are double that
experienced by the general population, since there is no data on the topic. Should
the estimates be too high, with the "true" rate of deaths and institutionalisations
closer to that of the general population, the NNS and NNT estimates after 10 years
may be closer to estimates for the general population than those presented for the
COPD population. However, until such time as accurate estimates are available,
more accurate assessments can not be made.



























































































as a result of hip fracturea6
Table 67 - Model input - rates of hip fracture, mortality, and institutionalisation (in general and following hip fractures) by age group
and COPD status
f Mortality rates are identical for males and females, either in the general population
institutionalisation are identical forthe general population and the COPD population.













NNS and NNT estimates from the model are calculated from comparing groups
allocated to treatment before and after treatment takes place. These simulate the
control and intervention arms of a RCT and are algebraically equivalent to standard
epidemiological formulae listed earlier as follows:
1
NNT =number of events in control group - number of events in intervention qroup
number of people in control group number of people in intervention group
number of events in control orouo - number of events in intervention qroup
number treated
number treated
number of events in control group - number of events in intervention group
number treated = NNT used in model
1
number of hip fractures prevented
5.13 Calculating NNS esfi'mafes
NNS estimates are calculated by using the following formulae, which are





number of hip fractures prevented
number of people treated
1
hip fracture prevented
number of people screened
number of hip fractures prevented
NNS equation used in model
number of people with disease
number of people in population
number of people screened




Prevalence of the disease at the threshold BMD g is calculated by determining the
percentage of the normal population below g.
5,14 Resu/fs - N/Vf andfVNS estimates
5.14.1 NNS and NNT estimates for treatino oatients in the oeneral oooulation and
patients with COPD for 1 vear
Estimates for NNT and NNS for preventing fractures over 1 year are listed in Table
68.
Table 68 - Modelled estimates of NNS and NNT for screening females and
males aged 55, 65 and 75 years, to treat patients with bone density of Z<-1.0,
Z<-1.5, Z<-2.O or'T<-2.5 with dai alendronate for 1 r
f "Treatment decision" is the Z-score andardised for age and gender) at which the
general population or the COPD population (who have all been screened) are treated

























































































































































































































































5.14.2 NNS and N NT estimates for treati no oatients in the qeneral population and
patients with COPD for 10 vears
The number needed to screen and treat for 10 years are summarised in Table 69,
with the data for NNS and NNT estimates after 10 years as a comparison. Data for
NNS and NNT for treatment for 10 years in the group of patients beginning treatment
at age 75 has not been tabulated because we consider that these estimates are not
robust at such an advanced age. See Chapter 6 for further discussion on this idea.
The most useful aspect of using modelling to estimate NNS and NNT is that mortality
and institutionalisation rates are factored in, making the estimates more realistic.
The extent to which the 10 year NNS and NNT figures obtained from the Markov
simulation take into account deaths and institutionalisation rates is also illustrated in
Table 69. Further discussion on this idea can be found in Chapter 6.1.4 on page
169.
The hip fractures prevented after one year and after ten years are indicated in
separate columns. The NNS and NNT estimates for ten years (using cumulative hip
fractures prevented) are not adjusted for mortality or institutionalisations. These
have been compared to the NNS and NNT estimates obtained using the Markov
simulations (which do include mortality and institutionalisations).
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Table 69 - Modelled estimates of NNS and NNT for screening females and males aged 55, 65 and 75 years, to treat patients with















































































































































































































































































5.15 Summary of NNT and NÂ/S findings
lf the Z-score at which patients are treated decreases:
a NNT decreases
O NNS increases
as the underlying hip fracture rate increases
lf BMD (in g/cm2) is held constant, as age increases
a NNT decreases
. NNS decreases
as the underlying hip fracture rate increases
The likelihood (prevalence) of having a l-score less than a given value (eg f<-2.5)
increases with age as the underlying hip fracture rate increases.
(NB The underlying hip fracture rate increases with advancing age - this is input into
the model.)
5.15.1 Which qroups have the lowest NNS estimates?
NNS estimates are lowest in the high Z-score groups eg Z<-1.0. This is due to the
low disease prevalence in the high Z-score groups where there are fewer numbers of
hip fractures to be prevented by the treatment.
5.15.2 Which qroups have the lowest NNT estimates?
NNT is lowest in the women, in the lowest standard deviation scores and the oldest
age groups where the effect of treatment and the fracture risk is highest.
5.15.3 Comparison of the qeneral population and the COPD population
lf people of a given age and gender are treated in either the general population or the
COPD population, both groups will have similar NNT (similar underlying hip fracture




Men have lower underlying rate of hip fracture than females at a given age and Z-
score, and therefore higher NNS and NNT.
Conclusion
Using literature equations and Markov simulations, approximately 6100 65 year old
women in the general population with BMD of Z<-1.5 need to be screened and 408
need to be treated to prevent one hip fracture with daily alendronate treatment for
one year.
For ten years of daily alendronate treatment (taking account of hip fractures,
institutionalisations and deaths which occur over the ten year period), approximately
430 of these women would need to be screened and 29 treated to prevent one hip
fracture.
Approximately 1840 65 year old women in the COPD population with BMD Z<-1.5
need to be screened and 380 need to be treated to prevent one hip fracture with daily
alendronate treatment for one year. For ten years of daily alendronate treatment,
approximately 165 of these women would need to be screened and 34 treated to
prevent one hip fracture.
Number needed to screen decreases with increasing disease prevalence.
Number needed to treat decreases as hip fracture rates increase.
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Ghapter 6 - Discussion of modelled estimates of number needed to
screen and number needed to treat to prevent hip fractures over
one and ten years with daily alendronate
6.1 Challenges fo model inputs
6.1 .1 Choice of fracture tvpe
There are many sites at which bones can fracture. We have chosen to focus on hip
fractures for the following reasons.
Morbidity after hip fractures is high,251 but there is no excess mortality after vertebral
fracture.2s2 Part of this may be due to the age distribution of hip and vertebral
fractures, with hip fractures common in the very elderly, and vertebral fractures more
commonly occurring at a younger age.2s2'2s3
Hip fractures nearly always result in hospitalisation,2sa and are therefore easier to
study in an epidemiological context than fractures of the ribs or vertebra, which are
asymptomatic in a high proportion of cases and therefore under-diagnosed in the
short term.sr'52
ln the COPD population, fractures of the vertebra and rib are common.tss'tsu This
would be an argument for using these fractures instead of, in addition to hip
fractures, or indeed using all fractures. However, using only one type of fracture that
is able to be easily identified in epidemiological terms is also a good place to begin
economic analysis as the scenarios required for modelling are less complex.
6.1.2 Choice of data source for hip fractures
We have chosen to use data from centralised Commonwealth sources2st lsee Table
78). There have been no population based studies of hip fracture incidence in South
Australia, although there have been several others in Australia - in Dubbo,s1
Geelongsr'5'Tasmanias3 and Western Australia.2sB There is geographical variation
within Australia,s3 and therefore using Australia-wide data may not be readily
generalisable to Adelaide. While this is a valid comment, we were not able to obtain
any more valid data for our region than from hospital separations, and this data will
be able to be generalised to Australia as a whole, but with the known geographic
variation we must expect some variation from the average data in individual regions.
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6.2 Challenges to model assumptions
6.2.1 Assumption of 100% compliance with screeninq
This model assumes that all patients of the selected gender aged 55, 65 or 75 have a
screening DXA. This assumption is unlikely to be fulfilled in reality. However, the
next best assumption to make in the realworld may be that a random selection of
patients (which would approximate a representative sample of the entire population
of that gender and age). Or, is it a more correct assumption to make that the patients
presenting for screening would not be a representative sample? In reality, screening
could be either:
1) representative
2) non-representative, where patients who present for screening are mostly high-risk
3) non-representative, where patients who present for screening are mostly low risk
These scenarios are explored below.
6211 The case for e reoresentative samole of the oopulation presentinq for
densitometrv
lf the people presenting for densitometry had a similar statistical distribution to the
general population (that is, they are a representative sample), then the NNS
estimates for a given time period, age, gender and treatment group would be similar
to those in Chapter 5. This would be essentially the same as starting with a smaller
screened population than that used in our simulations (N=1000).
6,2.1.2 e case for non-random tno where more hioh risk than low risk
patients present for densitometrv
More high-risk patients may present for densitometry because they are motivated to
attend screening because they know, or they perceive that they have risk factors that
may predispose them to developing low BMD. These may include being a
postmenopausal woman, or having used high dose corticosteroids on a long{erm
basis, and so on. There is some literature evidence for this - with one investigation
reporting a high prevalence of low BMD in densitometry of self-referred women, with
an estimated 60% of women having reduced BMD on screening.2ss
ln this situation, NNS estimates for a chosen time period, age, gender, and treatment
decision would be decreased, because proportionally more patients of a chosen age
and gender who would require treatment than those would not require treatment
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attend densitometry. The actual reduction would depend on the difference in fracture
risk of the group who present for screening, compared to the underlying population.
6.2.1.3 The case for non-random screeninq where more low risk than hioh risk
patients present for densitometrv
More low risk patients may present for screening DXA because they are less sick or
not extremely elderly. Therefore, they are able to leave home and come to where the
DXA machine resides, and they are physically able to get up onto the bed
underneath the DXA machine and lie flat on their back for 10-15 minutes withoui any
medical consequences. There is some evidence for this, with one study in peri-
menopausal women finding that densitometry non-attenders had lower risk of having
reduced BMD than attenders. Non-attenders were more likely to be significantly
heavier (with high body weight likely to decrease the risk of having low BMD). Other
differences between the groups were confounded by social class (sedentary lifestyle)
and body weight (lower HRT use).260 However, the number of non-attenders was
small (N=6), and therefore more research is required to ensure this is not a spurious
result.
ln this situation, the NNS estimates for a chosen time period, age, gender, and
treatment decision would be increased over the modelled estimates listed in Chapter
5. This is because more patients would need to be screened to identify the patients
to be treated for a chosen time period, age, gender, and treatment decision. The
NNT would not change for a chosen time period, age, gender, and treatment decision
because the effect of treatment would be the same regardless of how many patients
were treated.
Therefore, the strongest evidence suggests that less than 10O% of people will
present for screening, and that the people who present will have higher risk of low
BMD than if those who presented for screening were a random sample of the
population as a whole.
6.2.2 Assumption of RCT level of compliance with treatment
Non-compliance with treatment regimens is defined as patients who do not take the
medications they have been prescribed in the "correct" manner. The level of
compliance assumed by the model is equal to that found in the RCT's on which the
estimate of the effect of treatment is based (SeeTable 62). These RCT's are all
i ntent to treat a n a lyses. 2 43'244'245'1 45'246'1 os
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The level of compliance with treatment found in RCT's could be considered to be the
"gold standard" level. Achieving higher levels of compliance in regular clinical
practice than those found in RCT's is unlikely, because patients who take part in
RCT's are likely to be different to regular patients.laT For example, they may have
less co-morbidities and be more motivated to take their tablets as directed than
would otherwise have been expected. Non-compliance affects treatment efficacy by
reducing the benefit of treatment over placebo.
6.2 21 Will oatients at medium risk or hioh risk of develooino osteoporotic fractures
to with alendronate
Patients at high risk of developing osteoporotic fractures (eg Z.-2) may be more
likely to take their medication at levels similar to the compliance rates found in RCT's
than those at medium risk (eg Z-score between -1 and -2). This may be because
they are more motivated to receive treatment because they realise they are at high
risk for their age of experiencing a fracture. However, the patients at very high risk of
sustaining osteoporotic fractures (Z<-2) may be less likely to take prescribed
alendronate medication because they may be unable to tolerate or take alendronate
medication as directed, not necessarily because they are unmotivated to improve
their BMD. Alternatively, they may have gastro-oesophageal co-morbidities, or are
bedridden and unable to sit upright for half an hour after taking the tablets. Either
scenario, or a combination of both, is possible. However, at the current time there is
no evidence to suggest which scenarios may be more accurate.
6.2.2.2 Whv treatment compliance is difficult to estimate
While all forms of non-compliance reduce treatment efficacy and therefore increase
NNT and NNS, the way non-compliance is defined and the point at which it occurs
has implications for cost-effectiveness analyses. For example, patients who undergo
screening densitometry, and are identified as having low BMD but who never seek
treatment may incur fewer costs than patients whom are prescribed anti-osteoporotic
medications but never consume the tablets. The proportion of patients who would not
comply at individual stages of the screening and treatment program would need to be
estimated - an extremely difficult exercise - and therefore attempts at measuring
compliance as part of this modelling exercise have not been attempted.
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6.2 3 Whv do oatients exit the model when thev are institutionalised?
There are complex issues and uncertainties around the fracture risk of
institutionalised patients, as the change to their fracture risk after institutionalisation is
difficult to accurately estimate.
lnstitutionalised patients may have a higher risk of hip fracture than non-
institutionalised patients, as they may be quite elderly, and have additional risk
factors for falls, such as reduced muscle strength, Parkinson's disease, poor vision,
physical inactivity, psychotropic medications, or medications which may induce
postural hypotension.lss
lf patients are suffering mental impairment (such as through dementia), they may
have difficulty following instructions for taking alendronate. For example, they may
not remember to sit upright after taking the tablets, and go back to bed instead. This
would place these people at increased risk of developing serious adverse events
relating to alendronate ingestion, such as oesophageal ulceration.26l lnstitutionalised
patients are a heterogenous group, to which the above considerations apply to a
greater or lesser extent. The change in individual or overall fracture risk maybe
extremely difficult to estimate, and may be independent of BMD change. Therefore,
institutionalised patients have been "dropped out" of the model after their
institutionalisation, in a similar manner to patients who have died, because of the
difficulties in making accurate estimates of changes to their fracture risk.
6.2.4 Whv oes the orevalence of hav tno BMD within a oarticular treatment
decision chanqe with aqe in the COPD population?
The difference between the mean BMD of the COPD and the general populations is
always 5%. This is an assumption of the model. However, as the mean BMD of the
general population decreases with advancing age, the difference between the
general population and the COPD population BMD decreases. Therefore, the lower
the mean BMD of the general population becomes (in the oldest age groups), the
closer the prevalence of a particular Z-score in the COPD population becomes to that
of the general population.
The prevalence of a particular treatment decision (such as Z<-1.0) in the COPD
groups is different between men and women because men and women have a
different standard deviation (0.1 3 glcm2 for men and O. 12 gtcm2 for women).
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alendronate for ten vears
At the age group who begin treatment at age 75 and continue treatment until age 84
(unless exiting the model after experiencing hip fracture, death or institutionalisation),
the rates of hip fracture and mortality and institutionalisation are high - both in
general and as a result of a hip fracture. With such a large percentage of patients
exiting the treatment group due to death, or institutionalisation per annum, especially
in the COPD groups, the number of people in the treated group dwindles markedly
over ten years - see Table 68 on page 156. We know little about the interaction of
all the factors involved at such an advanced age and even less about what may
occur in subgroups such as patients with COPD. Therefore, we can not be confident
about how the independent contributions of mortality and institutionalisation may
change the overall pattern of what happens with the prevention of hip fractures in this
age group. Therefore NNS and NNT estimates after alendronate treatment for 10
years in men and women beginning treatment at age 75 has not been tabulated in
this thesis. However, the estimates in the same groups after treatment for one year
are sufficiently low that policy decisions on whether to screen and treat different
subgroups of either the general population or the COPD population with alendronate
could be made with the data on one year of treatment only - see Table 69 on page
161 . Therefore, estimating NNS and NNT for alendronate treatment after ten years
would not be necessary.
6.2.6 How much difference does the Markov simulation (including mortality and
institutionalisation) reallv make on estimates of NNS and NNT?
As discussed earlier, the Markov simulation takes into account patients exiting from
the model in a variety of ways (death, institutionalisation) when calculating the
outcomes for the following year. Subsequent iterations of the Markov model provide
simulated results after a number of years have passed.
By adding the hip fractures prevented for each year when starting treatment at age
55, 65 or 75, and treating patients with BMD at or below the chosen threshold for
treatment for '10 years, an estimate of "cumulative hip fractures prevented" is
created. This does not take into account deaths or institutionalisations. Comparing
this with the estimates of NNS and NNT and hip fractures prevented after ten years
of alendronate treatment produced by the Markov model illustrates the difference
made by taking mortality and institutionalisations into account (See Table 69). The
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ratios of the NNS and NNT estimates developed using the hip fractures prevented
from the cumulative model to the hip fractures prevented developed from the Markov
model for ten years of alendronate treatment was 0.69 in 55 year olds, and 0.61 -O.64
in 65 year old males and females in the general population (regardless of treatment
decision). This means that 44ô2% increases in NNS and NNT estimates are seen
when mortality and institutionalisation are taken into account. The ratio between
these parameters in the COPD population are smaller again - with 0.65 - 0 68 in
men and women with COPD commencing treatment at age 55, and 0.53 - 0.55 in
men and women with COPD commencing treatment at age 65. Therefore, a 47-92o/o
increase in number of people needing to be screened and treated to prevent hip
fraciures is seen in the COPD population when deaths and institutionalisations are
considered. Therefore, estimates of NNS and NNT developed from short term RCT
studies may underestimate the true NNS and NNT required to prevent hip fractures.
This has significant implications for screening and treatment programs, and suggests
that the NNS and NNT estimates obtained for periods longer than one year need to
take into account patients who no longer take treatment (due to death or
institutionalisation). The scope of screening programs needs to be increased
accordingly, by a factor of 44-92% depending on the age of the patients and whether
or not they have COPD.
Conclusion
The model assumption of 1OO% compliance with screening is unlikely in practice.
The most likely alternative scenario is that a higher-risk group than the underlying
population would present for screening, which would reduce NNS estimates.
There is insufficient evidence to suggest whether or not patients in the general
population would have different levels of compliance to the patients in randomised
controlled trials.
The hip fracture rates of institutionalised and extremely elderly patients such as 75
year olds treated for ten years with daily alendronate are surrounded by much
uncertainly, and are therefore difficult to accurately assess.
NNS and NNT estimates (after ten years of daily alendronate treatment) may
underestimate true hip fracture rates by 50-90% if deaths and institutionalisations are
not taken into account.
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6.3 Drscøssíon of modelled results
the modelled estimates of
6.3.1 .1 Levels of absolute fracture risk
The most important determinant of NNT is the level of absolute fracture risk. The
statistic NNT is the reciprocal of absolute risk reduction (1/ARR)- the reduction in
absolute risk conferred in patients receiving the intervention compared to patients
receiving the placebo. Therefore, NNT will vary in populations with different
underlying risk of the event (in this case, hip fractures) (See subject inclusion criteria
in Table 62).
Age and (initial) BMD are the strongest known risk factors for hip fracture and are, in
part, independent. Therefore, absolute values for BMD have different significance at
different ages.262 Advancing age is associated with decreased absolute 8MD,1011
but may also be associated with aging-related physiological changes eg poor
balance, poor health or co-morbidities.
6.3.1.2 Other factors contributino to chanoes in absolute risk
Certain subgroups of the general population have a higher risk of hip fracture.
Theses include patients with previous vertebral fractures (subgroup with low BMD in
whom fractures have already occurred), and patients with significant co-morbidities,
such as COPD.
6.3.1.3 Non-linear effect of alendronate treatment
Data on long term (7-year) treatment in post-menopausal women shows that
alendronate increases hip BMD for 3-5 years, and then prevents bone loss for 2
years.24 Therefore, the duration for which patients are treated will affect absolute
risk. This is because response to alendronate treatment is not linear, with patients
treated for longer periods of time sustaining lesser increases in BMD (or BMD may
remain stable) over the last 1-2 years of 7 years of alendronate treatment than they
do in the first 1 -2 years. This additive effect has not been included in this model: it is
not currently known if this effect continues indefinitely, and there is no data on the
effect of alendronate treatment for periods of longer than 7 years.
Treatment effect has been assumed to be linear for the results presented in this
thesis. All factors that influence NNT will ultimately influence NNS because NNS is
algebraically linked to NNT.
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6.3 1.4 Comparison between NNT estimates in the qeneral population and patients
with COPD
Despite there being a larger number of people treated for a given age, duration of
treatment and treatment decision, there are also a larger number of hip fractures
prevented in the COPD group than the general population, because the COPD
population has a higher underlying rate of hip fracture. However, the ratio between
the number treated and the number of hip fractures prevented in the COPD and the
general populations are similar, and thus there are equivalent differences in absolute
risk between the treated and non-treated groups ("control" and "intervention" groups)
in the COPD and general populations.
This also illustrates that the effect of treatment is the same in both the COPD and the
general populations - which was an assumption of the model in any case.
6.3.2 What affects the modelled estimates of NNS?
While NNT estimates are similar for a given treatment decision and gender between
both the general population and the COPD population (the model assumes that the
effect of treatment is the same in both groups because the fracture rates are the
same), the NNS estimates are consistently lower in the COPD group. There are two
explanations for this. One can be explained using the "literature" version of the NNS
formulae (NNS=NNT/prevalence of disease). The prevalence of having a BMD
within Z-score groups at the lower end of the normal distribution is higher in the
COPD groups because the COPD distribution is shifted down '10% compared to the
general population (see prevalence figures for each Z-score group in Table 68).
The second explanation is best illustrated using the "model" version of the NNS
formulae (NNS = number screened/hip fractures prevented). The number of people
screened in the general population and the COPD population is the same (N=1000),
but there are more hip fractures prevented in the COPD group because the hip
fracture rate is higher. Therefore, screening patients with COPD at an earlier age
than people in the general population may be able to be justified because the NNS is
lower.
The lower ends of the normal distribution are over-represented in terms of hip
fracture risk, and,.as expected, the lowest standard deviation groups have the
highest rates of hip fractures for their relative size. For example the Z<-2 group in the
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general population comprise only 20Â of the general population, but 1 5.8% of the hip
fractures, compared to the Z<-1 .5 group which has 2.6x as many people (6.7%
prevalence) by only 1.9x the fractures.
6.4 How do we assess whether NfVS and NNT estimates are reasonable?
NNS and NNT estimates are best used as a component of cost-effectiveness
analyses, such as cost per quality adjusted life years gained ($/QALY's), or cost per
life years gained ($/LYG) rather than estimates unto themselves. "High" estimates of
NNS and NNT may still be cost effective depending on the cost of the intervention
and the direct and indirect savings of adverse events prevented. Comparisons can
be made to estimates of NNS and NNT for other interventions for chosen time
periods, populations and treatment decisions to assess relative efficacies of the
interventions.
6.4.1 Literature estimates of NNS and NNT from screeninq and treatment studies
Literature estimates of NNS and NNT from screening and treatment studies
investigating the prevention of deaths from cancer and strokes are listed in Table 70
and Table 71. Considerations of these NNS and NNT estimates illustrate a number
of useful points.
Consideration of the studies on anti-hypertensive drugs listed in Table 71 provides
additional data to support the importance of using models to simulate NNS and NNT
estimates. There are similar issues in hypertension as there are in osteoporosis
regarding the effect of advancing age on hypertension, the choice of blood pressure
reading to use as a treatment decision, and the mode of measurement used to
determine blood pressure. In addition, clinical trials may not be representative of the
underlying population.
It is fundamental that NNS and NNT estimates be considered to be specific for a
particular population with a specified underlying risk of the adverse event, for
treatment with a particular agent for a specified period of time. Pooling numbers
needed to treat may not be reliable, as the background level of risk varies between
trials in a non-random fashion, and will confound the treatment effect.263 The use of
different entry criteria, such as age, or disease criteria like blood pressure or BMD, or
even the use of different equipment to measure different criteria - will also change the
prevalence of the group treated in the general population, affecting the number
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needed to screen. However, pooled NNS and NNT estimates are still created by
some authors, despite these problems2t'- See Table 70 andTableTl.
Despite these issues, when the NNS and NNT estimates generated by our model
(Table 72) are compared with the NNS and NNT estimates tabulated in Table 71, the
comparisons are favourable. The NNT estimates for treating 65 year old women in
either the general population or the COPD population for 10 years, or treating 75
year old women (in either population) for 1 year are well within the ranges of NNT for
preventing deaths using anti-hypertensive and anti-dyslipidemic drugs for 4-9 years.
The ranges of absolute and relative risks are similar between the treatments
preventing death from cardiovascular disease. The NNS estimates are much higher
for the prevention of hip fractures than prevention of deaths form cardiovascular
disease (the prevalence of having Z<-1.5 is much lower than the prevalence of
hypertension or dyslipidemia). However, the NNS for preventing hip fractures with
alendronate listed in Table 72 are either comparable or much lower than the NNS
estimates for preventing cancer-specific mortality from breast or colorectal cancer
from screening trials over 8-9 years.
Therefore, the NNS and NNT estimates developed from our modelling analysis are
comparable to NNS and NNT estimates available for treatment of other conditions
using various interventions. ln particular, the estimates of NNT and NNS for
screening and treating'.75 year old women for 1 year (either in the general or COPD
population), 65 year old women with COPD for 1 and 10 years, and 65 year old
women in the general population for '10 years appear particularly promising.
However, as stated earlier, NNS and NNT estimates need to be considered within
the context of cost-effectiveness analyses to decide if the groups listed above would






















































Table 70 - NNS and NNT to prevent I death for screenin grams to prevent
cancer of the breast and colon rom Rembold et al.1
$ Negative NNS indicates that mortality was higher in the screened population.
NB These are screening trials where the outcome of interest was deaths, rather than a
surrogate endpoint. Therefore, no NNT estimates have been listed. See Chapter 5.2.
Table 71 - NNS and NNT to prevent one death with cardiovascular agents ¡n
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Table 72 - NNS and NNT to prevent one fracture with alendronate treatment for
1-10 ars ¡n women in the eneral ulation and with COPD
f Estimates are for treating women (either in the general population or the COPD population) with
Z<-1.5, and beginning treatment with daily al.e^ndronate (10 mg) at age indicated. The data on
osteoporosis trials (except Black ef al. 1996'"" and Cummings ef al.'1998'"') are from the modelled
estimates of NNS and NNT discussed in this thesis.
Conclusion
NNS and NNT estimates generated as part of this project are comparable to other
NNS and NNT estimates available in the literature. However, before it is decided
whether screen¡ng and treating any subgroups of the COPD or general populations is
worthwhile, NNS and NNT estimates need to be considered in the context of other
cost-effectiveness analyses.
Chapter 6 conclusion
. 1O0Yo compliance with screening is unlikely to occur in practice. The people who
present for screening are more likely to be at higher risk of having low BMD than
those who do not attend. This may reduce NNS estimates
. There is no evidence to suggest whether or not patients in the general population
would have different levels of compliance with treatments to the patients who
participated in randomised controlled trials of daily alendronate.
. lt is difficult to accurately estimate the hip fracture rates of people who are








NNS and NNT estimates after ten years of daily alendronate treatment may
underestimate true hip fracture rates by 50-90% if deaths and institutionalisations
which take place over that ten year period are not taken into account.
The number of people who need to be treated (NNT) to prevent one hip fracture is
approximately equal for people in the general population, and people with COPD
of the same gender, BMD who are treated for the same length of time with daily
alendronate.
NNS estimates are consistently lower in the COPD group (compared to people in
the general population) for groups of the same gender, BMD and period of daily
alendronate treatment. This is because the prevalence of low BMD and the rates
of hip fracture are higher for any particular Z-score group in the COPD population
Therefore, treating patients with COPD may be justified at a younger age than for
people in the general population.
NNS and NNT estimates generated as part of this project are comparable to other
NNS and NNT estimates available in the literature. However, these estimates
need to be considered within the context of a cost-effectiveness analysis before




Chapter 7 - Gombining the results of a risk factor analysis with
results from number needed to screen and number needed to treat
modelling
7.1 Development of an algorithm for identifying COPD patients requiring
bone densitometry
Earlier in this thesis a risk factor model which can be used to identify 35% of patients
with asthma or airways disease who do NOT require bone densitometry has been
described (See Table 44 in Chapter 4.6.7 )
The results from the risk factor model could be developed into a screening algorithm
such as Figure 18.
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WHIGH OF YOUR RESPIRATORY PATIENTS SHOULD YOU REFER FOR BONE
DENSITY TESTING?
People who have ASTHMA, EMPHYSEMA, CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD), or CHRONIC BRONCHITIS and who answer YES




NO NEED FOR PATIENT
TO HAVE DXA SCAN
IF MY PATIENT HAS LOW BONE DENSITY, HOW MUCH DIFFERENCE WILL
TREATMENT MAKE?
Daily alendronate (1Omg/day) increases bone density of the femoral neck by 3.0 -
6.2%; and lumbar spine by 6.2 8.8% over 3-4 years in post-menopausal
women.244'243'24s'145 Treatment reduces the relative risk of fractures of the hip and
spine by 21-51% and 45-55% in relative terms (relative riskredu_ction) and O.22-1.1%
and 1 .6-21% in absolute terms (absolute risk reduclion¡.2aa'z+t'tts
HOW MUCH WILL THE TEST COST?
The Medicare scheduled fee is $68.85 for a DXA of hip and spine.13
HOW CAN MY PATIENT OBTAIN A FREE BONE DENSITY TEST?
Patients with certain medical conditions can obtain a free DXA scan eg
glucocorticosteroid use. Consult the current edition of the Medicare Benefits
Schedule Book for more details.l3
Patients who have bone density in the lowest 6.5% for their age and gender (Z-score
Z<-1.5) are eligible for free DXA tests every 2years after their initial DXA scan.13
Figure 18 - lnformation for physicians to aid in identifying patients to send for
bone densitometry
s Developed in a study population aged 45-79 years with risk factors for osteoporosis. Exclusion
crite ri a i nclud e contrai nd ications for alend ron ate treatment.
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Smoked < 80 pack years
Cu rrently taking wa darin
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7.2 Application of reduction in patients requiring screening to number
needed to treat
There are two major components to this thesrs:
a) a method for determining the number needed to screen and number needed to
treat for preventing hip fractures with daily alendronate has been described in
chapter 5.13, with results in Table 68 and Table 69 on pages 159 and 161 .
b) the results of the risk factor model for identifying people with respiratory disease
who are at increased risk of having low age- and gender-matched BMD as described
in Chapter 4 (which begins on page 98), and in Figure 18 on page 179.
Combining these two concepts enables the estimation of the scale of a disease-
screening program in men and women with asthma and ain¡vays disease, which
identifies high-risk persons who would benefit from densitometry.
The pre-screening tool recommends that 65% of patients receive densitometry, and
that 35% are excluded from densitometry. Those who are recommended for
densitometry will include most of the people who have low BMD, and are therefore at
higher risk of sustaining a hip fracture, but does not include all of them (false
negative rate of 14o/o). Therefore, the number of hip fractures prevented has been
adjusted because some patients (14%) who have low BMD (2.-1.5) will have been
missed (sensitivity =86%). Therefore, the formulae listed in Chapter 5.12 on page
158 needs to be modified from the following formulae:
NNS = number of people screened
Number of hip fractures prevented
le screened
number of hip fractures in - number of hip fractures in
"control" group "intervention" group
to:
NNS number of peoole screened in model l=1000) " 0.65
number of hip fractures
in the "control" group
((number of hip fractures
in the control group *O.14)
+ (number of hip fractures in the
"intervention" group- 0. 86))
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Therefore, the new number of hip fractures for the "intervention" group will consist of
86% of people who receive treatment - and therefore have the reduced hip fracture
rate of treated patients); and 1 4o/o o'f people assigned to the "intervention" group who
will not receive treatment - and therefore will have the hip fracture rate of untreated or
"control" patients.










((event rate in the "control group"*O.14)
+ (event rate in the
"intervention" group" 0.86))
Therefore, the new event rate for the "intervention" group will consist of 86% of
people receiving treatment (and therefore have the reduced hip fracture rate of
treated patients) and 1 4o/o of people assigned to the "intervention" group who will not
receive treatment and therefore will have the hip fracture rate of untreated or "control"
patients.
The rafes of the events have been used to calculate NNT, whereas the number of
events have been used in the NNS calculations. This is because I considered that in
each case, these were the simplest formulaes to use - there are alternate algebraic
expressions for these formulae (See Chapters 5.11 and 5.12).
The results of using the adjusted NNS and NNT formulae to derive NNS and NNT




Table 73 - NNS and NNT for preventing hip fractures with treatment with daily
alendronate 10m for one r with the use of the re-screening tool
NNS estimates are reduced by 25% in each Z-score group, age and gender when
the pre-screening tool is used. Explanations include:
a) fewer people are screened (because 35% are eliminated from screening)
b) fewer hip fractures are prevented (because 14% of those who would receive
treatment under "modelled" conditions would not receive treatment when the pre-
screening questionnaire is used prior to densitometry)
However, the ratio between a) and b) above results in the screening of a higher-risk
group than if the entire group had received densitometry.
NNT estimates are a little higher in each Z-score group, (16%) age and gender when
the pre-screening tool is used. Explanations include:
a) fewer hip fractures prevented because there is a reduction in the difference in
absolute risk of hip fractures between "control" and "intervention" groups












































































































This chapter presents results for the NNS and NNT for preventing hip fractures with
daily alendronate in men and women with COPD aged 55-75 and with BMD of Z<-
1.O, Z<-1.5, and Z<-2.O after the use of the pre-screening tool discussed in Chapter 4
(which has sensitivity of 86% and specificity of 41o/o). This is done by taking account
of the lesser number of patients screened and the change in the hip fracture rate or
number of hip fractures than under ideal or ("modelled") conditions.
The use of the pre-screening tool prior to densitometry captures a higher-risk
population than if everyone was screened, and everyone with low BMD was treated.
However, since 14% of patients who would othen¡vise fulfil the requirements of
treatment (because they have low enough BMD) are not treated (false negatives),
the effectiveness of treatment is reduced by just over 14% (16%)-
7.4 General conclusion
The cost-effectiveness of using the pre-screening tool prior to DXA depends on the
cost of all components - densitometry, alendronate treatment, and costs of missed
cases of low bone density such as nursing home admissions, hospitalisation and so
on. The cost of missed cases of low BMD may outweigh the cost of a larger
screening program in which all people with COPD aged 55 -75 receive densitometry.
An alternative to the disadvantages of using the pre-screening model discussed
above is to recommend ALL patients aged 55-75 with COPD receive densitometry,
but the final decision on which model to use would ultimately be decided by cost-
effectiveness analyses, taking into account the cost of screening, fractures sustained
and savings encountered by preventing fractures.
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Chapter I - Thesis conclusions
Chapter 2.1 - Does low bone itv cause sufficient mortalitv and morbiditv to
warrant routine screeninq?
Large numbers of Australians sustain fractures (particularly hip fractures) and the
associated poor outcomes have significant public health implications. This
magnitude of the problem will increase dramatically over time as Australia's
population ages, and there are more people in the age groups with high fracture
incidence. People with chronic airways limitations such as asthma, emphysema and
COPD have high levels of actual bone fracture, low BMD, and associated high risk of
developing osteoporotic fractures. Consequently, the morbidity and mortality
associated with osteoporotic fractures for this group is particularly large. The
projected number of fractures in the next 30-50 years is sufficiently large to consider
a case for screen'ing for low BMD in patients with moderate to severe airurays
disease, with a view to lowering fracture rates in this group of people with treatments
for low bone density.
Risk factors for low BMD in patients with asthma or COPD include both risk factors
applicable to the wider community (such as activity, steroids, catabolic status
advancing age, low body weight) and also risk factors specific to respiratory disease
(such as poor lung function). Both general population and disease-specific risk
factors ought to be considered when designing a screening strategy to identify
patients at higher risk of developing low bone density. ln people with more severe
disease, the negative effect of taking corticosteroids, high alcohol and cigarette
consumption may overshadow small effects of other factors eg low calcium intake on
bone density.
Chapter 2.2 -
in preventinq or reducing morbiditv and mortalitv?
There are a number of treatments available for preventing osteoporotic fractures that
have been trialed in patients with respiratory disease, and people requiring daily oral
corticosteroids. The most effective treatments are bisphosphonates (especially
risedronate and alendronate). Most of the treatments studied in people taking daily
oral corticosteroids (including people with respiratory disease) are available in
Australia, but most treatments available are very expensive for the majority of
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patients who are not able to meet the PBS indications to receive the treatment at a
subsidised price.
Chapter 2.3 - en test available th NSIVE
acceotable to oatients?
DXA tests are cheap, safe, widely available, and the most dependable technique
currently available.
Chapter 2.4 - Does the screenino test have adequate predictive value?
Numerous guidelines have been drafted to identify patients at high risk of
osteoporotic fractures. However, their recommendations are inconsistent and not
implemented in regular clinical practice.
Evidence-based, systematic approaches to identifying high-risk subgroups for low
BMD prior to densitometry have been investigated. Most non-SCORE questionnaire
did not reach the "gold standard" of 9O% sensitivity, but SCORE validations did in
most populations studied. These screeníng tools may prove to be a cost-effective
addition to densitometry by reducing the number of patients requiring densitometry
by 10-33%. .
Chapter 3 - Methodoloqv of the develooment of a risk factor analvsis to develop a
screenino tool to identi fv oatients with resoiratorv disease who are at increased risk
of low bone densitv.
People with moderate to severe asthma, emphysema, COPD or chronic bronchitis
who had attended respiratory outpatients or had been hospitalised for their ainvays
disease at The Queen Elizabeth Hospital, the Lyell McEwin Health Service, or the
Royal Adelaide Hospital over 1999-2002 were targeted for the study. ln addition,
patients were sourced from a number of general practices in the Adelaide Western
Division of General Practice as well as a number of other sources. Patients who
scored more than 5 points on our pre-screening questionnaire and satisfied other
inclusion and exclusion criteria were invited for densitometry, and completed a more
detailed questionnaire on their health (screening questionnaire). This data was used
to test Hypothesis 1: that patients with "low" (2.-1.5) or "not low" (Zr-1.5) age- and
gender-matched BMD at either the neck of femur, total femur or lumbar spine differed
significantly for one or more risk factors for low BMD usin g a X2 test for categorical
variables, or logistic regression for continuous variables.
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Chapter 4 - factor anal sts screent to
patients with resoiratorv disease who a at increased risk of low bone densitv
Our sample was middle aged, with more men than women. Both men and women
were overweight and sedentary compared to reference populations. Men and
women had different patterns of risk factors, and the men had poorer health and
lower age- and gender-matched BMD than the women. Individual risk factors that
were associated with low BMD (with genders pooled) (p<0.25) were included in the
multivariate analysis. At a p value of entry of 0.1, the multiple logistic regression
"model" comprised three factors - having a body maSS index <20, smoking >80 pack
years of cigarettes, FEVr <60% predicted, and current use of warfarin. The
combination of these four risk factors corresponded to a sensitivity of 86% and
specificity of 41% and correctly classified 50% of patients. This was chosen in
preference to an alternative model comprising 96% sensitivity and 21% specificity,
which had a higher sensitivity but a poorer overall mix of sensitivity and specificity,
correctly classifying only 36% of patients. The chosen model had a positive
predictive value of 27o/o, and a negative predictive value of 92o/o, and had an area
under the ROC curve (AUC) of O.7. People who did not have any of the four risk
factors in the multivariate logistic regression (comprising 65% of our sample) who
had a risk of having Z<-1.5 of 13% or less would not be recommended for
densitometry. The use of pre-screening questionnaires has the potential to reduce
the cost of screening programs by -2O% by identifying subgroups who would not
benefit from dens itometry.
Chapter 5 - Methods and results for modelled estimates of number needed to screen
and number needed to treat to orevent hio fractures over one and ten vears with dailv
alendronate
Number needed to screen (NNS) is a measure of the number of people with defitred
characteristics who need to be screened (and then treated) for a disease to prevent
one death or adverse event for a particular period of time. Number needed to treat
(NNT) is number of people who need to be treated with a certain agent for a
particular period of time to prevent one death or adverse event. Providing screening
is useful, NNS (and NNT) provide a tangible guideline for busy clinicians to
conceptualise the scale of disease screening and treatment programs. NNS and
NNT estimates based on modelled populations provide information for today that is
relevant to the underlying population. Literature equations were used to estimate hip
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fracture rates, the effect of COPD and treatment with daily alendronate on BMD in
the short term. The rate of hip fractures in the longer term (and also the eflect of
fractures, mortality and institutionalisation on hip fracture rates and hence NNS and
NNT) was simulated after ten years using a Markov simulation.
NNS estimates are lowest in the groups with highest BMD eg Z<-1.0 where disease
prevalence and hip fracture rates are lowest. NNT estimates are lowest in the
groups with lowest BMD where the disease prevalence and hip fracture rates are
highest. Approximately 6100 65 year old women in the general population with BMD
of Z<-1.5 need to be screened and 408 need to be treated to prevent one hip fracture
with daily alendronate treatment for one year. For ten years of daily alendronate
treatment -43O of these women would need to be screened and -39 treated to
prevent one hip fracture. Approximately -1840 65 year old women in the COPD
population with BMD of Z<-1.5 need to be screened and 380 need to be treated to
prevent one hip fracture with daily alendronate treatment for one year. For ten years
of daily alendronate treatment -165 of these women would need to be screened and
-34 treated to prevent one hip fracture.
Chapter 6 -
alendronate
Chapter 6.1 - Challenges to model inputs
Hip fractures were chosen because this fracture type is easily identifiable with few
fractures evading detection, and results in high rates of mortality and morbidity. We
chose to use Commonwealth data because no local population-based data is
available, and national hospital statistics can be generalised to the overall Australian
community.
Chapter 6.2 - Challenqes to model assumptions
The model assumption of IOOYo compliance with screening is unlikely in practice.
The most likely alternative scenario is that a higher-risk group than the underlying
population would present for screening, which would reduce NNS estimates.
There is insufficient evidence to suggest whether or not patients in the general




The hip fracture rates of institutionalised and extremely elderly patients such as 75
year olds treated for ten years with daily alendronate are surrounded by much
uncertainly, and are therefore difficult to accurately assess.
NNS and NNT estimates (after ten years of daily alendronate treatment) may
underestimate true hip fracture rates by 50-90% if deaths and institutionalisations are
not taken into account.
Chapter 6.3 - Discussion of modelled results
The number of patients needing to be treated (NNT) is approximately equal for
patients with COPD and in the normal population for groups of the same gender,
BMD and treatment period.
NNS estimates are consistently lower in the COPD groups for people of the same
gender, BMD and treatment period as the prevalence and hip fracture rates are
higher for a given group in the COPD population.
Chapter 6.4 - How do we assess whether NNS and NNT estimates are reasonable?
NNS and NNT estimates generated as part of this project are comparable to other
NNS and NNT estimates available in the literature. However, before it is decided
whether screening and treating any subgroups of the COPD or general populations is
worthwhile, NNS and NNT estimates need to be considered in the context of other
cost-effectiveness analyses.
Chapter 7 - Combininq the results of a risk factor analvsis with results from number
needed to screen and number needed to treat modelling
This chapter presents results for the NNS and NNT for preventing hip fractures with
daily alendronate in men and women with COPD aged 55-75 and with BMD of Z<-
1 .0, Z<-1.5, and Z<-2.O after the use of the pre-screening tool discussed in Chapter 4
(which has sensitivity of 86% and specificity of 41%). This is done by taking account
of the lesser number of patients screened and the change in the hip fracture rate or
number of hip fractures than under ideal or ("modelled") conditions.
The use of the pre-screening tool prior to densitometry captures a higher-risk
population than if everyone was screened, and everyone with low BMD was treated
However, since 14o/o of patients who would otheruvise fulfil the requirements of
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treatment (because they have low enough BMD) are not treated (false negatives),
the effectiveness'of treatment is reduced.
Chapter 7.4 - General conclusion
The cost-effectiveness of using the pre-screening tool prior to DXA depends on the
cost of all components - densitometry, alendronate treatment, and costs of missed
cases of low bone density such as nursing home admissions, hospitalisation and so
on. The cost of missed cases of low BMD may outweigh the cost of a larger
screening program in which all people with COPD aged 55 -75 receive densitometry
An alternative to the disadvantages of using the pre-screening model discussed
above is to recommend ALL patients aged 55-75 with COPD receive densitometry,
but the final decision on which model to use would ultimately be decided by cost-
effectiveness analyses, taking into account the cost of screening, fractures sustained




Appendix 1 - Summary tables of studies included in Chapter 1 (Table 74,f able75,
Table 76)
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Women aged 70-79 from
population based listings
White women, from population
based listings
White volunteers
White volunteers in good health
Women from a general practice
Women in placebo arm of RCT
6mo-3yr post menopause
Normal white women referred to
menopause clinic






















































































known to affect bone
metabolism
No diseases known to
affect bone metabolism
No diseases known to
affect bone metabolism




on BMD scan, nil else
Terminal illness, unable
















































































outpatients stratifi ed for
steroid usage
Asthmatics taking ICS





















































OCS course in last 6






























































































































































Appendix 2 - pre-sc
GP's details:
This is a study for men and women aged between 45 and B0
years of age with asthma or a¡rways disease
/ The person must have asthma, emphysema, COPD or chronic bronchitis
./ They must not currently be taking alendronate (Fosamax)
,/ They must not currently be taking Losec (Omeprazole), Somac (Pantoprazole), or
Zolon (Lansoprazole)
lf your patients' scores add to five (5) or more in the following list, they are eligible to participate in
screenins ror the Osteoporosis frocture prevention tríol ín osthmo, emphysemo
Ond ChfoníC bfonChítis *f'¡"n is being conducted on patients from TQEH, LMHS and the Royal
Adelaide Hospital at TQEH.
'¡k A woman aged over 50 years of age?
Jr A¿mitted to hospital at least once for respiratory illness in the last five years?
-¡k Bone fracture since age 40?
* lignt for height?






'rt Spirometry FEVI < 75% of pred icted? (score, oó predicted)
FEVI < 50% of predicted? (score, % predicted) . .
(FVC (score, % Pt"di"t"dì .... ...
* Physical activity? Limited? (able to walk less than 300m unaided)







* Used more than 3 courses of oral steroids in the past 2 years? (No )
'* Used high doses of puffer steroids eg <1.5 mg/day beclamethasone
dipropionate fo¡ <2 years or equivalent. Record name/dosage:
rk Current or previous smoker of <40 pack years?
Duration total
Average amount smoked/day
)tf fhrs score fofals to 5 or more then this patient is eligible for the
screening phase of the study
Exclusion criteria
People with moderate/severe renal insufficiency, women with current or planned pregnancies, people
with oesophageal stricture, oesophageal achalasia, inability to stand/sit upright for 30 mins, upper









Appendix 3 - Scree ning questionn aire
Today's date
Name
(DOB must be 1 Jan 1920 - 31 December 1 955 in 2000)
Height (cm)
Check General Practitioner address is correct
* What do the doctors tell you is wrong with your lungs? eg COPD, asthma, emphysema, chronic
bronchitis, C.A.L., other
















* Hormone replacement therapy Yes
* Calcium tablets Yes
* Thyroxine (Oroxine) Yes
* Maintenance oral prednisoloneYes
Jr Anticonvulsants Yes
* Current use diuretics (fluid tabs)Yes
* Ever taken any diuretics? Yes
* Calcitriol (Rocaltrol) Yes












(Ihiazide diuretic? Yes No
* Did
* Yes
r mother break bones after she was 40?
No Don't know
* Have you taken any booster courses of steroid tablets overthe past 2 yrs?
These are usually known as Prednisolone, Panafcort, or Cortisone Yes
Number
Do you smoke or have you smoked?
lf yes, for how long? years. (Started Stopped
How many cigarettes per day (on average) did you smoke over this time?







* lf yes, how old were you when you reached menopause?
Yes
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* Have you broken any bones since you were 40 years old?









* Have you had either of your hips replaced? Yes No lf yes, which one?
* How many times have you been admitted to hospital for lung problems in the last 5 years?
(include year)
None 1-2 3-5 5+ Year(s)
* I'd like to get an idea of your exercise tolerance. Can you please tell me how far you can walk by




* Leisure time activitv:
l've got some questions l'd like to ask you about the activity that you do during your leisure time.
These questions might sound a little silly depending on what you actually do but I'd like you to answer
them as asked.
During leisure time do you play sport?
never / seldom / sometimes / often / always
During leisure time do you watch TV?
never / seldom / sometimes / often / always
During leisure time do you walk?
never / seldom / sometimes / often / always
During leisure time do you ride a bike?
never / seldom / sometimes / often / always
During leisure time do you do heavy outside work (eg lawn mowing)
never / seldom / sometimes / often / always
How many minutes did you walk &/ or ride a bike per day to and from work, or shopping?
less than 5 minutes / 5 to 15 / 15 to 30 / 30 lo 45 I more than 45 minutes





















Mean BMD (g/cm')Mean BMD (g/cm')Age
MalesFemales
Appendix 4 - Reference bone mineral density data
Table 77 - Reference bone mineral density data showing mean and standard
deviation for males and females in the reference opulation (Lunar data 217 )
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Appendix 5 - Hip fracture incidence
Table 78 - Number of separations for fracture of femur (ICD-9-CM 820,821 ICD-
1O-AM S72), sex and age group - 1994/95 to 1998/99 for private and public
hos tals Australia Source: Australian lnstitute of Health and Welfare





































































































































































































Number of separations forfracture of femur(lCD-9-CM 820,821 ICD-1O-AM S72), sex and age group
- 1994/95 to 1998/99
Males FemalesMales Females Males FemalesMales FemalesMales Females
1 998/991997t981996t971 995/961 994/95
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Appendix 6 - Worked examples of calculation of pre-treatment fracture rates
Worked examples of calculation of pre-treatment fracture rates at or helow
treatment th reshold Z<-1
Pre-treatment fracture rate for 55 year old women BELOW the treatment threshold of
z<-1
Population risk of hip fracture=O.O47o/o
p =0.881 glcmz (2=-1=0.761glcm2)
o=0.12
RR=2.6
=0.05% x 0.761 - 0.881 - log"2.6
o.12
o (0.761 - 0.881)
o.12
x by 0.12 > =0.05% X o(0.761 - 0.881) - (log"Z.0 xO.12)
o (0.761 - 0.881)
=O.14o/o
Pre-treatment fracture rate for a 55 year old women AT the treatment threshold Z=-1
Population risk of hip fracture=O.05%
p =0.881 glcm2 (Z=-1=) 0.761 g/cm2)
o=0.12
RR=2.6




Appendix 7 - Conference abstracts
HIP FRACTURE PREVENTION USING ALENDRONATE. TWO MODELS FOR
NUMBER NEEDED TO TREAT AND SCREEN
L.L. Smithl, B.J. Smithl, B. Pekarsky2, J.A Harford3, S.A. Appletonl, P. Phillipsl K.D. Pile1"
lUniversity Department of Medicine 2KPMG consultants. 3Department of Public Health, The
University of Adelaide.
Number needed to treat (NNT) and needed to screen (NNS) are useful for determining
efficacy and scale of disease treatments and screening programs. Hip fractures result in
morbidity and mortality, warranting screening for osteoporosis (OST) in high-risk populations.
Alendronate (ALN) has been shown to increase bone mineral density (BMD) and reduce
fracture (#) rate numerous studies. Modelling analyses are useful, as long-term # studies are
difficult to conduct. Modelling studies can provide information for today.
To derive NNS for normal patients subsequently treated with ALN using DEXA to prevent
one hip #. (1) A literature derived model using hip # incidence in ALN treated groups, and
population BMD data. (2) Markov model including BMD reduction and fracture risk data for
COPD (chronic obstructive pulmonary disease) and non-COPD groups, used to determine
hip # risk, and treatment responses by gender and initial BMD. (1)Post-menopausal women
aged 65-74 years with starting BMD of 0.565+0.07 g/cm3 (mean, SD)1, estimated prevalence
of OST of 29o/o in this age group. Control hip # rate of 2.2% over 1 year, vs 1.1% in the
treated group, relative risk reduction of 59o/o and absolute risk reduction of 1.1o/o.
NNT=1/ARR=90; NNS=NNT/underlying prevalence=310. 2) We calculated the ratio of 64-
year-old women with COPD treated with ALN for 1 year PHFP. Women with mild OST (Z=-1
) -2 SD's) required 213 women treated PHFP, moderate OST (7-2 ) -3) 78 women
PHFP, and severe OST (Z<-3) 33 women PHFP. For healthy women aged 64 years the
numbers are248,87,35.
We estimate that literature derived NNT/NNS calculations are reasonable. Markov modelling
shows fewer women aged 64 need to be treated PHFP as BMD rises. Numbers of women
treated PHFP does not differ greatly between COPD and normal groups. Further analyses
will show if these interventions are cost-effective.
References:1. Black D.M. ef a/. Lancet'1996; 348:1535-41
The Australian Rheumatology Association Conference, Hobart 2000. Poster presentation
Page 200
Appendix 7 - Conference abstracts
A TOOL FOR IDENTIFYING MEN AND WOMEN WITH RESPIRATORY DISEASE WHO
DO NOT REQURE BONE DENSITY SCREENING
Smith LL*, Smith BJ, McElroy HJ, Phillips PJ, Pile KD
Clinical Epidemiology andHealth Outcomes Unit, The Queen Elizabeth Hospital, Adelaide.
Patients with respiratory disease have decreased mean bone mineral density (BMD) and increased risk
of bone fractures. Risk factor models poorly predict patients who have low BMD. Therefore, we
developed a screening tool to identiff patients unlikely to require bone densitometry. A cross-
sectional convenience sample (N:239) of patients with respiratory disease was assessed using dual-
energy x-ray absorptiometry (DXA) and analysed using multiple stepwise logistic regression. The
prevalence of low BMD, defined as a Z-score <-1.5 at lumbar spine, neck of femur or total femur, was
2l%. Participants with respiratory disease and ALL of: BMI >20; smoked <80 pack years; not
currently using warfarin; FEV¡ >-60yo predicted were NOT recommended for DXA, thereby
eliminating 35%o of participants. The sensitivity, specificity, positive predictive value and negative
predictive values were 86, 41,27 and92o/o respectively; area under the ROC curve was 0.7. Our pre-
screening tool may assist clinicians to identify those not requiring BMD screening, allowing more
effective use of DXA resources.
Australasian Epidemiology Association conference, Sydney 2001
Poster presentation.
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A TOOL FOR IDENTIFYING MEN AND WOMEN WITH RESPIRATORY DISEASE WHO DO NOT
REQUIRE BONE DENSITY SCREENING
Laura Smithr 2, Brian Smith2, Pat Phillipst 3, Kevin Piler 
a
University of Adelaide Department of Medicinet; Clinical Epidemiology and Health Outcornes Unit2.
Endocrinology Unit3, Rheumatology Unit4, TQEH, Woodville SA.
Osteoporotic fractures result in high morbidity and mortality. Patients with respiratory disease have decreased
mean bone mineral density (Bl\D) and increased risk of bone fractures, warranting consideration of osteoporosis
screening in this patient goup. Therefore, we developed a screening tool to identify patients untikely to require
bone densitomeûry using risk factors selected from the literature.
A cross-sectional convenience sarnple (N=239) of patients with mild to severe respiratory disease was assessed
using dual-energy x-ray absorptiometry (DXA) and analysed using multiple stepwise logistic regression The
prevalence of low BMD, defined as a Z-score of <-1.5 at the lumbar spine, neck of femur or total femur, was
2l%o.
At selected sensitivity of 860/o, specificity was 4lo/o, positive predictive value @PV; was 2'7o/c', negative
predictive value (NPV) was 92%o. The area under the curve was 0.70. Pa¡ticipants with respiratory disease and
ALL of: BMI>20; smoked <80 pack years; not currently using warfarin; FEVr >600/o of predicted were NOT
recommended for DXA, thereby eliminating 35o/o of partrcipants.
Our screening tool is moderately informative, easy to administer, and may assist a GP or respiratory physician to
identif, people with respiratory disease at low risk of osteoporosis who do not require bone densiry screening
with DXA. Specificity and PPV of this tool at stated sensitivity is poor, with many patients recomrnended for
DXA screening having normal BMD. NPV is high, enabling osteoporosis to be confidently excluded in people
not recommended for screening DXA. Additional risk factors usually considered predictive of osteoporosis eg
prednisolone usage, previous fractures did not add frrther information regarding risk of low BMD for our data.
Our tool excludes one third of our target population, allowing more effective use of the limited resources of
DXA. Despite the small proporlion of participants not recommended for screening DXA such progrzuns may
prove to be cost-effective when cost ofaverted fractures is considered.
North West Adelaide Health Service Research Day,200l. Oral presentation.
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NTIMBER NEEDED TO SCREEN AND NUMBER NEEDED TO TREAT FOR PREVENTING HIP
FRACTURES IN MEN AND WOMEN WITH COPD




Number needed to screen (NNS) and number needed to treat (NNT) are integral components of
today's disease screening programs. Hip fractures cause significant morbidity and moftality, with
COÉO patients at high ii.È oi sustaining osteoporotic fractures, with bone density (BMD) at l}yo
below mean for age. Therefore consideration of screening for and treating low BMD in men and
women with COPD is warranted. The effect of alendronate (ALN) therapy on BMD and hip fracture
rates can be accurately modelled to provide public health data today. NNS and NNT estimates were
developed using fraciure rates derived from literature equations, and extended over l0 years using
Markov simulations and mortality estimates. NNS and NNT for starting ALN treatment in men and
\¡/omen in the general population and with COPD at age 55 and 65 with BMD of 1, l -5 and 2 standard
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1,642 (5,008) ll0 (335)





Female (male) Female (male)
NNS NNT




The NNS to prevent one hip fracture after l0 years ALN treatment
women with COPD and reduces significantly in the elderly and with
is markedly less in both men and
reducing BMD. Further analYses
will show if screening and treatment is cost-effective in these groups
Supported by the NHMRC. Key words: Osteoporosis, number needed to screen, number needed to
treat, alendronate, COPD. Nominations for awards: None.
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